To Our Fellow Shareholders,
Associates and Customers
INTRODUCTION
2020 was an extraordinary and historic year for Hillrom
and the world at large.
Before sharing with you my perspective on the
performance of our business, please join me in
thanking our more than 10,000 associates around the
world. Whether in our manufacturing facilities or in
our Field Service centers, in hospitals or at home, our
team members performed brilliantly throughout the
pandemic – work that continues in 2021.
Their collaboration, their unified focus on patients and
their caregivers, brought a level of vitality to our vision
and mission that is humbling, and are an enormous
source of pride to me and to my leadership team.
"
Our employees collaboration,
their unified focus on patients
and their caregivers, brought
a level of vitality to our vision
and mission that is humbling,
and are an enormous source
of pride to me and to my
leadership team.
To all of my Hillrom colleagues the world over –
you have my deepest appreciation. Thank you.
"
FISCAL 2020
CEO letter
John P. Groetelaars
President and Chief Executive Officer
2020 FINANCIAL HIGHLIGHTS
Over the past several years, we have significantly
diversified our business, strengthening our business
model with enhanced value propositions, and
improving our durable growth profile through R&D
and deployment of capital into M&A. Our continued
balanced approach towards growth and investment
has led to an exciting and compelling transformation.
Our strategy, long-term fundamentals, growth
prospects and investment thesis remain intact. And
despite challenging circumstances posed by the
pandemic, Hillrom's overall financial performance has
been strong.
ABOUT HILLROMHillrom is a global medical technology leader whose 10,000 employees have a single purpose: enhancing outcomes for patients and their caregivers by advancing connected care. Around the world, our innovations touch over 7 million patients each day. They help enable earlier diagnosis and treatment, optimize surgical efficiency and accelerate patient recovery while simplifying clinical communication and shifting care closer to home. We make these outcomes possible through connected smart beds, patient lifts, patient assessment and monitoring technologies, caregiver collaboration tools, respiratory care devices, advanced operating room equipment and more, delivering actionable, real-time insights at the point of care. Learn more at hillrom.com.For more information, please contact your local distributor or Hillrom sales representative at 1-800-535-6663.hillrom.com 130 E. Randolph St. Suite 1000, Chicago, IL 60601Hill-Rom reserves the right to make changes without notice in design, specifications and models. The only warranty Hill-Rom makes is the express written warranty extended on the sale or rental of its products.© 2019 Hill-Rom Services, Inc. ALL RIGHTS RESERVED. XXXXXX rev X DD-MMM-20XX ENG – US 2020 FINANCIAL
HIGHLIGHTS CONTINUED
Revenue
For fiscal 2020, worldwide revenue of $2.88
billion, including more than $570 million in
new product revenue, declined 1 percent
on a reported and constant currency basis.
Hillrom’s core revenue advanced 3 percent
for the year, including contributions from
acquisitions of approximately 200 basis
points and approximately $180 million from
one-time COVID-related purchases.
Earnings Per Share
Hillrom reported GAAP earnings of $3.32
per diluted share in fiscal 2020 compared
to $2.25 per diluted share for fiscal 2019.
Adjusted earnings of $5.53 per diluted share
advanced 14% after adjusting for the 2019
divestiture of our surgical consumables
business, and exceeded the company’s
projection of at least $5.40 per diluted share.
We are proud we have delivered this level of
performance.
Cash Flow
Cash flow from operations for fiscal 2020
was $482 million, reflecting an improvement
of $81 million versus the prior year, a 20%
increase. Capital expenditures totaled $106
million, resulting in free cash flow of $376
million, a 15% increase compared to 2019.
Our debt-to-EBITDA ratio at the end of
September was 2.9x, and we returned $129
million to shareholders through dividends
and share repurchases during fiscal 2020.
1 Core revenue excludes foreign currency,
divestitures, non-strategic assets the company
exited and the Surgical Solutions international
OEM business.
Synclara™ Cough System
2020 HIGHLIGHTS
Hillrom achieved significant milestones in 2020 aimed at realizing our
vision of Advancing Connected Care™, transforming the portfolio
through innovation and M&A, and delivering sustainable value to
shareholders. Highlights include:
. Advancing category leadership with more than $570 million in new
product revenue during fiscal 2020. Contributing to this perfor-
mance were several innovative products, including the company’s
portfolio of smart beds, vital signs monitoring devices, respiratory
and vision products, as well as Integrated Table Motion.
. Playing a critical role in the global fight against COVID-19 and
significantly increasing manufacturing capacity to meet elevated
demand for select products, including med-surg and ICU hospital
beds, non-invasive ventilators, patient monitoring devices, and cer-
tain physical assessment tools and consumables.
. Rapidly developing and introducing more than a half-dozen new
products, many used in support of COVID-19 treatment, in the
areas of care communications, remote monitoring, respiratory
health and surgical workflow. These products expand the compa-
ny’s diverse portfolio and include the following: Voalte® Extend™, a
simplified mobile communication platform that enables patient to
caregiver communication; the Extended Care Solution™, a con-
nected remote vital signs monitoring device that allows clinicians to
shift care closer to home; the Welch Allyn® Spot Vital Signs® 4400
next generation vital signs device, which allows clinicians
to remotely receive a complete set of vitals, including SPO2,
temperature and blood pressure; two new respiratory devices:
Volara™ System for oscillation and lung expansion therapy for use
in both the acute and home settings, and Synclara™ cough system
to help clear mucus from upper airways; and the PST 500, a preci-
sion surgical table that streamlines workflow in the operating room.
. Enhancing the company’s portfolio of connected care solutions
with three acquisitions, Excel Medical Electronics LLC, Connecta
Soft, and Videomed S.r.l, bringing advanced, actionable point-of-
care data to caregivers and healthcare provider organizations.
. Generating operating cash flow for the year of $482 million,
reducing debt by $147 million, and delivering significant value to
shareholders through increased dividends and share repurchases.
During fiscal 2020, Hillrom raised its dividend for the tenth con-
secutive year and returned $129 million to shareholders through
dividends and share repurchases. The company’s strong financial
position is supported by a healthy balance sheet, including $297
million in cash and cash equivalents, and revolving credit facilities
totaling $1.2 billion that can be used to address capital needs as
necessary.
. Demonstrating commitment and support of local, national and
international communities with both monetary and product do-
nations totaling more than $6.5 million, including medical devices
well-suited for critical and intensive care environments to 25 U.S.
hospitals fighting COVID-19.
Ecovadis Gold
Award for
Sustainable
Procurement
Great Place
To Work®
DiversityInc
Noteworthy
Company
. Promoting excellence in the workplace and commitment to diver-
sity, inclusion and belonging initiatives as the recipient of multiple
awards and recognitions, including the Ecovadis Gold Award for
Sustainable Procurement, Great Place To Work® certification in
France and Mexico, and DiversityInc Noteworthy Company. Hillrom
also extended gender diversity in the boardroom, bringing women
representation to 36 percent of the company’s board of directors.
Voalte® Extend™
Welch Allyn® Spot Vital
Signs® 4400
Volara™ System
PST 500
LONG-TERM OUTLOOK
This pandemic has demonstrated that our strong,
diversified portfolio provides us with unique solutions
and capabilities to tackle accelerated transformation
in the global health care environment. Hillrom is very
well positioned to benefit from these new trends in
2021 and into the future, and with fiscal 2021 well
underway, we are observing signs of improved trends
as the economic recovery progresses and countries
the world over begin vaccine distribution.
I am confident that as we cycle through difficult
comparisons from 2020 and with fiscal 2021 as a new
baseline, we are well positioned to deliver on both our
long-term aspirations and growth objectives in a post-
COVID world.
CONCLUSION
As I reflect on the progress of our business transformation,
I am extremely proud of what we have accomplished. Our
global Hillrom team has continuously displayed a winning
spirit, and has risen to the challenges posed by the pandemic.
"
Our mission has never been more
vital: every day, around the world,
we enhance outcomes for patients
and their caregivers.
"
Our mission has never been more vital: every day, around the
world, we enhance outcomes for patients and their caregivers.
We look forward to the future with conviction as we build
on a solid foundation in pursuit of our vision of Advancing
Connected Care™.
John P. Groetelaars
President and Chief Executive Officer
January 2021
RECONCILIATION OF GAAP TO OPERATING INCOME
Year Ended September 30, 2020
Year Ended September 30, 2019
Operating
Margin
Income
Before
Income
Taxes
Income
Tax
Expense
Diluted
EPS
Operating
Margin
Income
Before
Income
Taxes
Income
Tax
Expense
Diluted
EPS
12.8%
$271.2
$48.2
$3.32
10.9%
$208.6
$56.4
$2.25
GAAP Basis
Adjustments:
Acquisition and integration costs and
related fair value adjustments
—%
(0.6)
1.8
(0.04)
0.9%
28.1
5.3
0.34
Acquisition-related intangible
asset amortization
Field corrective actions
Regulatory compliance costs
Special charges
Tax law and method changes
Debt refinancing costs
(Gain) loss on business combinations
Pension settlement expense
Litigation expenses and awards
COVID-19 related costs and
benefits, net
3.7%
109.0
26.1
1.23
4.2%
122.4
28.6
1.38
0.2%
0.5%
1.4%
—%
—%
—%
—%
—%
4.9
15.6
41.5
—
16.1
(2.8)
8.4
(1.2)
1.2
3.7
9.2
—
3.7
0.05
0.18
0.48
—
0.18
(4.4)
0.02
1.9
0.10
0.2%
0.5%
1.0%
—%
—%
—%
—%
(0.3)
(0.01)
0.1%
0.2%
1.4
0.7
0.02
—%
5.6
15.3
28.4
—
4.0
15.9
—
2.0
—
1.4
3.6
6.9
(4.8)
0.9
(12.4)
—
0.5
—
0.06
0.17
0.32
0.07
0.05
0.42
—
0.02
—
Adjusted Basis
18.8%
$463.5
$91.8
$5.53
17.8%
$430.3
$86.4
$5.08
ABOUT HILLROMHillrom is a global medical technology leader whose 10,000 employees have a single purpose: enhancing outcomes for patients and their caregivers by advancing connected care. Around the world, our innovations touch over 7 million patients each day. They help enable earlier diagnosis and treatment, optimize surgical efficiency and accelerate patient recovery while simplifying clinical communication and shifting care closer to home. We make these outcomes possible through connected smart beds, patient lifts, patient assessment and monitoring technologies, caregiver collaboration tools, respiratory care devices, advanced operating room equipment and more, delivering actionable, real-time insights at the point of care. Learn more at hillrom.com.For more information, please contact your local distributor or Hillrom sales representative at 1-800-535-6663.hillrom.com 130 E. Randolph St. Suite 1000, Chicago, IL 60601Hill-Rom reserves the right to make changes without notice in design, specifications and models. The only warranty Hill-Rom makes is the express written warranty extended on the sale or rental of its products.© 2019 Hill-Rom Services, Inc. ALL RIGHTS RESERVED. XXXXXX rev X DD-MMM-20XX ENG – US
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
(Mark One)
☑ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the fiscal year ended September 30, 2020
OR
☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from ____ to ____
Commission File No. 1-6651
HILL-ROM HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Indiana
(State or other jurisdiction of incorporation)
130 E. Randolph St. Suite 1000
Chicago, IL
(Address of principal executive offices)
35-1160484
(I.R.S. Employer Identification No.)
60601
(Zip Code)
Securities registered pursuant to Section 12(b) of the Act:
Registrant’s telephone number, including area code: (312) 819-7200
Title of Each Class
Common Stock, without par value
Trading Symbol
HRC
Name of Each Exchange on Which Registered
New York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☑ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☑
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90
days. Yes ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of
the Exchange Act. Large accelerated filer ☑ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over
financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
☑
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑
The aggregate market value of the registrant’s voting common equity, held by non-affiliates of the registrant, was approximately $6.7 billion, based on the closing sales price of
$100.60 per share as of March 31, 2020 (the last business day of the registrant’s most recently completed second fiscal quarter). There is no non-voting common equity held by
non-affiliates. The registrant had 66,812,909 shares of its common stock, without par value, outstanding as of November 11, 2020.
Documents incorporated by reference.
Certain portions of the registrant’s definitive Proxy Statement to be delivered to shareholders in connection with the Annual Meeting of Shareholders to be held on March 10, 2021
are incorporated by reference into Part III of this Annual Report on Form 10-K.
1
Table of Contents
PART I
DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS
This Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995, as amended, with respect to general economic conditions, our financial condition, results of operations, cash flows and
business and our expectations or beliefs concerning future events, including the demand for our products, the ability to operate
our manufacturing sites at full capacity, future supplies of raw materials for our operations, product launches, share
repurchases, international market conditions, expectations regarding our liquidity, our capital spending, plans for future
acquisitions and divestitures, and our operating plans. These forward-looking statements can generally be identified by phrases
such as we or our management “expects,” “anticipates,” “believes,” “estimates,” “intends,” “plans to,” “ought,” “could,” “will,”
“should,” “likely,” “appears,” “projects,” “forecasts,” “outlook” or other similar words or phrases. There are inherent risks and
uncertainties in any forward-looking statements. We caution readers not to place undue reliance on any forward-looking
statements. All statements that address our future operating performance or events or developments that we expect or anticipate
will occur in the future are forward-looking statements.
Our forward-looking statements are based on management’s expectations and beliefs as of the time this Form 10-K is filed with
the Securities and Exchange Commission in the United States (“SEC”) or, with respect to any document incorporated by
reference, as of the time such document was prepared. Although we believe that our expectations are reasonable, we can give
no assurance that these expectations will prove to have been correct, and actual results may vary materially due to various
factors. These factors include those described in Part I, Item 1A “Risk Factors” of this Form 10-K. Our actual results also could
be materially adversely impacted by the length and severity of the on-going coronavirus pandemic (“COVID-19,” “the
pandemic,” or “the virus”) and related impacts on our business, results of operations, financial condition, and prospects. Except
as required by applicable law or regulations, we undertake no obligation to update, amend or clarify any forward-looking
statements to reflect changed assumptions, the occurrence of anticipated or unanticipated events, new information or
circumstances or any other developments or changes.
Item 1.
BUSINESS
General
Hill-Rom Holdings, Inc. (the “Company,” “Hillrom,” “we,” “us,” or “our”) was incorporated on August 7, 1969, in the State of
Indiana and is headquartered in Chicago, Illinois. We are a global medical technology leader whose approximately 10,000
employees have a single purpose: enhancing outcomes for patients and their caregivers by Advancing Connected Care™.
Around the world, our innovations touch over 7 million patients each day. Our products and services help enable earlier
diagnosis and treatment, optimize surgical efficiency and accelerate patient recovery while simplifying clinical communication
and shifting care closer to home. We make these outcomes possible through digital and connected care solutions and
collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices,
advanced equipment for the surgical space and more, delivering actionable, real-time insights at the point of care.
Segment Information
We disclose segment information that is consistent with the way in which management operates and views the business. Our
operating structure contains the following reportable segments:
•
•
•
Patient Support Systems – globally provides an ecosystem of our digital and connected care solutions: devices,
software, communications and integration technologies that improve care and deliver actionable insights to caregivers
and patients in the acute care setting. Key products include care communications and mobility solutions, connected
med-surg and ICU bed systems, sensors and surfaces, safe patient handling equipment and services.
Front Line Care – globally provides integrated patient monitoring and diagnostic technologies – from hospital to
home – that enable and support Hillrom’s connected care strategy. Our diverse portfolio includes secure, connected,
digital assessment technologies to help diagnose, treat and manage a wide variety of illnesses and diseases, including
respiratory therapy, cardiology, vision screening and physical assessment.
Surgical Solutions – globally enables peak procedural performance, connectivity and video integration products that
improve collaboration, workflow, safety and efficiency in the operating room, such as surgical video technologies,
tables, lights, pendants, precision positioning devices and other accessories.
3
Table of Contents
Net revenue, segment profitability and other measures of segment reporting for each reportable segment are set forth in Note
14. Segment Reporting of our Consolidated Financial Statements included under Part II, Item 8 of this Form 10-K.
Products and Services
Patient Support Systems. Our Patient Support systems business include a variety of specialty frames and surfaces (such as
medical surgical beds, intensive care unit beds, and bariatric patient beds), patient mobility solutions, non-invasive therapeutic
products and surfaces, and our information technologies and software solutions in our Care Communications portfolio. These
products are sold globally and are built to advance mobility, reduce patient falls and caregiver injuries, improve caregiver
efficiency and prevent and care for pressure injuries. In addition, we also sell equipment service contracts for our capital
equipment, primarily in the United States. Approximately 53%, 51% and 50% of our revenue in fiscal 2020, 2019 and 2018 was
derived from this segment.
Front Line Care. Our Front Line Care products include our patient monitoring and diagnostics products from Welch Allyn and
our respiratory health products. Our patient monitoring and diagnostics products from Welch Allyn include products in each of
the following four categories: patient exam and diagnostics, patient monitoring, diagnostic cardiology and vision screening and
diagnostics. Our respiratory health products include non-invasive devices that provide respiratory support and assist patients in
the mobilization of retained blockages. Front Line Care products are sold globally within multiple care settings including
primary care, acute care, extended care and home care (primarily respiratory health products). Approximately 36%, 34%, and
34% of our revenue in fiscal 2020, 2019 and 2018 was derived from products within this segment.
Surgical Solutions. Our Surgical Solutions products include tables, lights, pendants and operating room integration technology
utilized within the surgical setting. We also offer a range of positioning devices for use in shoulder, hip, spinal and lithotomy
surgeries as well as platform-neutral positioning accessories for nearly every model of operating room table. Approximately
11%, 15%, and 16% of our revenue in fiscal 2020, 2019 and 2018 was derived from products within this segment.
We have extensive distribution capabilities and broad reach across all health care settings. We primarily operate in the
following channels: (1) sales and rentals of products to acute and extended care facilities worldwide through both a direct sales
force and distributors; (2) sales and rentals of products directly to patients in the home; and (3) sales into primary care facilities
(primarily Welch Allyn products) through distributors. Through our network of 163 North American and 39 international
service centers, and approximately 2,000 service professionals, we provide technical support and services and rapidly deliver
our products to customers as-needed, providing our customers flexibility to purchase or rent select products. This extensive
network is critical to serving our customers and securing contracts with Group Purchasing Organizations (“GPOs”) and
Integrated Delivery Networks (“IDNs”).
No single customer represents more than 10% of our revenue.
4
Table of Contents
Acquisitions and Dispositions
Acquisitions
During fiscal 2020 and 2019, we acquired the following companies:
Fiscal Year
2020
Company Name
Description of the Business
Description of the Acquisition
Excel Medical
Electronics (“Excel
Medical”)
Clinical communications software
company located in the United States
Purchased all of the outstanding equity
interest.
2020
Connecta Soft, S.A. de
C.V. (“Connecta”)
Clinical communications software
company based in Mexico.
2020
2019
2019
Videomed S.r.l.
(“Videomed”)
Voalte, Inc. (“Voalte”) Clinical communications software company
Developer of integrated video solutions in
operating rooms located in Italy.
Breathe Technologies,
Inc. (“Breathe”)
located in the United States.
Developer and manufacturer of a patented
wearable, non-invasive ventilation
technology that supports improved patient
mobility. Located in the United States.
Purchased the multiplatform medical
device integration and connectivity
software programs, products, and solutions
of the company.
Purchased all of the outstanding equity
interest.
Purchased all of the outstanding equity
interest.
Purchased all of the outstanding equity
interest.
Asset Acquisition
During fiscal 2018, we acquired the right to use patented technology and certain related assets from a supplier to our Front Line
Care segment.
Dispositions
During fiscal 2019 and 2018, we disposed of the following:
Fiscal Year
2019
2018
Segment
Description of the Disposition
Surgical Solutions
Sold certain of our surgical consumable products and related assets.
Patient Support
Systems
Conveyed certain net assets related to our third-party rental business, comprised of
purchased moveable medical equipment that could be rented to customers.
Refer to Note 3. Business Combinations for additional information regarding acquisitions and dispositions.
Raw Materials
Principal materials used in our products for each business segment include electronic and electromechanical components,
carbon steel, aluminum, stainless steel, wood and laminates, petroleum-based products, such as foams and plastics, and other
materials, majority of our raw material components are available from multiple sources.
Prices fluctuate for raw materials and sub-assemblies used in our products based on a number of factors beyond our control.
Specifically, the fluctuating prices of certain raw materials, including metals, fuel, plastics and electronic components as well as
the impact from incremental China tariff had a direct effect on our profitability. Although we generally have not engaged in
hedging transactions with respect to raw material purchases, we have effectively mitigated a portion of the cost pressure
through improved operational efficiencies and enhanced supplier management.
Most of our contracts with hospital GPOs and other customers for the sale of products in North America permit us to institute
annual list price increases, although we may not always be able to raise prices sufficiently to offset all raw material cost
inflation.
5
Table of Contents
Competition
Across our business, we compete on the basis of clinical expertise, resulting product clinical utility and ability to produce
favorable patient outcomes, as well as value, quality, customer service, innovation and breadth of product offerings. We
evaluate our competition based on our segments.
The following table displays our significant competitors with respect to each segment:
Segments
Competitors
Patient Support Systems
Front Line Care
Arjo
LINET spol. s.r.o.
Paramount
Rauland, a Division of AMETEK, Inc.
Stryker Corporation
Vocera
Electromed, Inc.
Exergen Corporation
GE Healthcare
Heine Optotechnik
Midmark Corporation
Mindray Medical International
OMRON Healthcare, Inc.
Philips
Resmed
Riester
Schiller AG
Surgical Solutions
Draeger
Maquet, a Division of Getinge AB
MizuhoOSI
Skytron
Steris
Stryker Corporation
Additionally, we compete with a large number of smaller and regional manufacturers.
Regulatory Matters
FDA Regulation
We design, manufacture, install and distribute medical devices that are regulated by the U.S. Food and Drug Administration
(“FDA”) and similar agencies in other countries. The regulations and standards of these agencies evolve over time and require
us to make changes in our manufacturing processes and quality systems to remain in compliance. The FDA’s Quality System
regulations and the regulatory equivalents internationally set forth standards for our product design and manufacturing
processes, require the maintenance of certain records and provide for inspections of our facilities. From time to time, the FDA
performs routine inspections of our facilities and may inform us of certain deficiencies in our processes or facilities. In addition,
there are certain state and local government requirements that must be complied with in the manufacturing and marketing of our
products. See Item 1A. Risk Factors for additional information.
Environmental
We are subject to a variety of federal, state, local and foreign environmental laws and regulations relating to environmental and
health and safety concerns, including the handling, storage, discharge and disposal of hazardous materials used in, or derived
from our manufacturing processes. When necessary, we provide reserves in our financial statements for environmental matters.
We do not expect the remediation costs for any environmental issues in which we are currently involved to exceed $1.0 million.
Health Care Regulations
In March 2010, comprehensive health care reform legislation in the United States was signed into law through the passage of
the Patient Protection and Affordable Health Care Act and the Health Care and Education Reconciliation Act. The health care
industry continues to undergo significant change, both in response to this law and in response to other legislative and regulatory
actions. In addition to health care reform, Medicare, Medicaid and managed care organizations, such as health maintenance
organizations and preferred provider organizations, traditional indemnity insurers and third-party administrators are under
increasing pressure to control costs and limit utilization, while improving quality and health care outcomes. These objectives
are being advanced through a variety of reform initiatives including, but not limited to, accountable care organizations, value-
based purchasing, bundling initiatives and competitive bidding programs. We are also subject to a number of other regulations
around the world related to the sale and distribution of health care products. The potential impact of these regulations to our
6
Table of Contents
business is discussed further in Item 1A. Risk Factors and Part II, Item 7. Management’s Discussion and Analysis of Financial
Condition and Results of Operations, included in this Form 10-K.
Product Development
We pursue development of new products and product improvements internally. We maintain professional working relationships
with various medical professionals who assist in product research and development. New and improved products play a critical
role in our sales growth. We continue to place emphasis on the development of proprietary products and product improvements
to complement and expand our existing product lines. Our significant research and development activities are located in Acton,
Massachusetts; Batesville, Indiana; Cary, North Carolina; Irvine, California; Milwaukee, Wisconsin; Sarasota, Florida;
Skaneateles Falls, New York; Bologna, Italy; Pluvigner, France; Singapore; and Saalfeld and Puchheim, Germany.
Research and development is expensed as incurred. Research and development expense in the fiscal years ended September 30,
2020, 2019 and 2018 was $136.5 million, $139.5 million and $135.6 million.
In addition, certain software development technology costs for software to be sold or licensed to customers are capitalized as
intangibles and are amortized over a period of three to five years once the software is ready for its intended use. The amounts
capitalized in the fiscal years ended September 30, 2020, 2019 and 2018 was approximately $15.3 million, $8.0 million and
$2.4 million.
Patents, Trademarks and Trade Names
We own, and may license from others, a number of patents on our products and manufacturing processes, but we do not believe
any single patent or related group of patents is of material significance to any business segment or our business as a whole. We
also own a number of trademarks, trade names and service marks relating to our products and services. Except for the marks
“HillromTM”, “Hill-Rom®” and “Welch Allyn®”, we do not believe any single trademark, trade name or service mark is of
material significance to any business segment or our business as a whole.
Foreign Operations
Information about our foreign operations is set forth in tables relating to geographic information in Note 14. Segment Reporting
of our Consolidated Financial Statements included under Part II, Item 8 of this Form 10-K.
Human Capital Resources
As of September 30, 2020, Hillrom had approximately 10,000 employees worldwide, with approximately 6,000 employees in
the United States and approximately 4,000 employees outside of the United States. Hillrom’s global presence enables our
strategic priority of expanding internationally and penetrating emerging markets with our differentiated solutions. Our
employees are our most important assets and they set the foundation for our ability to achieve our strategic objectives. All of
our employees contribute to Hillrom’s success and, in particular, the employees in our manufacturing, sales, research and
development and quality assurance departments are instrumental in driving operational execution and strong financial
performance, advancing innovation and maintaining a strong quality and compliance program.
The success and growth of Hillrom’s business depend in large part on our ability to attract, retain and develop a diverse
population of talented and high-performing employees at all levels of our organization, including the individuals who comprise
our global workforce as well as executive officers and other key personnel. To succeed in a competitive labor market, Hillrom
has developed key recruitment and retention strategies, objectives and measures that we focus on as part of the overall
management of our business. These strategies, objectives and measures form the pillars of our human capital management
framework and are advanced through the following programs, policies and initiatives:
•
Competitive Pay and Benefits. Hillrom’s compensation programs are designed to align the compensation of our
employees with Hillrom’s performance and to provide the proper incentives to attract, retain and motivate employees to
achieve superior results. The structure of our compensation programs balances incentive earnings for both short-term and
long-term performance. Specifically:
◦ We provide employee wages that are competitive and consistent with employee positions, skill levels, experience,
knowledge and geographic location.
7
Table of Contents
◦ We engage nationally recognized outside compensation and benefits consulting firms to independently evaluate the
effectiveness of our executive compensation and benefit programs and to provide benchmarking against our peers
within the industry.
◦ We align our executives’ long-term equity compensation with our shareholders’ interests by linking realizable pay
◦
◦
with stock performance.
Annual increases and incentive compensation are based on merit, which is communicated to employees at the time of
hiring and documented through our talent management process as part of our annual review procedures and upon
internal transfer and/or promotion.
All employees are eligible for health insurance, paid and unpaid leaves, a retirement plan and life and disability/
accident coverage. We also offer a variety of voluntary benefits that allow employees to select the options that meet
their needs, including flexible time-off, telemedicine, paid parental leave, adoption assistance, a travel solution for
nursing moms, family building benefits, prescription savings solutions, Veterans' Health Administration coverage in
U.S. medical plans, transgender medical coverage, a personalized wellness program, a financial wellness program and
expanded coverage for diabetic employees.
•
Advancing and Celebrating Diversity, Inclusion and Belonging (“DIB”). DIB is vital to Hillrom’s ability to grow the
business and innovate in an ever-changing, fast-paced environment. Our diverse and inclusive workplace encourages
different perspectives and ideas, which we believe enables better business decisions and rapid innovation. The following
are highlights of Hillrom’s DIB program:
◦ We have established a DIB Council that provides strategic direction, guidance and advocacy for Hillrom's DIB
initiatives and advancements and is led by our Chief Executive Officer and Chief Human Resources Officer and
includes high-performing leaders from around the world.
As of September 30, 2020, women leaders made up 36% of Hillrom’s Board of Directors and 38% of Hillrom’s
Executive Leadership Team.
◦
◦ We sponsor multiple Employee Resources Groups, which are employee-led and open to all employees, including:
Pride Partnership; Individuals with Disabilities Empowered to Achieve; Veteran Employee Team; Embrace—A Black
Professional Organization; Professional Women’s Group; and HOLA (Hillrom Organization for Latinex
Advancement).
◦ We recruit diverse talent through local partnerships with organizations such as RecruitMilitary, HACE (Hispanic
Alliance for Career Enhancement), Diversity Best Practice, National Society of Black Engineers and Getting Hired
(focused on individuals with disabilities).
• Health and Safety. Health and safety are firmly rooted across Hillrom's global footprint. In fiscal 2020, Hillrom completed
the deployment across its manufacturing facilities of its new environmental health and safety management system, which is
designed to streamline data collection, ensure greater consistency and accuracy across global operations and improve health
and safety performance. We prioritize, manage and carefully track safety performance at all locations globally and integrate
sound safety practices to make a meaningful difference in every facet of our operations. During fiscal 2020, Hillrom
reduced its recordable injury rate compared to fiscal 2019 by 27% (0.38 recordable injuries per 100 workers per year) on a
company-wide basis and by 56% (0.32 recordable injuries per 100 workers per year) across its manufacturing operations.
In response to the COVID-19 pandemic and related mitigation measures, we implemented changes in our business in
March 2020 in an effort to protect our employees and customers, and to support appropriate health and safety protocols.
For example, we installed physical barriers between employees in production facilities, implemented extensive cleaning
and sanitation processes for both production and office administration spaces and implemented broad work-from-home
initiatives for employees in our administrative functions. While Hillrom’s essential workers (production and field service
employees) have continued to work at our facilities and provide vital service to our customers, most employees in our
administrative functions have effectively worked remotely since mid-March. During the fiscal year ended September 30,
2020, incremental non-recurring special compensation costs of $3.7 million were paid to Hillrom’s essential workers.
•
Labor Relations/Fair Labor Practice. We are committed to equal opportunity employment and working effectively with
existing unions. As of September 30, 2020, approximately 8% of our employees in the United States (including contingent
workers) worked under collective bargaining agreements. We have not experienced a work stoppage in the United States in
over 40 years, and we believe that our employee relations are satisfactory. The two collective bargaining agreements at our
primary U.S. manufacturing facility expire in January 2021 and January 2022. We are also subject to various collective
bargaining arrangements and/or national trade union agreements outside the United States. As of September 30, 2020,
approximately 65% of our employees outside the United States (including contingent workers) worked under such
arrangements.
8
Table of Contents
•
Recruitment, Training and Development. We use recruitment vehicles to attract diverse talent to our organization,
including partnerships with local and national organizations, HBCUs (Historically Black Colleges and Universities) and
various social media outlets. Hillrom invests in learning opportunities that foster a growth mindset. Our formal offerings
include a tuition reimbursement program, an e-learning platform known as Hillrom University (“HRU”) and virtual
workshops that support our culture, strategy and the development of crucial skills. To measure the impact of the
investments we make in our people, and to help us continually improve our human resources programs, we regularly track
a number of critical metrics, including the following:
◦
◦
Internal Hires: We track the percentage of open positions filled with internal candidates and use this metric as a
measure of how successfully we are promoting talent from within. For the fiscal year ended September 30, 2020, the
data was as follows:
Director and above: 34%
▪
▪ Manager and above: 45%
▪
All levels: 31%
Employee Satisfaction: We conduct an anonymous bi-annual engagement survey of our global workforce.
Administered and analyzed by an independent third-party, the survey results are reviewed by the executive officers.
The results of this engagement survey are shared with individual managers, who are then tasked with taking action
based on their employees’ anonymous feedback (both quantitative and qualitative). By paying close attention to the
results both at an aggregate enterprise level as well as at a department/business/work group level, Hillrom has been
able to enhance its culture of respect, help educate employees more effectively about our benefits offerings as well as
our learning and development opportunities and further improve our communications content, mechanisms and
frequency.
Executive Officers
The following sets forth certain information regarding our executive officers. The term of office for each executive officer
expires on the date his or her successor is chosen and qualified. No director or executive officer has a “family relationship” with
any other director or executive officer of the Company, as that term is defined for purposes of this disclosure requirement.
There is no understanding between any executive officer and any other person pursuant to which the executive officer was
selected.
John P. Groetelaars, 54, was elected President and Chief Executive Officer of Hillrom, effective May 2018. Previously, Mr.
Groetelaars was Executive Vice President and President of Becton, Dickinson and Company’s (“BD”) Interventional Segment.
Prior to the BD acquisition of C.R. Bard, Mr. Groetelaars was Group President at Bard, which he had joined in 2008. He
previously held positions of increasing responsibility with Boston Scientific Corporation, Guidant Corporation and Eli Lilly.
Barbara W. Bodem, 52, was elected Senior Vice President and Chief Financial Officer, effective December 2018. Before
joining Hillrom, she served as Senior Vice President, Finance at Mallinckrodt. Previously, she served in a variety of senior
finance roles for Hospira, Inc. and Eli Lilly, including serving as CFO of Lilly Oncology.
Amy Dodrill, 47, was elected Senior Vice President and President, Surgical Solutions, effective June 2019. She had previously
served as Vice President of our U.S. Surgical Solutions sales operations and prior to that, as an area vice president in our Patient
Support Systems business since joining Hillrom in October 2011. Before joining Hillrom, she held several senior leadership
roles at DynaVox Systems LLC and GE Healthcare.
Andreas G. Frank, 44, was elected Senior Vice President and President, Front Line Care, effective December 2018. He
previously served as Chief Transformation Officer and Senior Vice President Corporate Development and Strategy, since
joining Hillrom in October 2011. Before joining Hillrom, he was Director, Corporate Development at Danaher Corporation.
Previously, he worked in the Corporate Finance and Strategy practice at the consulting firm McKinsey & Company.
Paul Johnson, 55, was elected as Senior Vice President and President of Patient Support Systems, effective November 2016. He
had previously served as President, PSS North America, since joining Hillrom in February 2013. Before joining Hillrom, he
held various commercial leadership positions at Life Technologies and GE Healthcare.
Mary Kay Ladone, 54, was elected Senior Vice President, Corporate Development, Strategy and Investor Relations, effective
December 2018. She previously served as Vice President, Investor Relations, since joining Hill-Rom in July 2016. Before
9
Table of Contents
joining Hillrom, she served as Senior Vice President, Investor Relations, of Baxalta Incorporated. Previously, she served in a
variety of senior finance, business development and investor relations roles for Baxter International.
Kenneth Meyers, 58, was elected Senior Vice President and Chief Human Resources Officer, effective September 2015. Before
joining Hillrom, he was Senior Vice President and Chief Human Resources Officer at Hospira, Inc. Previously, he was a partner
at Mercer / Oliver Wyman Consulting. Prior to Mercer / Oliver Wyman, he served as Senior Vice President, Human Resources,
for Starbucks International.
Deborah M. Rasin, 54, was elected Senior Vice President, Chief Legal Officer and Secretary, effective January 2016. Before
joining Hillrom, she was General Counsel for Dentsply International Inc. Previously, she served as General Counsel at
Samsonite Corporation and as a senior attorney at General Motors.
Richard M. Wagner, 52, was elected Vice President, Controller and Chief Accounting Officer, effective May 2018. Before
joining Hillrom, he was Vice President, Finance at Cree, Inc. and prior to that role, he served as Vice President, Corporate
Controller at Dentsply Sirona, Inc.
Availability of Reports and Other Information
Our website is www.hillrom.com. We make available on this website, free of charge, access to our annual, quarterly and current
reports and other documents we file with, or furnish to, the SEC as soon as practicable after such reports or documents are filed
or furnished. We also make available on our website position specifications for the Chairperson, members of the Board of
Directors (“Board”) and the Chief Executive Officer, our Global Code of Conduct (and any amendments or waivers), the
Corporate Governance Standards of our Board and the charters of each of the standing committees of the Board. All of these
documents are also available to shareholders in print upon request.
Item 1A.
RISK FACTORS
Our business involves risks related to economic, market, regulatory and legislative factors in the jurisdictions in which we
operate. The following information about these risks should be considered carefully together with the other information
contained herein. The risks described below are not the only risks faced by Hillrom. Additional risks not currently known or
considered immaterial also might result in adverse effects on our business. Any of these risks could have a material adverse
impact on our business, financial condition, future results or cash flows. The order in which these factors appear should not be
construed to indicate their relative importance or priority.
COVID-19 Risks
Our business, results of operations, financial condition and prospects could be materially and adversely affected by the
ongoing COVID-19 pandemic and the related effects on public health.
In December 2019, there was an outbreak of a novel strain of coronavirus (COVID-19) in China that has since spread to nearly
all regions of the world. The outbreak was subsequently declared a pandemic by the World Health Organization in March 2020.
To date, the COVID-19 outbreak and preventive measures taken to contain or mitigate the outbreak have caused, and are
continuing to cause, business slowdowns or shutdowns in affected areas and significant disruption in global financial markets.
In response to the COVID-19 pandemic and related mitigation measures, we implemented changes in our business in March
2020 to protect our employees and customers through appropriate health and safety protocols. For example, we installed
physical barriers between employees in production facilities, implemented extensive cleaning and sanitation processes for both
production and office administration spaces, and implemented broad work-from-home initiatives for employees in our
administrative functions. Implementing these measures resulted in additional costs in fiscal 2020, which we expect will
continue in fiscal 2021 as we work to address employee safety. These additional costs did not have a material impact on our
Statements of Consolidated Income during fiscal 2020, and we anticipate a similar impact for fiscal 2021.
Although we experienced some challenges in connection with the COVID-19 pandemic, including declines in revenue related
to project delays in our care communications business and reduced demand for certain of our patient exam and diagnostic
products, at this time, we have not experienced a negative impact on our liquidity or results of operations. While we generally
expect the level of demand for our products negatively impacted by the COVID-19 pandemic to recover as we progress through
fiscal 2021, we are unable to predict the ultimate impact of the COVID-19 outbreak, including the nature and timing of when
10
Table of Contents
demand recovery may occur. The continued spread of COVID-19 could negatively impact our business, results of operations,
financial condition and prospects in a number of ways in the future. For example, it could, among other things:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
interrupt, slow, or render our supply chains inoperable, resulting in more expensive alternative sources of labor and
materials or an inability to find such alternative sources of labor and materials for our products;
subject us to governmental mandates and quarantines that may require forced shutdowns of our facilities for extended
or indefinite periods due to public health measures;
increase regulation of our industry, up to and including the exercise of war powers under The Defense Production Act
of 1950, as amended, which could require us to turn over our production capabilities to the U.S. Government;
substantially interfere with general commercial activity related to our customer base if our customers' businesses are
affected by the outbreak, including through delays or reductions of purchases of our products;
diminish our ability to adequately predict customer demand for our products, which could adversely impact our ability
to effectively manage inventory levels;
cause health care providers to limit or restrict access to their facilities to only essential personnel for a material amount
of time, adversely impacting our ability to complete installations of our care communications offerings and operating
room equipment, and limiting contact with our sales personnel;
reduce the number of ambulatory care or office visits if health care providers prioritize pandemic-related treatment and
governmental and industry associations recommend the deferral of elective surgeries;
cause our employees, including key executives, our production and service workforce and functional team members to
become ill, quarantined or otherwise unable to work or travel due to health reasons or governmental restrictions;
increase absenteeism or cause workplace disruption related to employees working from home or remotely;
contribute to adverse changes in general domestic and global economic conditions, including recession or economic
slowdown and disruption of domestic and international credit markets, which could negatively impact our customers'
ability to pay us as well as our ability to access capital that could in the future negatively affect our liquidity;
result in the establishment of trade barriers that disrupt the flow of goods and increase costs associated with logistics
and transportation;
decrease our ability to grow our business through mergers, acquisitions and other similar business arrangements during
any such pandemic or other outbreak as targets focus on operating their respective businesses;
negatively impact innovation and development of new products as our research and development (“R&D”) teams may
be required to work from home and resources and energy may be redirected during any such outbreak; or
contribute to a recession or market correction that could adversely affect the value of our common stock.
The situation surrounding the COVID-19 pandemic remains fluid, and given its inherent uncertainty, it could have an adverse
impact on our business in the future. The duration and extent of the impact from the COVID-19 pandemic depends on future
developments that cannot be accurately predicted at this time, such as the severity and transmission rate of the virus, the extent
and effectiveness of containment actions and the impact of these and other factors on our employees, customers, suppliers,
service providers and business partners. If COVID-19 continues to spread and escalate domestically or internationally, or if
governments impose additional measures intended to mitigate the spread and related effects of the pandemic, the risks described
above could be elevated significantly.
Should these conditions persist for a prolonged period, the COVID-19 pandemic, including any of the above factors and others
that are currently unknown, could have a material adverse impact on our business, results of operations, financial condition and
prospects and could heighten many of our known risks described in this Item 1A. Risk Factors, any of which could have a
material effect on us.
Regulatory Risks
We face significant uncertainty in our industry due to government health care reform, healthcare reform laws, changes
in Medicare, Medicaid and other governmental medical program reimbursements and for which we cannot predict how
such reforms will impact our operating results.
In March 2010, the U.S. Congress adopted and President Obama signed into law comprehensive health care reform legislation
through the passage of the Patient Protection and Affordable Health Care Act (H.R. 3590) and the Health Care and Education
Reconciliation Act (H.R. 4872) (collectively, “the Healthcare Reform Act”). The provisions of the Healthcare Reform Act are
intended to expand access to health insurance coverage and improve the quality of healthcare over time. However, other
provisions of the legislation, including Medicare provisions, aim to decrease costs through comparative effectiveness research,
and pilot programs to evaluate alternative payment methodologies could result in pricing pressure or negatively impact the
demand for our products.
11
Table of Contents
We cannot predict with certainty what additional future health care initiatives, if any, will be implemented at the federal or state
level, or what the ultimate effect of federal health care reform or any future legislation or regulation will have on us. Globally,
managed care organizations, such as Medicare and Medicaid in the United States, are facing increasing pressure to both control
health care utilization and to limit reimbursement. Changes in reimbursement programs or their regulations, including
retroactive and prospective rate and coverage criteria changes, competitive bidding for certain products and services, and other
changes intended to reduce expenditures (domestically or internationally), could adversely affect the portions of our businesses
that are dependent on third-party reimbursement or direct governmental payments. Moreover, to the extent that our healthcare
provider customers experience reimbursement pressure resulting in lower revenue for them, their demand for our products and
services might decrease. The impact of the above-mentioned items could have a material adverse impact on our business,
results of operations and cash flows.
Failure by us or our suppliers to comply with FDA regulations and similar foreign regulations applicable to the
products we design, manufacture, install or distribute could expose us to enforcement actions or other adverse
consequences.
We design, manufacture, install and distribute medical devices that are regulated by the FDA and similar agencies in other
countries. Failure to comply with applicable regulations could result in future product recalls, injunctions preventing the
shipment of products or other enforcement actions that could have a material adverse effect on our revenue and profitability.
Additionally, certain of our suppliers are subject to FDA regulations. The failure of these suppliers to comply with regulations
could adversely affect us as regulatory actions taken by the FDA against those manufacturers can result in product shortages,
recalls or modifications. We are also subject to the European Medical Device Regulation, which was adopted by the European
Union (“EU”) as a common legal framework for all EU member states. These regulations require companies that wish to
manufacture and distribute medical devices in EU member states to meet certain quality system and safety requirements and
ongoing product monitoring responsibilities, and obtain a “CE” marking (i.e., a mandatory conformity marking for certain
products sold within the European Economic Area) for their products. Various penalties exist for non-compliance with the laws
implementing the European Medical Device Regulations which if incurred, could have a material adverse impact on our
business, results of operations and cash flows.
We could be subject to substantial fines or damages and possible exclusion from participation in federal or state
health care programs if we fail to comply with the laws and regulations applicable to our business.
We are subject to stringent laws and regulations at both the federal and state levels governing the participation of durable
medical equipment suppliers in federal and state health care programs. From time to time, the government seeks additional
information related to our claims submissions, and in some instances government contractors perform audits of payments made
to us under Medicare, Medicaid, and other federal health care programs. On occasion, these reviews identify overpayments for
which we submit refunds. At other times, our own internal audits identify the need to refund payments. We believe the
frequency and intensity of government audits and review processes has grown and we expect this will continue in the future,
due to increased resources allocated to these activities at both the federal and state Medicaid level, and greater sophistication in
data review techniques.
If we are considered to have violated these laws and regulations, we could be subject to substantial fines, damages, possible
exclusion from participation in federal health care programs such as Medicare and Medicaid and possible recoupment of any
overpayments related to such violations. While we believe that our practices materially comply with applicable state and federal
requirements, the requirements might be interpreted in a manner inconsistent with our interpretation. Failure to comply with
applicable laws and regulations, even if inadvertent, could have a material adverse impact on our business.
Failure to comply with regulations due to our contracts with U.S. government entities could adversely affect our
business and results of operations.
Our business contracts with U.S. government entities are subject to specific rules, regulations and approvals applicable to
government contractors. U.S. government agencies often reserve the right to conduct audits and investigations of our business
practices to assure our compliance with these requirements. Our failure to comply with these or other laws and regulations
could result in contract terminations, suspension or debarment from contracting with the U.S. federal government, civil fines
and damages and criminal prosecution. In addition, changes in procurement policies, budget considerations, unexpected U.S.
developments, such as changes in the funding or structure of Department of Veterans Affairs or other government agencies to
which we sell our products and services, might adversely affect sales to U.S. government entities.
12
Table of Contents
Capital and Credit Risks
We have a substantial amount of indebtedness. This level of indebtedness could adversely affect our ability to raise
additional capital to fund operations, our flexibility in operating our business and our ability to react to changes in the
economy or our industry.
As of September 30, 2020, we had $1,878.0 million of indebtedness outstanding net of certain issuance costs. As a result of this
debt, we have significant demands on our cash resources. The level of debt could, among other things:
•
•
•
•
•
•
•
•
require us to dedicate a large portion of our cash flow from operations to the servicing and repayment of our debt,
thereby reducing funds available for working capital, capital expenditures, research and development expenditures and
other general corporate requirements;
limit our ability to obtain additional financing to fund future working capital, capital expenditures, research and
development expenditures and other general corporate requirements;
limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate,
including the continued impacts of COVID-19, which could require additional resources or a reallocation of capital to
respond to changing priorities;
restrict our ability to make strategic acquisitions or dispositions or to maximize business opportunities;
adversely affect our credit rating, with the result that the cost of servicing our indebtedness might increase;
adversely affect the market price of our common stock;
limit our ability to apply proceeds from an offering or asset sale to purposes other than the servicing and repayment of
debt; and
cause us to fail to meet payment obligations or otherwise default under our debt, which will give our lenders the right to
accelerate the indebtedness and exercise other rights and remedies against us.
In addition to the indebtedness we had outstanding as of the fiscal year ended September 30, 2020, we might incur substantial
additional indebtedness in the future, which could cause the related risks to intensify. We may refinance all or a portion of our
indebtedness on or before their respective maturities. We cannot provide assurances that we will be able to refinance any of our
indebtedness on commercially reasonable terms or at all. The terms of any additional debt might give the holders rights,
preferences, and privileges senior to those of holders of our common stock, particularly in the event of liquidation. The terms of
any new debt might also impose additional and more stringent restrictions on our operations than are currently in place. If we
are unable to refinance our debt, we might default under the terms of our indebtedness, which could lead to an acceleration of
the required repayment of the outstanding balance. We do not expect that we could repay all of our outstanding indebtedness if
the repayment of such indebtedness was accelerated.
Our variable rate indebtedness subjects us to interest rate risk, which could cause our debt service obligations to
increase significantly.
Borrowings under the Senior Credit Agreement and Securitization Facilities will be at variable rates of interest and expose us to
interest rate risk. If interest rates were to increase, our debt service obligations on the variable rate indebtedness would increase
even though the amount borrowed remained the same, and our net income and cash flows, including cash available for
servicing our indebtedness, will correspondingly decrease. Assuming all loans under the Senior Credit Agreement and
Securitization Facilities were fully drawn, each quarter point change in interest rates, excluding the effects of any interest rate
swap agreements, would result in a $5.9 million change in annual interest expense on our indebtedness under the Senior Credit
Agreement and Securitization Facilities. In the future, we may enter into additional interest rate swaps that involve the
exchange of floating for fixed rate interest payments in order to reduce interest rate volatility. However, we may not maintain
interest rate swaps with respect to all of our variable rate indebtedness, and any swaps we enter into may not fully mitigate our
interest rate risk.
Our Senior Credit Agreement, Securitization Facilities and certain derivative instruments use the London Interbank Offered
Rate (“LIBOR”) as a benchmark for establishing interest rates. On July 27, 2017, the United Kingdom’s Financial Conduct
Authority announced that it intends to phase out LIBOR by the end of December 2021. We may have to negotiate new credit
terms or potentially incur additional indebtedness that rely on an alternative interest rate method to LIBOR as a result of the
LIBOR phase out. Any legal or regulatory changes made in response to LIBOR’s future discontinuance may result in, among
other things, a sudden or prolonged increase or decrease in LIBOR, a delay in the publication of LIBOR, or changes in the rules
or methodologies in LIBOR. In addition, alternative methods to LIBOR may not yet have been established by the end of
December 2021, and the impact of such alternative methods may be impossible or impracticable to determine. While we do not
13
Table of Contents
expect that the transition from LIBOR will have a material adverse effect on our results of operations and cash flows, it is still
uncertain at this time.
Adverse developments in general domestic and worldwide economic conditions and instability and disruption of credit
markets could have an adverse effect on our operating results, financial condition, or liquidity.
We are subject to risks arising from adverse changes in general domestic and global economic conditions, including recession
or economic slowdown and disruption of domestic and international credit markets. The credit and capital markets could
experience extreme volatility and disruption that could lead to periods of recessionary conditions and depressed levels of
consumer and commercial spending. These recessionary conditions could cause customers to reduce, modify, delay or cancel
plans to purchase our products and services. If our customers reduce investments in capital expenditures or utilize their limited
capital funds to invest in products that we do not offer, it could negatively impact our operating results. Even if our revenue
remains constant, our profitability could decline if there is a shift to sales of product mix or geographic locations with less
favorable margins. Moreover, volatility in the credit markets could adversely affect our suppliers’ access to capital and
therefore their ability to continue to provide an adequate supply of the materials we use in our products and may result in higher
supply costs.
If worldwide economic conditions worsen, we would expect our customers to scrutinize costs resulting from pressures on
operating margin due to rising supply costs, reduced investment income and philanthropic giving, increased interest expense,
reimbursement pressure, reduced elective health care spending and uncompensated care.
Operating and Product Risks
We operate in a highly competitive industry that is subject to the risk of declining demand and pricing pressures, which
could adversely affect our operating results.
Demand for our products and services depends in large part on overall demand in the health care market. With the health care
market’s increased focus on hospital asset and resource efficiency as well as reimbursement constraints, spending for some of
our products could decline over time. Further, the competitive pressures in our industry could cause us to lose market share
unless we increase our commercial investments or reduce our prices, which could adversely impact our operating results.
The nature of this highly competitive marketplace demands that we successfully introduce new products into the market in a
cost-effective manner (more fully detailed below). These factors, along with possible legislative developments and others,
might result in significant shifts in market share among the industry’s major participants, which includes us. Accordingly, if we
are unable to effectively differentiate ourselves from our competitors in terms of new products and diversification of our
product portfolio through business acquisitions, then our market share, sales and profitability could be adversely impacted
through lower volume or decreased prices.
Our future financial performance will depend in part on the successful introduction of new products into the
marketplace in a cost-effective manner.
Our future financial performance will depend in part on our ability to influence, anticipate, identify and respond to changing
consumer preferences and needs, including those impacted by COVID-19, or a possible resurgence of COVID-19. We can
provide no assurances that our new products will achieve commercial acceptance in the marketplace. We might not correctly
anticipate or identify trends in customer preferences or needs or might identify them later than competitors do. In addition,
difficulties in manufacturing or in obtaining regulatory approvals might delay or prohibit introduction of new products into the
marketplace. Further, we might not be able to develop and produce new products at a cost that allows us to meet our goals for
profitability. We may not be able to obtain patent protection on our new products or be able to defend our intellectual property
rights globally. Warranty claims and service costs relating to our new products might be greater than anticipated, and we might
be required to devote significant resources to address any quality issues associated with our new products, which could reduce
the resources available for further new product development and other matters. In addition, the introduction of new products
might also cause customers to defer purchases of existing products.
Failure to successfully introduce new products in a cost-effective manner, or delays in customer purchasing decisions related to
the evaluation of new products, could cause us to lose market share and could materially adversely affect our business.
14
Table of Contents
We might not be able to grow or achieve expected cost savings or profitability if we are unable to successfully acquire
and integrate, or form business relationships with, other companies.
We have in the past, and expect in the future, to grow our business through mergers, acquisitions and other similar business
arrangements. We might not be able to identify suitable acquisition candidates or business relationships, negotiate acceptable
terms or receive necessary financing on acceptable terms for such acquisitions or relationships. Additionally, we might become
responsible for liabilities associated with businesses that we acquire to the extent they are not covered by indemnification from
the sellers or by insurance. Even if we can consummate acquisitions, such acquisitions could be dilutive to earnings and might
not be successfully integrated to fully realize the expected benefits. Our integration efforts might also divert management and
other resources from other important matters, and we could experience delays or unusual expenses in the integration process,
including intangible asset impairments, which could result in significant charges in our Consolidated Financial Statements
included under Part II, Item 8 of this Form 10-K. Moreover, the margins for these companies might differ from our historical
gross and operating margins resulting in a material adverse effect on our results of operations.
Our business is significantly dependent on major contracts with GPOs, IDNs, and certain other distributors and
purchasers.
A majority of our U.S. hospital sales and rentals are made pursuant to contracts with hospital GPOs. At any given time, we are
typically at various stages of responding to bids, negotiating and renewing expiring GPO agreements. Failure to be included in
certain of these agreements could have a material adverse effect on our business, including product sales and service and rental
revenue.
Our participation in such programs often requires increased discounting or restrictions on our ability to raise prices, and failure
to participate or to be selected for participation in such programs might result in a reduction of sales to the member hospitals. In
addition, the industry is showing an increased focus on contracting directly with health systems or IDNs (which typically
represent influential members and owners of GPOs). IDNs and health systems often make key purchasing decisions and have
influence over the GPO’s contract decisions, and often request additional discounts or other enhancements. Further, certain
other distributors and purchasers have similar processes to the GPOs and IDNs and failure to be included in agreements with
these other purchasers could have a material adverse effect on our business.
Our international sales and operations are subject to risks and uncertainties that vary by country and which could have
a material adverse effect on our business and/or results of operations. Compliance with international laws and
regulations, import and export limitations, trade agreements, anti-corruption laws, and exchange controls may be
difficult, burdensome and expensive.
International sales represent approximately 32% of our total sales in fiscal 2020. We anticipate that international sales will
continue to represent a significant portion of our total sales in the future. In addition, we have multiple manufacturing facilities
and third-party suppliers that are located outside of the United States. As a result, our international sales, as well as our sales in
the United States, of products produced or sourced internationally, are subject to risks and uncertainties that can vary by
country, such as political instability, economic conditions, foreign currency exchange rate fluctuations, changes in tax laws,
regulatory and reimbursement programs and policies, and the protection of intellectual property rights. COVID-19 could
contribute to these conditions or trigger legislative or regulatory responses that could directly or indirectly effect our business.
In addition, our collections of international receivables are subject to economic pressures and the actions of some governmental
authorities that have initiated various austerity measures to control health care and other governmental spending.
We are subject to compliance with various laws and regulations, including the U.S. Foreign Corrupt Practices Act, the U.K.
Bribery Act, and similar anti-bribery laws in other jurisdictions, which generally prohibit companies and their intermediaries
from making bribes or other improper payments to officials for the purpose of obtaining or retaining business. We are also
subject to limitations on trade with persons in sanctioned countries. Our exposure to international markets increases the inherent
risks of encountering such issues. While our employees, distributors and agents are required to comply with these laws and
regulations, no assurance can be given that our training and internal policies and procedures will always protect us from
violations of these laws, despite our commitment to legal compliance and corporate ethics. The failure to comply with these
laws and regulations could subject us to severe fines and penalties that could have a material impact on our financial condition,
results of operations and cash flows.
15
Table of Contents
We might not be successful in achieving expected operating efficiencies and sustaining or improving operating expense
reductions, and might experience business disruptions and adverse tax consequences associated with restructuring,
realignment and cost reduction activities.
Over the past few years, we have initiated several restructuring, realignment and cost reduction initiatives. While we expect to
realize efficiencies from these actions, these activities might not produce the full efficiency and cost reduction benefits we
expect. Further, such benefits might be realized later than expected, and the ongoing costs of implementing these measures
might be greater than anticipated. If these measures are not successful or sustainable, we might undertake additional
realignment and cost reduction efforts, which could result in future charges. Moreover, our ability to achieve our other strategic
goals and business plans might be adversely affected and we could experience business disruptions with customers and
elsewhere if our restructuring and realignment efforts and our cost reduction activities prove ineffective. These actions, the
resulting costs, and potential delays or potential lower than anticipated benefits might also impact our foreign tax positions and
might require us to record tax reserves against certain deferred tax assets in our international business.
We are involved on an ongoing basis in claims, lawsuits and governmental proceedings relating to our operations, as
well as product liability or other liability claims that could expose us to adverse judgments or could adversely affect the
sales of our products.
We are involved in the design, manufacture and sale of health care products, which face an inherent risk of exposure to product
liability claims if our products are alleged to have caused injury or are found to be unsuitable for their intended use. Amongst
other claims, we are, from time to time, a party to claims and lawsuits alleging that our products have caused injury or death or
are otherwise unsuitable. It is possible that we will receive adverse judgments in such lawsuits, and any such adverse judgments
could be material. Although we carry insurance with respect to such matters, this insurance is subject to varying deductibles and
self-insured retentions and might not be adequate to cover the full amount of any particular claim. In addition, any such claims
could negatively impact the sales of products that are the subject of such claims or other products.
Materials and Manufacturing Risks
Increased prices for, or unavailability of, raw materials or sub-assemblies used in our products could adversely affect
profitability or revenue. Specifically, our results of operations could be adversely affected by high prices for metals, fuel,
plastics and other petroleum-based products, and the impact of U.S. and foreign legislation, regulations and trade
agreements relating to the materials we import. We also rely on single suppliers for the procurement of several raw
materials and sub-assemblies.
Our profitability is affected by the prices and availability of the raw materials and sub-assemblies used in the manufacture of
our products. These prices might fluctuate based on many factors beyond our control, including, but not limited to, changes in
supply and demand, general economic conditions, including the ongoing impact of COVID-19, or a possible resurgence of
COVID-19, labor costs, fuel related delivery costs, competition, and currency exchange rates. Our business is also subject to
risks associated with U.S. and foreign legislation, regulations and trade agreements relating to the materials we import,
including quotas, duties, tariffs or taxes, and other charges or restrictions on imports, which could adversely affect our
operations and our ability to import materials used in our products at current or increased levels. We cannot predict whether
additional U.S. and foreign customs quotas, duties (including antidumping or countervailing duties), tariffs, taxes or other
charges or restrictions, requirements as to where raw materials must be purchased, additional workplace regulations or other
restrictions on our imports will be imposed in the future or adversely modified, or what effect such actions would have on our
costs of operations. Future quotas, duties or tariffs may have a material adverse effect on our business, financial condition,
results of operations or cash flows. Future trade agreements could also provide our competitors with an advantage over us, or
increase our costs, either of which could have a material adverse effect on our business, financial condition, results of
operations or cash flows.
Significant increases in the cost of raw materials or sub-assemblies that cannot be recovered through increased prices of our
products could adversely affect our results of operations. There can be no assurance that the marketplace will support higher
prices or that such prices and productivity gains will fully offset any commodity cost increases in the future. We generally have
not engaged in hedging transactions with respect to raw material purchases but do enter into fixed price supply contracts at
times. Future decisions not to engage in hedging transactions or ineffective hedging transactions might result in increased cost
volatility, potentially adversely impacting our profitability.
Our dependency upon regular deliveries of supplies from certain suppliers means that interruptions or stoppages in such
deliveries could adversely affect our operations until arrangements with alternate suppliers could be made. Several of the raw
materials and sub-assemblies used to manufacture our products currently are procured only from a single source. If any of these
16
Table of Contents
single-source suppliers were unable or unwilling to deliver these materials for an extended time, we might not be able to
manufacture one or more products and our business could suffer. We might not be able to find acceptable alternatives, and any
such alternatives could result in increased costs.
The majority of our products are manufactured at a single facility or location, and the material damage or loss of, or
partial or complete labor-related work stoppage at, one or more of these facilities or locations could prevent us from
manufacturing some of the various products we sell.
We manufacture most of our products in a single facility or location. If an event (including any weather or natural disaster or
disruptions in connection with COVID-19) occurred that resulted in material damage or loss of, or partial or complete labor-
related work stoppage at, one or more of these manufacturing facilities or we lacked sufficient labor to fully operate the facility,
we might be unable to transfer manufacturing of the relevant products to another facility or location in a cost-effective or timely
manner, if at all. This potential inability to transfer production could occur for several reasons, including but not limited to a
lack of necessary relevant manufacturing capability at another facility, or the regulatory requirements of the FDA or other
governmental regulatory bodies. Such an event could materially negatively impact our financial condition, results of operations
and cash flows.
We might be adversely affected by regulations relating to conflict minerals.
The SEC has adopted rules regarding disclosure for public companies whose products contain conflict minerals (commonly
referred to as tin, tantalum, tungsten and gold) that originate from the Democratic Republic of the Congo (“DRC”) and/or
adjoining countries. The implementation of these requirements could adversely affect the sourcing, availability and pricing of
materials used in the manufacturing of our products. In addition, we will incur additional costs to comply with the disclosure
requirements, including costs related to determining the source of any of the relevant minerals used in our products. Since our
supply chain is complex and multilayered, we might be unable to ascertain with sufficient certainty the origins for these
minerals despite our due diligence procedures, which in turn might harm our reputation. We might also face difficulties in
satisfying customers who might require that our products be certified as DRC conflict free, which could harm our relationships
with these customers and/or lead to a loss of revenue. These requirements also could have the effect of limiting the pool of
suppliers from which we source these minerals, and we might be unable to obtain conflict-free minerals at prices similar to the
past, which could increase our costs and adversely affect our manufacturing operations and our profitability.
Employee and Pension Plan Risks
The assets in our pension plans are subject to market disruptions. In addition, our pension plans are underfunded.
Our primary pension plan invests in a variety of equity and debt securities subject to market risks. In addition, our pension plans
are underfunded by $80.1 million based on our projected benefit obligation and fair value of plan assets as of September 30,
2020. Market volatility and disruption could cause declines in asset values or fluctuations in assumptions used to value our
liability and expenses. If this occurs, we might need to make additional pension plan contributions and our pension expense in
future years might increase.
A portion of our workforce is unionized, and we could face labor disruptions that would interfere with our operations.
Approximately 8% of our employees in the United States (including contingent workers) work under collective bargaining
agreements. Approximately 65% of our employees outside the United States (including contingent workers) work under various
collective bargaining arrangements and/or national trade union agreements. Although we have not recently experienced any
significant work stoppages as a result of labor disagreements, we cannot ensure that such a stoppage will not occur in the future.
The two collective bargaining agreements at our primary U.S. manufacturing facility expire in January 2021 and January 2022,
respectively. Our inability to negotiate satisfactory new agreements or a labor disturbance at one of our principal facilities could
have a material adverse effect on our operations.
We might not be able to attract, retain and develop key personnel.
Our future performance depends in significant part upon the continued service of our executive officers and other key
personnel. The loss of the services of one or more of our executive officers or other key employees could have a material
adverse effect on our business, prospects, financial condition and results of operations. Our success also depends on our
continuing ability to attract, retain and develop highly qualified personnel, and as competition for such personnel is intense,
there can be no assurance that we can do so in the future.
17
Table of Contents
Cybersecurity and Information Technology Risks
The rationalization and transformation of our Enterprise Resource Planning (“ERP”) software solutions and other
information technology systems could result in significant disruptions to our operations.
We are in the process of rationalizing and transforming our ERP software solutions and other complementary information
technology systems, which is expected to be completed over the next several years. The implementation of these solutions and
systems is highly dependent on the coordination of numerous software and system providers and internal business teams. We
could experience changes in our operational processes and internal controls, which in turn could require significant capital
investments and change management, including recruiting and training of qualified personnel. The interdependence of these
solutions and systems is key to the successful completion of the initiatives. The failure of any one solution or system could have
a significant impact on our business processes and information systems, including loss or corruption of data, delayed shipments,
decreases in productivity as our personnel and third-party providers implement and become familiar with new systems,
increased costs and lost revenues, which could have an adverse effect on our overall information technology infrastructure and
as a result, could have an adverse impact on our business, results of operations and cash flows.
Difficulties in implementing new or upgraded information systems or system failures could also result in significant disruptions
to our business, the incurrence of unanticipated expenses and the diversion of management’s attention from key strategic
initiatives and could have a material adverse effect on our capital resources, financial condition, results of operations or cash
flows.
We are increasingly dependent on the consistent functioning of our information technology and cybersecurity systems
along with our information technology dependent product portfolios. If we are exposed to any intrusions, disruptions,
corruption, or destruction, or if we fail to maintain the integrity of our systems or products, or the privacy of our data,
our business and our reputation could be materially adversely affected.
We are increasingly dependent on consistent functioning of our information technology and cybersecurity systems for our
infrastructure and software-based products. Our information systems require an ongoing commitment of significant resources to
maintain, protect, and enhance existing systems and develop new systems to keep pace with continuing changes in information
processing technology, regulatory standards, integration of acquisitions, and the increasing need to protect patient, customer
and supplier information. The new EU-wide General Data Protection Regulation (“GDPR”), which became applicable on May
25, 2018, imposes more stringent data protection requirements and provides for greater penalties for noncompliance. Our
products include technologies that support connectivity and decision support infrastructure, which could be subject to intrusion,
disruption or corruption and could impact the quality of care patients receive or the confidentiality of patient information. In
addition, third parties might attempt to hack into our products or systems and might obtain proprietary information. As a result
of the COVID-19 pandemic, we may face increased cybersecurity risks due to our reliance on internet technology and the
number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit
vulnerabilities. If we fail to maintain or protect our information technology and cybersecurity systems and information
technology dependent products effectively, we could lose existing customers or suppliers, have difficulty attracting new
customers or suppliers, have problems that adversely impact internal controls, have difficulty preventing, detecting and
controlling fraud, have disputes with customers and suppliers, have regulatory sanctions or penalties imposed, have increases in
operating expenses, incur expenses or lose revenues as a result of a data privacy breach, or suffer other adverse consequences.
Any significant breakdown, intrusion, interruption, corruption, or destruction of these systems, as well as any data breaches,
could have a material adverse effect on our business.
Tax Risks
Unfavorable outcomes related to uncertain tax positions could result in significant tax liabilities.
We have recorded tax benefits related to various uncertain tax positions taken or expected to be taken in a tax return. While we
believe our positions are appropriate, the U.S. Internal Revenue Service (“IRS”), state or foreign tax authorities could disagree
with our positions, which could result in a significant tax payment.
18
Table of Contents
General Risk Factors
Our stock price and trading volume has been, and may continue to be, volatile from time to time and we might
experience continued fluctuations in the future that could negatively impact the value of our outstanding shares.
The market for our common stock has, from time to time, experienced significant price and volume fluctuations that might have
been unrelated to our operating performance. We believe that a variety of factors could cause the price of our common stock to
fluctuate, perhaps substantially, including:
•
•
•
•
•
•
•
•
•
•
•
•
new, or changes in, analyst recommendations, guidelines or studies that could affect the use of our products;
announcements and rumors of developments related to our business, including changes in reimbursement rates or
regulatory requirements, proposed and completed acquisitions, or the industry in which we compete;
published studies and reports relating to our products and markets in which we participate;
quarterly fluctuations in our actual or anticipated operating results;
general conditions in the U.S. or worldwide economy, including the impact of COVID-19 that has spread globally;
our stock repurchase program;
announcements of technological innovations;
new products or product enhancements by us or our competitors;
developments in patents or other intellectual property rights and litigation;
developments in relationships with our customers and suppliers;
the implementation of health care reform legislation and the adoption of additional reform legislation in the future; and
the ability to or extent of integrating our acquisitions.
Any such fluctuations in the future could adversely affect the market price of our common stock.
Item 1B.
UNRESOLVED STAFF COMMENTS
We have not received any comments from the staff of the SEC regarding our periodic or current reports that remain unresolved.
19
Table of Contents
Item 2.
PROPERTIES
The principal properties used in our operations are listed below. All facilities are suitable for their intended purpose, are being
efficiently utilized and are believed to provide adequate capacity to meet demand for the next several years.
Description and Primary Use
Owned/Leased
Location
Acton, MA
Batesville, IN
Cary, NC
Charleston, SC
Chicago, IL
Irvine, CA
Milwaukee, WI
Sarasota, FL
St. Paul, MN
Skaneateles Falls, NY
Suzhou, China
Taicang, China
Pluvigner, France
Puchheim, Germany
Light manufacturing, development and distribution of health care
products; Office administration
Manufacturing, development and distribution of health care products;
Office administration
Development of health care products; Office administration
Light manufacturing and distribution of health care products;
Office administration
Corporate headquarters; Office administration
Manufacturing, development and distribution of health care products;
Office administration
Manufacturing, development and distribution of health care products;
Office administration
Development and distribution of health care products; Office
administration
Office administration and distribution of health care products; Service
center
Manufacturing, development and distribution of health care products;
Office administration
Manufacturing of health care products
Light manufacturing and distribution of health care products
Manufacturing, development and distribution of health care products;
Office administration
Development of health care products; Office administration
Saalfeld, Germany
Manufacturing, development and distribution of health care products;
Office administration
Navan, County Meath, Ireland Office administration
Bologna, Italy
Tijuana, Mexico
Monterrey, Mexico
Development of heath care products; Office administration
Manufacturing and distribution of health care products; Office
administration
Manufacturing of health care products; Office administration
Amsterdam, Netherlands
Office administration
Singapore
Luleå, Sweden
Development of health care products; Office administration
Manufacturing and distribution of health care products;
Office administration
Leased
Owned
Leased
Leased
Leased
Leased
Owned
Leased
Leased
Owned
Leased
Leased
Owned
Owned/Leased
Owned
Owned
Leased
Leased
Owned
Leased
Leased
Owned
In addition to the foregoing, we lease a number of warehouse distribution centers, service centers, sales offices and other
facilities throughout the United States, Australia, Canada, Western Europe, Mexico, Middle East, the Far East, and Latin
America.
20
Table of Contents
Item 3.
LEGAL PROCEEDINGS
See Note 16. Commitments and Contingencies of our Consolidated Financial Statements included under Part II, in Item 8 of
this Form 10-K for information regarding legal proceedings in which we are involved.
Item 4.
MINE SAFETY DISCLOSURES
Not applicable.
Item 5.
MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS
AND ISSUER PURCHASES OF EQUITY SECURITIES
Market Information and Shareholders
Our common stock is traded on the New York Stock Exchange under the ticker symbol HRC and there are approximately
80,200 shareholders of record.
Dividends
The declaration and payment of cash dividends is at the sole discretion of our Board and depends upon many factors, including
our financial condition, earnings potential, capital requirements, alternative uses of cash, covenants associated with debt
obligations, legal requirements, and other factors considered relevant by our Board. We have paid cash dividends on our
common stock every quarter since our initial public offering in 1971. We intend to continue to pay quarterly cash dividends
comparable to those paid in the periods covered by the Consolidated Financial Statements included within Item 8 of Part II of
this Form 10-K.
Issuer Purchases of Equity Securities
Period
July 1, 2020 - July 31, 2020
August 1, 2020 - August 31, 2020
September 1, 2020 - September 30, 2020
Total
Total
Number
of Shares
Purchased 1
714 $
50 $
132 $
896
Average
Price Paid
per Share
111.80
95.39
82.49
Total Number
of Shares
Purchased as
Part of Publicly
Announced Plans
or Programs
Approximate
Dollar Value
of Shares That
May Yet Be
Purchased Under
the Programs 2
— $
— $
— $
—
163.4
163.4
163.4
1 Shares purchased in the quarter ended September 30, 2020 were in connection with employee payroll tax withholding for
restricted stock distributions.
2 In September 2019, the Board approved an additional $170.0 million for share repurchases. The below table reflects the date
of Board approval, the authorized dollar value of the shares to be repurchased under each approval and the availability to
repurchase as of September 30, 2020. There is no expiration date or plans to terminate this program in the future.
Board Approval Date
November 2017
September 2019
Totals
Authorized Dollar
Value
Dollar Value of
Shares Purchased
Prior to Fiscal 2020
Dollar Value of
Shares Purchased in
Fiscal 2020
Availability to
Purchase as of
September 30, 2020
150.0
170.0
102.5
—
$
320.0 $
102.5 $
47.5
6.6
54.1 $
—
163.4
163.4
21
Table of Contents
Stock Performance Graph
The following graph compares the return on our common stock with that of Standard & Poor’s 500 Stock Index (“S&P 500”)
and our peer groups* for each of the last five fiscal years ended September 30. The composition of our current peer group (the
“2020 Peer Group”) has not changed since the date of our Annual Report on Form 10-K for fiscal 2019. The 2020 Peer Group
is aligned with the peer group used in our most recent compensation study done for executive compensation purposes. The
graph below assumes that the value of the investment in our common stock, the S&P 500 and our 2020 Peer Group was $100
on October 1, 2015 and that all dividends were reinvested.
HRC
S&P 500
2020 Peer Group
2015
2016
2017
2018
2019
2020
$
100 $
100
100
119 $
113
132
142 $
131
153
182 $
152
198
202 $
155
214
161
175
261
*
For purposes of the Stock Performance Graph above, our 2020 Peer Group is comprised of: Agilent Technologies,
Inc., Avanos Medical, Inc. (formerly Halyard Health, Inc.), Bio-Rad Laboratories, Inc., Bruker Corporation, The
Cooper Companies, Inc., Dentsply Sirona, Inc., Edwards Lifesciences Corporation, Hologic, Inc., Intuitive Surgical,
Inc., Mednax, Inc., Patterson Companies, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, ResMed, Inc., Steris
plc, Teleflex Incorporated, Varian Medical Systems, Inc., Waters Corporation and West Pharmaceutical Services, Inc.
Certain other information required by this item will be contained under the caption “Equity Compensation Plan Information” in
our definitive Proxy Statement to be delivered to shareholders in connection with the Annual Meeting of Shareholders to be
held on March 10, 2021, and such information is incorporated herein by reference.
22
Table of Contents
Item 6.
SELECTED FINANCIAL DATA
PART II
The following table presents our selected consolidated financial data for each of the last five fiscal years ended September 30.
The data included below should be read together with Item 7 of Part II of this Form 10-K, Management's Discussion and
Analysis of Financial Condition and Results of Operations, and Item 8 of Part II of this Form 10-K, Financial Statements and
Supplementary Data, and related notes to Consolidated Financial Statements.
(In millions, except per share data)
2020
2019
2018
2017
2016
Net revenue
Net income
Net income attributable to common shareholders
Net income attributable to common shareholders per basic share
Net income attributable to common shareholders per diluted
share
Total assets
Long-term obligations
Cash flows from operating activities
Capital expenditures
Cash flows from investing activities
Cash flows from financing activities
Cash dividends per basic share
$ 2,881.0 $ 2,907.3 $ 2,848.0 $ 2,743.7 $ 2,655.2
223.0
223.0
3.35
152.2
152.2
2.28
252.4
252.4
3.81
132.3
133.6
2.04
122.8
124.1
1.90
3.32
2.25
3.73
1.99
1.86
4,671.1
4,919.0
4,360.0
4,528.7
4,262.4
1,655.7
1,783.1
1,790.4
2,120.4
1,938.4
481.7
105.9
401.4
73.4
395.2
89.5
311.1
97.5
281.2
83.3
(131.2)
(249.0)
(82.4)
(389.4)
(97.7)
(695.0)
304.7
(356.6)
0.87
0.83
0.78
70.6
0.71
(141.9)
0.67
23
Table of Contents
Item 7.
Overview
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
Hill-Rom Holdings, Inc. (“we,” “us,” or “our”) is a global medical technology leader whose approximately 10,000 employees
have a single purpose: enhancing outcomes for patients and their caregivers by Advancing Connected Care™. Around the
world, our innovations touch over 7 million patients each day. Our products and services help enable earlier diagnosis and
treatment, optimize surgical efficiency and accelerate patient recovery while simplifying clinical communication and shifting
care closer to home. We make these outcomes possible through connected smart beds, patient lifts, patient assessment and
monitoring technologies, caregiver collaboration tools, respiratory health devices, advanced equipment for the surgical space
and more, delivering actionable, real-time insights at the point of care.
Industry Trends
The unprecedented COVID-19 global pandemic placed significant pressure on health care providers globally. Not only did
health systems manage the real and anticipated influx of infectious patients through emergent response, they were required to
address a variety of factors including ensuring appropriate critical care capacity, facilitating supply chain needs for personal
protective equipment (“PPE”) and high demand medical devices and addressing ongoing staffing challenges. The resulting
focus on COVID-19 patients resulted in mandates to reduce elective surgeries, effectively reducing a key health system revenue
source, placing financial pressure on providers. We expect consumers to continue to be wary about visiting healthcare facilities,
driving continued demand for telehealth and care in lower acuity settings.
We see the pandemic representing a force which has and will continue to accelerate several global health care trends:
Telehealth and Remote Care. COVID-19 essentially accelerated the need and greater acceptance of virtual care. Although
available for some time, the adoption of telehealth virtual visits has gained wide acceptance from patients, providers and more
importantly payers. We see this trend continuing and the environment is ripe for continued growth. Additionally, with shortages
of physician specialties, telemedicine (i.e., eICU) within the walls of the hospitals will also increase due to the need for access
and the desire for lower cost care.
Digital Transformation. Connected care cannot only take place through virtual means, but also through the digital
transformation of connected devices and decision support tools. Providers will utilize communication tools, sensors, wearables,
artificial intelligence and predictive analytics to generate meaningful and real-time information about patients to maximize
clinical insights, improve workflow, enable earlier intervention and enhance the patient’s experience.
Lower Cost Care Settings. Growing pressure on health care costs are resulting in a continued migration of care from the acute
care hospital into lower cost care settings. We believe that this trend increases the demand for more solutions to care for these
patients, many of whom are medically complex, in lower acuity settings such as ambulatory surgery centers, outpatient centers
and the home. Opportunities include improved medical technologies, remote monitoring, communication solutions and
information technologies.
Provider Consolidation. The financial pressures experienced via COVID-19 place an even greater chasm between providers
that can weather hardship and those that cannot. We expect economic considerations, competition and other factors will lead to
ongoing consolidation of customers.
Economic and Clinical Value. The overriding importance of improved quality of care metrics will maintain the focus on
improving outcomes related to pressure injuries, patient falls, patient deterioration and sepsis. Hospitals may experience
reduced reimbursement for hospital-acquired adverse events, creating a stronger connection between these adverse events and
hospital revenue levels. Therefore, we believe that health care providers will seek to do business with partners that can
demonstrate improved clinical, and consequently, economic outcomes.
Demand for Health Care Services. Patient and provider demand for health care products and services is expected to continue to
grow over the long-term as a result of many factors, including an aging population and an increasing number of chronic patients
across all care settings, including hospitals, extended care facilities, outpatient settings and in the home. At the same time,
health care providers will also be under continued pressure to improve efficiency and control costs.
24
Table of Contents
Strategic Priorities
We believe we have aligned our strategic priorities to accommodate the evolving global health care landscape.
Advancing category leadership with differentiated solutions and innovation. Health care systems today are challenged to treat
the rising incidence of complex diseases and conditions while reducing costs, increasing efficiency and improving patient
outcomes. We are well positioned to meet demand for innovative, differentiated solutions that drive a clear value proposition
for customers. We are executing on a strong pipeline of impactful medical technologies, communication tools and information
technologies to build on our category leadership and provide caregivers the products and solutions needed to enhance patient
care and outcomes.
Expanding internationally and penetrating emerging markets. International markets continue to expand access to health care for
their growing populations, presenting significant opportunity to expand our presence with our differentiated solutions. By
focusing on product categories and innovations with the highest growth potential, coupled with our ‘One Hillrom’ approach to
enhance our strong global channel and footprint, we will continue to enhance our international presence, penetrate emerging
markets, and drive accelerated growth.
Transforming the portfolio with select business development and optimization initiatives. Business development has played an
important role in our transformation in the last several years, by strengthening and diversifying the portfolio. We will continue
to deploy capital on opportunities that align with our strategy and meet our financial objectives. We enhanced our growth
prospects by divesting non-strategic assets and redirecting resources to advance category leadership in higher-growth, higher-
margin opportunities. We will continue to evaluate and pursue opportunities that further optimize our business portfolio.
Driving operational execution and strong financial performance. Investing to support future growth is key to our success, while
maintaining strong financial discipline and operational performance. We are executing on a variety of initiatives to drive
operating efficiencies, including consolidation of our manufacturing footprint, lowering sourcing costs, improving productivity,
and optimizing business processes. Savings generated from these actions will provide flexibility to reinvest in strategic
priorities to drive growth, including continued innovation to drive category leadership and investments to further our
international presence, particularly in emerging markets.
The Impacts of COVID-19 on Hillrom
COVID-19 has impacted global economies as travel, leisure and discretionary consumer spending has reduced significantly
causing companies to make commensurate changes to their investments, human capital, and financial outlooks. The United
States and countries around the world continue to take precautionary and preventive measures to reduce the spread of
COVID-19.
Revenues and Customers
Hillrom experienced significant fluctuations in demand across its portfolio of products as health care customers prioritized the
treatment of patients diagnosed with COVID-19. We experienced a significant increase in demand for select products within
Patient Support Systems and Front Line Care used in the treatment of COVID-19 patients. For the fiscal year ended September
30, 2020, we recognized revenue of approximately $180 million related to non-recurring demand for respiratory health
ventilators, intensive care unit and med-surg beds and specialty surfaces. We also experienced lower revenue in our care
communications business and Surgical Solutions business due to project delays resulting from hospital access restrictions and
delays in elective surgical procedures. Additionally, a decline in doctor office visits due to COVID-19 restrictions and concerns
resulted in lower demand for our products used within the physician practice setting.
For fiscal 2021, we expect hospitals and physician practices to advance toward more normal operating activities over the course
of our fiscal year with intermittent and localized impacts from COVID-19. We anticipate lower demand for products used to
treat COVID-19 as demand is less widespread than experienced early in the pandemic. We also anticipate a gradual recovery in
the demand for other products, such as information technologies and software solutions in Patient Support Systems, patient
diagnostic tools in Front Line Care and operating room infrastructure in Surgical Solutions. Our outlook for fiscal 2021 can be
affected by efforts across the world to control the spread of COVID-19 through improved testing and contact tracing and the
development and availability of an effective vaccine.
25
Table of Contents
Operations and Workforce
We experienced no significant supply chain constraints nor significant increases in supply costs, and we were able to secure raw
materials and components for manufacturing products in high demand due to COVID-19.
Our productions facilities have remained open and employment levels have remained consistent. Many employees in our
administrative functions have effectively worked remotely since mid-March. We have implemented the necessary precautions
to allow our employees to work safely and effectively in our manufacturing and service facilities. In other areas of the business,
we have adapted our processes and used technology to continue to effectively execute on our strategic priorities as well as daily
operating activities.
We will continue to assess our workforce requirements in response to evolving customer demand related to COVID-19.
As disclosed in Note 1. Summary of Significant Accounting Policies, we benefited from government programs within the
various jurisdictions in which we operate in the form of subsidies, incentives, cost relief and payment deferrals. Management
will continue to evaluate these opportunities as well as the related requirements or restrictions to support our operations and
workforce in a manner that allows us to continue to operate efficiently and effectively.
For further discussion, see the risk factor within Item 1. Business, Item 1.A Risk Factors, entitled “Our business, results of
operations, financial condition and prospects could be materially and adversely affected by the ongoing COVID-19
pandemic and the related effects on public health.”
Use of Non-GAAP Financial Measures
The accompanying Consolidated Financial Statements and related notes are presented in accordance with accounting principles
generally accepted in the United States (“GAAP”). In addition to the results reported in accordance with GAAP, we routinely
provide operating margin, income before taxes, income tax expense and earnings per diluted share results on an adjusted basis
as we believe these measures contribute to the understanding of our financial performance, provide additional analytical tools to
understand our results from core operations and reveal underlying operating trends. These measures exclude strategic
developments, acquisition and integration costs and related fair value adjustments, gains and losses associated with disposals of
businesses or significant product lines, regulatory costs related to updating existing product registrations to comply with the
European Medical Device Regulations, Special charges as described in Note 10. Special Charges of this Form 10-K, the
transitional impacts of the U.S. Tax Cuts and Jobs Act (the “Tax Act”), changes in tax accounting methods, and other tax law
changes as described in Note 11. Income Taxes of this Form 10–K, expenses associated with these tax items, the impacts of
significant litigation matters, certain impacts of the COVID-19 pandemic and other unusual events. We also exclude expenses
associated with the amortization of purchased intangible assets. These adjustments are made to allow investors to evaluate and
understand operating trends excluding their impact on operating income and earnings per diluted share.
Management uses these measures internally for planning, forecasting and evaluating the performance of the business. Investors
should consider these non-GAAP measures in addition to, not as a substitute for, or as superior to, measures of financial
performance prepared in accordance with GAAP.
In addition, we present certain results on a constant currency basis, which compares results between periods as if foreign
currency exchange rates had remained consistent period-over-period. We monitor sales performance on an adjusted basis that
eliminates the positive or negative effects that result from translating international sales into U.S. dollars. We calculate constant
currency by applying the foreign currency exchange rate for the prior period to the local currency results for the current period.
We believe that evaluating growth in net revenue on a constant currency basis provides an additional and meaningful
assessment to both management and investors.
Results of Operations
Fiscal Year Ended September 30, 2020 Compared to the Fiscal Year Ended September 30, 2019
In this section, we provide an overview of our results of operations. We disclose segment information that is consistent with the
way in which management operates and views the business.
26
Table of Contents
Net Revenue
(In millions)
Revenue:
Year Ended
September 30
2020
2019
Change
As
Reported
Constant
Currency
Change As
Reported
Change As
Reported
Constant
Currency
U.S.
OUS
Product sales and service
$ 2,571.2 $ 2,615.0
Rental revenue
309.8
292.3
Total net revenue
$ 2,881.0 $ 2,907.3
(1.7) %
6.0 %
(0.9) %
(1.3) %
6.1 %
(0.5) %
(6.0) %
7.4 %
(4.4) %
8.0 %
(3.1) %
7.5 %
9.3 %
(2.5) %
8.7 %
Revenue:
Patient Support Systems
$ 1,539.1 $ 1,490.5
Front Line Care
Surgical Solutions
1,025.0
316.9
978.1
438.7
Total net revenue
$ 2,881.0 $ 2,907.3
3.3 %
4.8 %
(27.8) %
(0.9) %
3.6 %
5.2 %
(27.6) %
(0.5) %
(0.1) %
1.0 %
(43.1) %
(4.4) %
14.1 %
14.4 %
15.6 %
16.0 %
(12.1) %
(11.9) %
7.5 %
8.7 %
OUS - Outside of the United States
Consolidated Revenue
Product sales and service revenue decreased 1.7% on a reported basis, and 1.3% on a constant currency basis for the fiscal year
ended September 30, 2020 compared to the fiscal year ended September 30, 2019. The decrease was the result of the
disposition of the surgical consumable products business in August 2019 and lower revenues as a result of COVID-19 within
Surgical Solutions. This decrease was partially offset by increased global revenue for Patient Support Systems and Front Line
Care, which primarily reflects the net impacts of COVID-19.
Rental revenue increased 6.0% on a reported basis, and 6.1% on a constant currency basis for the fiscal year ended September
30, 2020 compared to the fiscal year ended September 30, 2019. The increase was due to higher deployment of the Patient
Support Systems rental portfolio, which was primarily driven by COVID-19 patient needs.
Business Segment Revenue
Patient Support Systems revenue increased 3.3% on a reported basis and 3.6% on a constant currency basis for the fiscal year
ended September 30, 2020 compared to the fiscal year ended September 30, 2019. The increase was driven primarily by global
sales growth for intensive care unit and med-surg beds and increased U.S. rental revenues primarily due to COVID-19, as well
as recent acquisitions. The increase was partially offset by lower revenue in our care communications business due to project
delays resulting from hospital access restrictions. Revenue for the fiscal year ended September 30, 2020 does not reflect
approximately $2.4 million of revenue that was eliminated in fair value purchase accounting adjustments to deferred revenue
related to recent acquisitions.
Front Line Care revenue increased 4.8% on a reported basis and 5.2% on a constant currency basis for the fiscal year ended
September 30, 2020 compared to the fiscal year ended September 30, 2019. The increase was primarily driven by non-invasive
ventilator sales under U.S. federal and state government contracts as well as growth internationally in patient monitoring and
physical assessment tools primarily related to COVID-19. The increases were partially offset by a decline in doctor office visits
due to COVID-19 restrictions that resulted in lower demand for patient diagnostic tools, such as vision screening and
cardiology.
Surgical Solutions revenue decreased 27.8% on a reported basis and 27.6% on a constant currency basis for the fiscal year
ended September 30, 2020 compared to the fiscal year ended September 30, 2019, predominantly due to the disposition of the
surgical consumable products business in August 2019. Additionally, global revenues declined as a result of COVID-19-related
hospital access restrictions that delayed capital projects and installations, as well as deferred patient elective surgical
procedures. These decreases were partially offset by higher demand for integrated operating tables during the first six months of
fiscal 2020.
27
Table of Contents
Gross Profit
(In millions)
Gross Profit 1
Product sales and service
Percent of Related Net Revenue
Rental
Percent of Related Net Revenue
Total Gross Profit
Percent of Total Net Revenue
Year Ended September 30
2020
2019
$
1,311.3
$
1,284.3
51.0 %
49.1 %
163.8
52.9 %
140.7
48.1 %
$
1,475.1
$
1,425.0
51.2 %
49.0 %
1 Gross Profit is calculated as net product sales and service revenue and rental revenue less the related cost of goods sold or
rental expenses as disclosed on the face of the Statements of Consolidated Income.
Product sales and service gross profit increased by $27.0 million or 2.1% for the fiscal year ended September 30, 2020
compared to the fiscal year ended September 30, 2019. The increase in gross profit was primarily driven by increased sales
volume of higher margin products in Patient Support Systems and Front Line Care, which primarily reflects the impact on
demand for products used to treat COVID-19 patients. The increase in gross profit can also be attributed to strategic changes
including recent acquisitions and the disposition of the surgical consumable products business in August 2019, as well as
reduced costs due to improved efficiency in manufacturing and service activities.
Rental gross profit increased by $23.1 million or 16.4% for the fiscal year ended September 30, 2020 compared to fiscal year
ended September 30, 2019. The increase in rental gross profit was driven by higher volumes and lower servicing costs
associated with the Patient Support Systems rental portfolio due to increased rental durations for COVID-19 patients.
Operating Expenses
(In millions)
Research and development expenses
Percent of Total Net Revenue
Selling and administrative expenses
Percent of Total Net Revenue
Acquisition-related intangible asset amortization
Percent of Total Net Revenue
Year Ended September 30
2020
2019
136.5
$
139.5
4.7 %
4.8 %
820.4
$
818.6
28.5 %
28.2 %
109.0
$
122.4
3.8 %
4.2 %
$
$
$
Research and development expenses decreased by $3.0 million, or 2.2%, for the fiscal year ended September 30, 2020
compared to the fiscal year ended September 30, 2019 due to the timing of projects. As a percentage of revenue, Research and
development expenses remained relatively consistent.
Selling and administrative expenses remained relatively flat for the fiscal year ended September 30, 2020 compared to the fiscal
year ended September 30, 2019. Selling and administrative expenses increased by $1.8 million, or 0.2%, predominantly due to
increased information technology costs, investments in emerging markets and higher compensation costs related to annual merit
increases. The increase is partially offset by lower travel expenses due to COVID-19 and lower acquisition and integration
costs during fiscal 2020.
Acquisition-related intangible asset amortization decreased by $13.4 million, or 10.9%, for the fiscal year ended September 30,
2020 compared to the fiscal year ended September 30, 2019 primarily due to the disposition of the surgical consumable
products business in August 2019, offset partially by amortization of acquired intangibles as a result of recent acquisitions. See
Note 4. Goodwill and Intangible Assets for additional information.
28
Table of Contents
Special Charges and Other
(In millions)
Special charges
Interest expense
Loss on extinguishment of debt
Investment income (expense) and other, net
$
$
Year Ended September 30
2020
2019
41.5 $
28.4
(74.0) $
(15.6)
(6.9)
(89.6)
(3.3)
(14.6)
In connection with various transformative initiatives, restructuring and exit activities, and organizational changes to improve
our business alignment and cost structure we recognized Special charges of $41.5 million for the fiscal year ended September
30, 2020, compared to $28.4 million for the fiscal year ended September 30, 2019. These charges related to the initiatives
described in Note 10. Special Charges.
Interest expense decreased $15.6 million, or 17.4%, for the fiscal year ended September 30, 2020 compared to the fiscal year
ended September 30, 2019 due to lower borrowing rates from the refinancing of senior unsecured notes of $425.0 million in
September 2019 and a lower interest rate environment that resulted in lower interest cost for our variable rate debt under the
Note Securitization and Revolving Credit Facilities. See Note 5. Financing Agreements for additional information.
Loss on extinguishment of debt was $15.6 million and $3.3 million for the fiscal years ended September 30, 2020 and 2019
related to the refinancing of senior unsecured notes of $425.0 million in September 2019 and the refinancing of the then-
existing senior secured credit facilities maturing in 2021 (the ‘‘Prior Senior Secured Credit Facilities’’) in August 2019. See
Note 5. Financing Agreements for additional information.
Investment income (expense) and other, net for the fiscal year ended September 30, 2020 was expense of $6.9 million
comprised primarily of the recognition of a non-cash pension plan settlement loss of $8.5 million and $2.0 million of losses
related to our cost and equity method investments, which was partially offset by a $3.0 million gain that represented the step up
to fair value of the historical investment of a company that was fully acquired during fiscal 2020. Investment income (expense)
and other, net was expense of $14.6 million for the fiscal year ended September 30, 2019 comprised primarily of the loss
recognized for the disposition of our surgical consumable products business in August 2019. See Note 2. Supplementary
Financial Statement Information, Note 3. Business Combinations and Note 8. Retirement and Postretirement Benefit Plans for
additional information.
Income Tax Expense
The effective tax rate was 17.8% for the fiscal year ended September 30, 2020 compared to 27.0% for the fiscal year ended
September 30, 2019. The effective tax rate for fiscal 2020 was favorably impacted by the reduction of the contingent
consideration accrual of $8.4 million, that is not subject to tax. The effective tax rate for fiscal 2019 was higher primarily due to
unfavorable impacts from the disposition of a subsidiary and unfavorable impacts from changes in uncertain tax positions. See
Note 11. Income Taxes for additional information.
The adjusted effective tax rate remained relatively flat for the fiscal year ended September 30, 2020 compared to the fiscal year
ended September 30, 2019, decreasing just 0.3%, from 20.1% to 19.8%.
Earnings per Share
Diluted earnings per share increased from $2.25 to $3.32 for the fiscal year ended September 30, 2020 compared to the fiscal
year ended September 30, 2019 primarily due to higher gross profits and lower tax rates, partially offset by the Loss on
extinguishment of debt of $15.6 million and a pension plan settlement of $8.5 million. See Note 5. Financing Agreements and
Note 8. Retirement and Postretirement Benefit Plans for additional information.
29
Table of Contents
Business Segment Divisional Income
(In millions)
Divisional income:
Patient Support Systems
Front Line Care
Surgical Solutions
Year Ended September 30
2020
2019
Change As
Reported
$
332.3 $
301.8
39.5
299.9
266.4
61.2
10.8 %
13.3 %
(35.5) %
Refer to Note 14. Segment Reporting for a description of how divisional income is determined.
Patient Support Systems divisional income increased 10.8% for the fiscal year ended September 30, 2020 compared to the fiscal
year ended September 30, 2019 primarily due to global revenue growth, which was predominantly related to COVID-19
demand, which expanded gross profit due to improved efficiency in manufacturing and service activities, as well as increased
rental durations.
Front Line Care divisional income increased 13.3% for the fiscal year ended September 30, 2020 compared to the fiscal year
ended September 30, 2019 primarily due to global sales growth, predominantly driven by COVID-19 related demand for non-
invasive ventilator sales under U.S. federal and state government contracts as well as patient monitoring and physical
assessment tools, which produced higher gross profits, and improved efficiency in manufacturing.
Surgical Solutions divisional income decreased 35.5% for the fiscal year ended September 30, 2020 compared to the fiscal year
ended September 30, 2019 predominantly due to the disposition of the surgical consumable products business in August 2019.
GAAP and Adjusted Earnings
Operating margin, income before income taxes, income tax expense and earnings attributable to common shareholders per
diluted share are summarized in the table below for the fiscal years ended September 30, 2020 and 2019. GAAP amounts are
adjusted for certain items to aid management in evaluating the performance of the business. Investors should consider these
measures in addition to, not as a substitute for, or as superior to, measures of financial performance prepared in accordance with
GAAP. Income tax expense is computed by applying a blended statutory tax rate based on the jurisdictional mix of the
respective before tax adjustment.
30
Table of Contents
(In millions)
GAAP Basis
Adjustments:
Acquisition and integration costs
and related fair value adjustments 1
Acquisition-related intangible
asset amortization 2
Field corrective actions 3
Regulatory compliance costs 4
Special charges 5
Tax law and method changes 6
Debt refinancing costs 7
(Gain) loss on business
combinations 8
Pension settlement expense 9
Litigation expenses and awards 10
COVID-19 related cost and
benefits, net 11
Adjusted Basis
Year Ended September 30
2020
Income
Before
Income
Taxes
Income
Tax
Expense
Operating
Margin
Diluted
EPS
Operating
Margin
2019
Income
Before
Income
Taxes
Income
Tax
Expense
Diluted
EPS
12.8 % $
271.2 $
48.2 $
3.32
10.9 % $
208.6 $
56.4 $
2.25
— %
(0.6)
1.8
(0.04)
0.9 %
28.1
5.3
0.34
3.7 %
109.0
26.1
0.2 %
0.5 %
1.4 %
— %
— %
— %
— %
— %
4.9
15.6
41.5
—
16.1
1.2
3.7
9.2
—
3.7
(2.8)
(4.4)
8.4
1.9
1.23
0.05
0.18
0.48
—
0.18
0.02
0.10
(1.2)
(0.3)
(0.01)
4.2 %
122.4
0.2 %
0.5 %
1.0 %
— %
— %
— %
— %
0.1 %
5.6
15.3
28.4
—
4.0
15.9
—
2.0
0.2 %
1.4
0.7
0.02
— %
—
28.6
1.4
3.6
6.9
(4.8)
0.9
(12.4)
—
0.5
—
1.38
0.06
0.17
0.32
0.07
0.05
0.42
—
0.02
—
5.53
86.4 $
91.8 $
430.3 $
463.5 $
17.8 % $
18.8 % $
5.08
1 Acquisition and integration costs and related fair value adjustments include legal and professional fees, temporary labor, consulting and
other costs related to the closing and integration of acquired businesses, including purchase accounting adjustments for deferred revenue
and other items, and contingent consideration. For fiscal 2020, a fair value adjustment of $4.6 million represents purchase accounting
adjustments to reflect deferred revenue and to reduce contingent consideration liabilities associated with our business combinations. See
Note 3. Business Combinations for further information.
2 Acquisition-related intangible asset amortization relates to the amortization of intangible assets associated with our business
combinations. See Note 3. Business Combinations and Note 4. Goodwill and Intangible Assets for further information.
3 Field corrective action costs relate to costs incurred to address broad-based product performance matters outside of normal warranty
provisions. These costs are included in Cost of goods sold.
4 Regulatory compliance costs relate to updating existing product registrations to comply with the European Medical Device Regulations.
These costs are included in Selling and administrative expenses.
5 Special charges represent a variety of costs associated with restructuring actions, including severance and related benefits, lease
termination fees, asset write-downs and temporary labor on shutdown of operations. It also includes costs related to a global information
technology transformation, including rationalizing and transforming our enterprise resource planning software solutions and other
complementary information technology systems. See Note 10. Special Charges for further information.
6 Tax law and method changes relate to tax expenses and related unrecognized tax benefits due to the Tax Cuts and Jobs Act enacted in the
United States in December 2017. See Note 11. Income Taxes for further information.
7 Debt refinancing costs are expenses related to the costs incurred to refinance our previously outstanding debt obligations during fiscal
2020 and 2019. In addition, the costs include duplicative interest of $0.5 million and $0.7 million for fiscal 2020 and 2019 due the timing
of our issuance and redemption of our Senior Notes. See Note 5. Financing Agreements for further information.
8 (Gain) loss on business combinations relates to gains and losses recorded in Investment income (expense) and other, net resulting from
business combinations during fiscal 2020 and 2019. See Note 3. Business Combinations for further information.
9 Pension settlement expense represents an actuarial loss totaling $8.4 million recorded as a component of Investment income (expense)
and other, net. See Note 8. Retirement and Postretirement Benefit Plans for additional information.
10 Litigation expenses and awards are the aggregate charges, costs or recoveries associated with litigation settlements. These costs are
recorded as a component of Investment income (expense) and other, net for fiscal 2020 and Selling and administrative expenses for fiscal
2019.
11 COVID-19 related costs and benefits, net primarily represent incremental non-recurring special compensation costs paid to essential
workers that continued to work in our production facilities and provide services to our customers, partially offset by funding received and
costs abated under government programs created in response to COVID-19. See Note 1. Summary of Significant Accounting Policies for
additional information.
31
Table of Contents
Fiscal Year Ended September 30, 2019 Compared to the Fiscal Year Ended September 30, 2018
Net Revenue
(In millions)
Revenue:
Year Ended
September 30
2019
2018
Change
As
Reported
Constant
Currency
Change As
Reported
Change As
Reported
Constant
Currency
U.S.
OUS
Product sales and service
$ 2,615.0 $ 2,469.6
5.9 %
7.3 %
Rental revenue
292.3
378.4
(22.8) %
(22.2) %
Total net revenue
$ 2,907.3 $ 2,848.0
2.1 %
3.4 %
Revenue:
Patient Support Systems
$ 1,490.5 $ 1,429.5
Front Line Care
Surgical Solutions
978.1
438.7
960.2
458.3
Total net revenue
$ 2,907.3 $ 2,848.0
4.3 %
1.9 %
(4.3) %
2.1 %
5.4 %
2.9 %
(2.0) %
3.4 %
OUS - Outside of the United States
11.2 %
(24.5) %
5.1 %
7.6 %
3.0 %
(0.1) %
5.1 %
(4.4) %
(9.6) %
(4.6) %
(5.2) %
(0.9) %
(8.2) %
(4.6) %
(0.3) %
(5.0) %
(0.5) %
(0.8) %
2.8 %
(3.8) %
(0.5) %
The following table reflects sales growth data for the fiscal year ended September 30, 2019, excluding the impacts of the
adoption of ASC 606, compared to the fiscal year ended September 30, 2018 to supplement our discussion and analysis of net
revenue for revenue streams and reportable segments:
(In millions)
Revenue:
Year Ended
September 30
U.S.
OUS
Adjusted
2019
2018
Change
Constant
Currency
Change
Change
Constant
Currency
Product sales and service
$ 2,502.8 $ 2,469.6
Rental revenue
389.3
378.4
Total net revenue
$ 2,892.1 $ 2,848.0
Revenue:
Patient Support Systems
Front Line Care
Surgical Solutions
$ 1,477.0 $ 1,429.5
960.2
458.3
976.4
438.7
Total net revenue
$ 2,892.1 $ 2,848.0
1.3 %
2.9 %
1.5 %
3.3 %
1.7 %
(4.3) %
1.5 %
2.7 %
3.4 %
2.8 %
4.5 %
2.7 %
(2.0) %
2.8 %
4.3 %
4.5 %
4.4 %
6.4 %
2.7 %
(0.1) %
4.4 %
(4.4) %
(9.6) %
(4.7) %
(5.3) %
(0.9) %
(8.2) %
(4.7) %
(0.3) %
5.0 %
(0.5) %
(0.9) %
2.7 %
(3.8) %
(0.5) %
Impact of ASC 606
Product sales and service revenue increased under ASC 606 by $112.2 million. This increase was primarily due to the
accelerated recognition and reclassification from Rental revenue of $95.3 million for Front Line Care where it was determined
for respiratory health products, there were no on-going performance obligations after delivery of the product to the customer,
whereas previously this revenue was recognized over the period the Company was reimbursed by third parties. It also reflects
an additional $13.5 million for Patient Support Systems due to the changes in the timing of revenue recognition based on when
the performance obligation related to certain products was determined to be satisfied.
32
Table of Contents
Rental revenue decreased under ASC 606 by $97.0 million. This decrease was primarily due to the reclassification to Product
sales and service revenue of $95.3 million for Front Line Care as described above.
Business Segment Revenue
Excluding the impact of adopting ASC 606, revenue increased 1.5% on a reported basis, or 2.8% on a constant currency basis,
for the fiscal year ended September 30, 2019 compared to the fiscal year ended September 30, 2018, primarily due to the
following:
Patient Support Systems revenue increased 3.3% on a reported basis and 4.5% on a constant currency basis for the fiscal year
ended September 30, 2019 compared to the fiscal year ended September 30, 2018. The increase was driven by strong growth in
med-surg frames and care communications platform in the United States, as well as incremental revenue from recent
acquisitions. Growth in the United States was partially offset by the divestiture of our third-party rental business in fiscal 2018
which contributed $12.2 million of Patient Support Systems revenue during the fiscal year ended September 30, 2018 and lower
international revenue, specifically in Canada related to large capital projects that occurred in fiscal 2018. Revenue for the fiscal
year ended September 30, 2019 does not reflect approximately $5.3 million of revenue that was eliminated in fair value
purchase accounting adjustments to deferred revenue related to recent acquisitions.
Front Line Care revenue increased 1.7% on a reported basis and 2.7% on a constant currency basis for the fiscal year ended
September 30, 2019 compared to the fiscal year ended September 30, 2018 primarily due to strong growth in our respiratory
health from new product launches, partially offset primarily by declines in our diagnostic tools for cardiology patients.
Surgical Solutions revenue decreased 4.3% on a reported basis and 2.0% on a constant currency basis for the fiscal year ended
September 30, 2019 compared to the fiscal year ended September 30, 2018, primarily due to the sale of the surgical consumable
products business in August 2019 and lower revenue in our international original equipment manufacturer (“OEM”) product
lines and due to larger projects in fiscal 2018 in the Middle East, partially offset by sales growth in integrated operating tables
in the United States.
Gross Profit
(In millions)
Gross Profit 1
Product sales and service
Percent of Related Net Revenue
Rental
Percent of Related Net Revenue
Total Gross Profit
Percent of Total Net Revenue
Year Ended September 30
2018
2019
$
1,284.3
$
1,195.5
49.1 %
48.4 %
140.7
48.1 %
198.7
52.5 %
$
1,425.0
$
1,394.2
49.0 %
49.0 %
1 Gross Profit is calculated as net product sales and service revenue and rental revenue less the related cost of goods sold or
rental expenses as disclosed on the face of the Statements of Consolidated Income.
Product sales and service gross profit increased by $88.8 million or 7.4% for the fiscal year ended September 30, 2019
compared to the fiscal year ended September 30, 2018. Over half of the increase was the result of the adoption of ASC 606,
which includes the reclassification of revenues and costs from Rental to Product sales and service for respiratory health and
recognition timing changes for the care communication platform sales. The remaining increase is due to new product growth in
respiratory health and Patient Support Systems, including recent acquisitions, and operational efficiencies, partially offset by
voluntary field corrective action costs and the disposition of our surgical consumable products business in August 2019.
Rental gross profit decreased by $58.0 million or 29.2% for the fiscal year ended September 30, 2019 compared to the fiscal
year ended September 30, 2018. A majority of the decrease was the result of the adoption of ASC 606, which includes
reclassification of the respiratory health products as described above. The remaining decrease is primarily related to the
disposition of our third-party rental business in fiscal 2018.
33
Table of Contents
Operating Expenses
(In millions)
Research and development expenses
Percent of Total Net Revenue
Selling and administrative expenses
Percent of Total Net Revenue
Acquisition-related intangible asset amortization
Percent of Total Net Revenue
Year Ended September 30
2019
2018
139.5
$
135.6
4.8 %
4.8 %
818.6
$
784.7
28.2 %
27.6 %
122.4
$
106.9
4.2 %
3.8 %
$
$
$
Research and development expenses increased for the fiscal year ended September 30, 2019 compared to the fiscal year ended
September 30, 2018 due to continued investment in new products. As a percentage of revenue, Research and development
expenses remained consistent.
Selling and administrative expenses increased $33.9 million, or 4.3%, for the fiscal year ended September 30, 2019 compared
to the fiscal year ended September 30, 2018 primarily due to higher acquisition and integration costs and regulatory compliance
costs during fiscal 2019, partially offset by higher litigation settlement expenses during fiscal 2018.
Acquisition-related intangible asset amortization increased by $15.5 million, or 14.5%, for the fiscal year ended September 30,
2019 compared to the fiscal year ended September 30, 2018 primarily due to recent acquisitions during fiscal 2019, offset
slightly by the disposition of the surgical consumable products business in August 2019.
Special Charges and Other
(In millions)
Special charges
Interest expense
Loss extinguishment of debt
Investment income (expense) and other, net
$
$
Year Ended September 30
2019
2018
28.4 $
77.6
(89.6) $
(3.3)
(14.6)
(95.0)
—
2.8
In connection with various organizational changes to improve our business alignment and cost structure, we recognized Special
charges of $28.4 million and $77.6 million for the fiscal year ended September 30, 2019 compared to the fiscal year ended
September 30, 2018. These charges relate to the initiatives described in Note 10. Special Charges.
Interest expense was lower for the fiscal year ended September 30, 2019 compared to the fiscal year ended September 30, 2018
mainly due to a decrease in long-term debt outstanding and the impact of our cross-currency swaps entered into in July 2018.
See Note 6. Derivative Instruments and Hedging Activity for additional information.
Loss extinguishment of debt relates to refinancing of the then-existing senior secured credit facilities maturing in 2021 (the
“Prior Senior Secured Credit Facilities”) in August 2019. See Note 5. Financing Agreements for additional information.
Investment income (expense) and other, net for the fiscal year ended September 30, 2019 primarily included the loss recorded
related to the disposition of our surgical consumable products business in August 2019. See Note 3. Business Combinations for
additional information.
34
Table of Contents
Income Tax Expense
The effective tax rate was 27.0% for the fiscal year ended September 30, 2019 compared to (28.0)% for the fiscal year ended
September 30, 2018. The increase was primarily due to tax benefits recorded in 2018 related to the Tax Act. See Note 11.
Income Taxes for additional information.
The adjusted effective tax rate for the fiscal year ended September 30, 2019 was 20.1% compared to 19.5% for the fiscal year
ended September 30, 2018. The higher adjusted tax rate in fiscal 2019 is primarily due to less excess tax benefits on deductible
stock compensation and the 2018 impacts of the Tax Act, including unfavorable impacts of global intangible low-taxed income
(“GILTI”), offset by favorable impacts of foreign-derived intangible income (“FDII”) and a reduction in the U.S. federal
corporate tax rate.
Earnings per Share
Diluted earnings per share decreased from $3.73 for the fiscal year ended September 30, 2018 to $2.25 for the fiscal year ended
September 30, 2019 primarily due to the one-time tax benefit recorded in fiscal 2018 related to the Tax Act, the loss on the
disposition of our surgical consumable products business, and the related tax expense incurred from organizational changes
executed to facilitate the disposition.
Business Segment Divisional Income
(In millions)
Divisional income:
Patient Support Systems
Front Line Care
Surgical Solutions
Year Ended September 30
2019
2018
Change As
Reported
$
299.9 $
266.4
61.2
285.0
253.0
53.1
5.2 %
5.3 %
15.3 %
Refer to Note 14. Segment Reporting for a description of how divisional income is determined.
Patient Support Systems divisional income increased 5.2% for the fiscal year ended September 30, 2019 compared to the fiscal
year ended September 30, 2018 primarily due to revenue growth in the United States, and lower operating expenses as a
percentage of revenue.
Front Line Care divisional income increased 5.3% for the fiscal year ended September 30, 2019 compared to the fiscal year
ended September 30, 2018 as a result of revenue growth and higher margins from new products.
Surgical Solutions divisional income increased 15.3% for the fiscal year ended September 30, 2019 compared to the fiscal year
ended September 30, 2018 as a result of revenue growth from operating tables, and lower operating expenses as a percentage of
revenue.
GAAP and Adjusted Earnings
Operating margin, income before income taxes, income tax expense, and earnings attributable to common shareholders per
diluted share are summarized in the table below for the fiscal years ended September 30, 2019 and 2018. GAAP amounts are
adjusted for certain items to aid management in evaluating the performance of the business. Investors should consider these
measures in addition to, not as a substitute for, or as superior to, measures of financial performance prepared in accordance with
GAAP. Income tax expense is computed by applying a blended statutory tax rate based on the jurisdictional mix of the
respective before tax adjustment.
35
Table of Contents
(In millions)
GAAP Basis
Adjustments:
Acquisition and
integration costs and
related fair value
adjustments 1
Acquisition-related
intangible asset
amortization 2
Field corrective actions 3
Regulatory compliance
costs 4
Litigation expenses and
awards 5
Special charges 6
Tax law and method
changes 7
Year Ended September 30
2019
Income
Before
Income
Taxes
Income
Tax
Expense
Operating
Margin
2018
Income
Before
Income
Taxes
Income
Tax
Expense
Diluted
EPS
Diluted
EPS
Operating
Margin
10.9 % $ 208.6 $
56.4 $
2.25
10.2 % $ 197.2 $
(55.2) $
3.73
0.9 %
28.1
5.3
0.34
0.3 %
8.1
2.2
0.09
4.2 %
122.4
0.2 %
5.6
0.5 %
15.3
0.1 %
1.0 %
2.0
28.4
28.6
1.4
3.6
0.5
6.9
1.38
0.06
0.17
0.02
0.32
3.8 %
106.9
— %
—
28.2
—
1.16
—
0.1 %
4.5
1.2
0.04
0.2 %
2.7 %
5.8
77.6
1.5
21.1
0.06
0.84
— %
—
(4.8)
0.07
— %
0.1
78.8
(1.16)
0.9
4.0
0.05
— %
— %
Debt refinancing costs 8
(Gain) loss on business
combinations 9
4.75
86.4 $
Adjusted Basis
1 Acquisition and integration costs and related fair value adjustments include legal and professional fees, temporary labor,
consulting and other costs related to the closing and integration of acquired businesses, including purchase accounting
adjustments for deferred revenue and other items, and contingent consideration. For the fiscal year ended September 30,
2019, related fair value adjustments of $8.5 million represent purchase accounting adjustments to reflect deferred revenue
and to increase contingent consideration associated with our business combinations. See Note 3. Business Combinations for
further information.
17.3 % $ 399.2 $
17.8 % $ 430.3 $
77.8 $
(12.4)
— %
— %
(1.0)
15.9
5.08
0.42
—
—
—
—
(0.01)
2 Acquisition-related intangible asset amortization relates to the amortization of intangible assets associated with our business
combinations. See Note 3. Business Combinations and Note 4. Goodwill and Intangible Assets for further information.
3 Field corrective action costs relate to costs incurred to address broad-based product performance matters outside of normal
warranty provisions. These costs are included in Cost of goods sold.
4 Regulatory compliance costs relate to updating existing product registrations to comply with the European Medical Device
Regulations. These costs are included in Selling and administrative expenses.
5 Litigation expenses and awards are the aggregate charges, costs or recoveries associated with litigation settlements. These
costs are included in Selling and administrative expenses.
6 Special charges represent a variety of costs associated with restructuring actions, including severance and related benefits,
lease termination fees, asset write-downs and temporary labor on shutdown of operations. It also includes costs related to a
global information technology transformation, including rationalizing and transforming our enterprise resource planning
software solutions and other complementary information technology systems. See Note 10. Special Charges for further
information.
7 Tax law and method changes relate to tax expenses and related unrecognized tax benefits due to the Tax Cuts and Jobs Act
enacted in the United States in December 2017. See Note 11. Income Taxes for further information.
8 Debt refinancing costs are expenses related to the costs incurred to refinance our previously outstanding debt obligations
during fiscal 2019. See Note 5. Financing Agreements for further information.
9 (Gain) loss on business combinations relates to gains and losses recorded in Investment income (expense) and other, net
resulting from business combinations during fiscal 2019 and 2018. See Note 3. Business Combinations for further
information.
36
Table of Contents
Liquidity and Capital Resources
(In millions)
Cash Flows Provided By (Used In):
Operating activities
Investing activities
Financing activities
Effect of exchange rate changes on cash
$
(Decrease) Increase in Cash, Cash Equivalents and Restricted Cash
$
Year Ended September 30
2019
2018
2020
481.7 $
(131.2)
(695.0)
7.2
(337.3) $
401.4 $
(249.0)
304.7
(6.3)
450.8 $
395.2
(82.4)
(356.6)
(5.0)
(48.8)
Net cash flows from operating activities and selected borrowings represented our primary sources of funds for growth of the
business, including capital expenditures and acquisitions. Our financing agreements contain certain restrictions relating to
dividend payments, the making of restricted payments and the incurrence of additional secured and unsecured indebtedness.
None of our financing agreements contain any credit rating triggers that would increase or decrease our cost of borrowings.
Changes in our credit rating can, however, impact the cost of borrowings and any potential future borrowings under any new
financing agreements.
Operating Activities
Cash provided by operating activities increased $80.3 million for the fiscal year ended September 30, 2020 compared to the
fiscal year ended September 30, 2019 primarily due to higher net income and higher collections of accounts receivable, partially
offset by higher inventory levels in anticipation of increased customer demand related to COVID-19.
Cash provided by operating activities increased $6.2 million for the fiscal year ended September 30, 2019 compared to the
fiscal year ended September 30, 2018 primarily due to higher operating profit and working capital improvements.
Investing Activities
Cash used in investing activities decreased $117.8 million for the fiscal year ended September 30, 2020 compared to the fiscal
year ended September 30, 2019 primarily due to the decrease in cash paid for acquisitions of $275.0 million. Refer to the table
below and Note 3. Business Combinations. The decrease is partially offset by the net proceeds of $166.6 million received from
the disposition of the surgical consumable products business in August 2019.
Cash used in investing activities increased $166.6 million for the fiscal year ended September 30, 2019 compared to the fiscal
year ended September 30, 2018 primarily due to cash paid for recent acquisitions during fiscal 2019, the acquisition of non-
marketable equity securities of $26.6 million as described in Note 2. Supplementary Financial Statement Information, as well as
the acquisition of the right to use patented technology and certain related assets from a supplier in our Front Line Care segment
of $17.1 million, as described in Note 3. Business Combinations. These uses of cash were offset by net proceeds of
$166.6 million from the sale of certain of our surgical consumable products and related assets, as described in Note 3. Business
Combinations.
Company Name
Date of Acquisition
Cash Paid
Excel Medical
Connecta
Videomed
Fiscal 2020 Totals
Voalte
Breathe
Fiscal 2019 Totals
January 10, 2020
May 18, 2020
July 21, 2020
April 1, 2019
September 3, 2019
$
$
$
$
13.1
7.5
7.8
28.4
175.8
127.6
303.4
37
Table of Contents
Financing Activities
Cash used in financing activities was $695.0 million for the fiscal year ended September 30, 2020 primarily driven by the
repayment of the senior unsecured 5.75% notes of $425.0 million and related prepayment penalty of $12.2 million on October
7, 2019 with the net proceeds of the senior unsecured 4.375% notes issued in September 2019, as well as repayments of $270.0
million related to the Revolving Credit Facility during fiscal 2020. Refer to Note 5. Financing Agreements for additional detail
regarding the fiscal 2019 refinancing and our existing financing agreements.
Cash provided by financing activities was $304.7 million for the fiscal year ended September 30, 2019, primarily driven by the
refinancing activities described in Note 5. Financing Agreements, including $419.7 million of net proceeds from the issuance of
senior unsecured notes and additional other borrowings, offset by repurchases of our common stock of $117.2 million executed
under the ongoing program described in Note 13. Common Stock, and dividend payments of $55.4 million.
Our debt-to-capital ratio was 52.1%, 60.8% and 55.0% as of September 30, 2020, 2019 and 2018.
Other Liquidity Matters
Our cash balances and cash flows generated from operations may be used to fund strategic investments, business acquisitions,
working capital needs, investments in technology and marketing, share repurchases and payments of dividends to our
shareholders. We believe that our cash balances and cash flows generated from operations, along with amounts available under
our financing agreements, will be sufficient to fund operations, working capital needs, capital expenditure requirements and
financing obligations for at least the next 12 months from the date of this filing.
Our cash flows from operating activities for the fiscal year ended September 30, 2020 were not materially adversely impacted
by COVID-19. There have been no changes to our cost of or access to our capital and funding sources. We have not identified
instability with the financial institutions with whom we maintain our financing relationships. We believe we can continue to
service our outstanding borrowings or other financial obligations.
As of September 30, 2020, there were no outstanding borrowings on the Revolving Credit Facility and available borrowing
capacity was $1,191.0 million after giving effect to the $9.0 million of outstanding standby letters of credit. As of
September 30, 2019, there were $80.0 million outstanding borrowings on the Revolving Credit Facility, and available
borrowing capacity was $1,112.8 million after giving effect to $7.2 million of outstanding standby letters of credit.
Our long-term debt instruments require nominal repayments over the next 12 months, with our next significant maturity
occurring in August 2024. Since the beginning of the global COVID-19 pandemic in December 2019, we have not experienced
liquidity constraints through either the movement of cash or under our Revolving Credit Facility. Furthermore, we have
successfully extended our 364-day accounts receivable securitization facilities as of April 27, 2020. As of September 30, 2020,
we were in compliance with all debt covenants under our financing agreements. See Note 5. Financing Agreements for
additional information on our financing agreements and outstanding debt obligations.
We do not anticipate incurring significant incremental capital expenditures due to the pandemic. We will continue to evaluate
the allocation of our capital spending and may delay discretionary capital spending or redirect capital spending to support the
increased demand for certain products used to treat patients diagnosed with COVID-19.
Refer to the section titled “The Impacts of COVID-19 on Hillrom” within Management’s Discussion & Analysis of Financial
Condition and Results of Operations for further information.
Over the long term, we intend to continue to pursue inorganic growth in certain areas of our business, but the timing, size or
success of any acquisition effort and the related potential capital commitments cannot be predicted. Refer to Note 3. Business
Combinations for additional detail regarding the acquisitions completed during fiscal 2020 and 2019.
In September 2019, the Board approved an additional $170.0 million for share repurchases. Refer to Item 5 of Part I of this
Form 10-K for additional information.
Our primary pension plan invests in a variety of equity and debt securities. Refer to Note 8. Retirement and Postretirement
Benefit Plans for additional detail regarding our retirement plans, including our benefit obligations, plan assets funded status
and estimated future benefit payments, among others.
38
Table of Contents
We intend to continue to pay quarterly cash dividends comparable to those paid in the periods covered by these financial
statements. However, the declaration and payment of dividends will be subject to the sole discretion of our Board and will
depend upon many factors, including our financial condition, earnings, capital requirements, covenants associated with debt
obligations, legal requirements and other factors considered relevant by our Board.
On September 15, 2020, we committed to a workforce reduction plan, which includes a voluntary retirement program and
involuntary severance actions. The actions under this plan will result in cash expenditures of approximately $35.0 million and
will be substantially complete in fiscal 2021.
In fiscal 2019, we repatriated $10.2 million of our cash and cash equivalents from outside the United States that was previously
taxed and paid no related foreign withholding tax. In fiscal 2020, we repatriated $12.2 million of our cash and cash equivalents
from outside the United States that was previously taxed, and paid no related foreign withholding tax. These repatriated funds
were used for working capital purposes or debt repayments. As of September 30, 2020, approximately 54.0% of our cash and
cash equivalents, excluding restricted cash, were held by our foreign subsidiaries.
With regard to our non-U.S. subsidiaries, it is our practice and intention to reinvest the earnings in those businesses to fund
capital expenditures and other operating cash needs. Because the undistributed earnings of non-U.S. subsidiaries are considered
to be permanently reinvested, no U.S. deferred income taxes or foreign withholding taxes have been provided on earnings
subsequent to the enactment of the Tax Act. Future repatriations of cash and cash equivalents, if any, held by our foreign
subsidiaries will generally not be subject to U.S. federal tax if earned prior to the enactment of the Tax Act. We believe that
cash on hand and cash generated from U.S. operations, along with amounts available under our financing agreements, will be
sufficient to fund U.S. operations, working capital needs, capital expenditure requirements and financing obligations.
The U.S. Internal Revenue Service and Treasury Department continue to release proposed guidance with respect to the Tax Act.
We continue to evaluate what impact, if any, each piece of guidance may have on our related tax positions and our effective tax
rate if, and when, such guidance is finalized.
Credit Ratings
In fiscal 2020, Standard and Poor’s Rating Services and Moody’s Investor Service issued credit ratings for Hillrom of BB+ and
Ba2, respectively, with stable outlooks.
Other Uses of Cash
We expect capital spending in fiscal 2021 to be approximately $100.0 million. Capital spending will be monitored and
controlled as the year progresses.
Off-Balance Sheet Arrangements
We have no material off-balance sheet arrangements.
Contractual Obligations, Contingent Liabilities and Commitments
To give a clear picture of matters potentially impacting our liquidity position, the following table outlines our contractual
obligations as of September 30, 2020:
(In millions)
Contractual Obligations
Long-term debt obligations
Interest payments relating to long-term debt 1
Operating lease liabilities
Pension and postretirement
health care benefit funding 2
Purchase obligations 3
Other obligations 4
Total contractual cash obligations
Payments Due by Period
1 - 3
Years
3 - 5
Years
Less Than
1 Year
Total
More Than
5 Years
$
1,890.6 $
293.9
84.5
23.3
239.1
42.2
2,573.6 $
$
39
222.5 $
71.0
25.1
3.1
224.7
2.5
548.9 $
125.0 $
159.6
34.6
1,088.4 $
44.7
14.4
4.6
14.4
16.9
355.1 $
4.7
—
15.2
1,167.4 $
454.7
18.6
10.4
10.9
—
7.6
502.2
Table of Contents
1 Interest payments on our long-term debt are projected based on the contractual rates of outstanding debt securities.
2 Excludes our master defined benefit retirement plan in the United States because we are not required to make any further
contributions in fiscal 2021.
3 Purchase obligations represent contractual obligations under various take-or-pay arrangements executed in the normal course
of business. These commitments represent future purchases in line with expected usage to obtain favorable pricing. Also
included are obligations arising from purchase orders for which we have made firm commitments. As a result, we believe that
the purchase obligations portion of our contractual obligations is substantially those obligations for which we are certain to pay,
regardless of future facts and circumstances. We expect to fund purchase obligations with operating cash flows and current cash
balances.
4 Other obligations include deferred compensation arrangements, self-insurance reserves and other various liabilities.
We also had commercial commitments related to standby letters of credit as of September 30, 2020 of $9.6 million.
In addition to the contractual obligations and commercial commitments disclosed above, we also have a variety of other
agreements related to the procurement of materials and services and other commitments. Many of these agreements are long-
term supply agreements, some of which are exclusive supply or complete requirements-based contracts. Also, we have an
additional $3.9 million of Other long-term liabilities as of September 30, 2020, which represent uncertain tax positions for
which it is not possible to determine in which future period the tax liability might be settled.
In conjunction with our acquisition and divestiture activities, we entered into certain guarantees and indemnifications of
performance, as well as, non-competition agreements for varying periods of time. Potential losses under the indemnifications
are generally limited to a portion of the original transaction price, or to other lesser specific dollar amounts for certain
provisions. Guarantees and indemnifications with respect to acquisition and divestiture activities, if triggered, could have an
adverse impact on our financial condition and results of operations.
We are also subject to potential losses from adverse litigation results that are not included in our self-insurance or other
reserves, because such potential losses are not quantifiable at this time and may never occur.
Critical Accounting Policies and Estimates
Our accounting policies, including those described below, often require management to make significant estimates and
assumptions using information available at the time the estimates are made. Such estimates and assumptions significantly affect
various reported amounts of assets, liabilities, revenue and expenses. If future experience differs significantly from these
estimates and assumptions, our results of operations and financial condition could be affected. Our most critical accounting
policies are described below.
Revenue Recognition
Revenue is recognized as performance obligations are satisfied, either at a point in time or over time, driven by the nature of the
obligation that is contracted to be provided to our customers. Revenue is measured as the amount of consideration we expect to
receive in exchange for transferring goods or providing services. A performance obligation is a promise in a contract to transfer
a distinct good or service to the customer, and is the unit of account in the contract. A contract’s transaction price is allocated to
each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Certain of
our contracts have multiple performance obligations. For contracts with multiple performance obligations, we allocate the
contract’s transaction price to each performance obligation using our best estimate of the standalone selling price of each
distinct good or service in the contract.
The majority of our capital equipment revenue is recognized at a point in time, primarily based on the transfer of title, except in
circumstances where we are also required to install the equipment, for which revenue is recognized upon customer acceptance
of the installation. Performance obligations involving the provision of services and revenue from rental usage of our products
are recognized over the time period specified in the contractual arrangement with the customer. Shipping and handling activities
are considered to be fulfillment activities and are not considered to be a separate performance obligation.
Revenue is presented net of several types of variable consideration including rebates, discounts and product returns, which are
estimated at the time of sale generally using the expected value method, although the most likely amount method is also used
40
Table of Contents
for certain types of variable consideration. These estimates take into consideration historical experience, current contractual and
statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment
patterns.
Certain costs associated with obtaining or fulfilling a contract are capitalized until such time as the related performance
obligations are completed and the related revenue is recognized.
Contract liabilities represent deferred revenues that arise as a result of cash received from customers at inception of contracts or
where the timing of billing for services precedes satisfaction of our performance obligations. Such remaining performance
obligations represent the portion of the contract price for which work has not been performed and are primarily related to our
installation and service contracts.
Taxes assessed by a governmental authority that are directly imposed on a revenue producing transaction between us and our
customers, including but not limited to sales taxes, use taxes and value added taxes, are excluded from revenue and cost.
Revenue and Accounts Receivable Reserves
For product sales, we record reserves resulting in a reduction of revenue for contractual discounts, as well as price concessions
and product returns. Likewise, rental revenue reserves, reflecting contractual and other routine billing adjustments, are recorded
as a reduction of revenue. Reserves for revenue are estimated based upon historical rates for revenue adjustments.
Provisions for doubtful accounts are recorded as a component of operating expense and represent our best estimate of the
amount of probable credit losses and collection risk in our existing accounts receivable. Receivables are generally reviewed for
collectability based on historical collection experience for each receivable type and are also reviewed individually for
collectability. Account balances are charged against the allowance when we believe it is probable the receivable will not be
recovered. We do not have any off-balance sheet credit exposure related to our customers.
If circumstances change, such as higher than expected payment defaults, claims denials, changes in our business composition or
processes, adverse changes in general economic conditions, instability or disruption of credit markets, or an unexpected
material adverse change in a major customer’s or payer’s ability to meet its obligations, our estimates of the realizability of
trade receivables could be reduced by a material amount.
Business Combinations, Goodwill and Intangible Assets
Due to our growth strategy, recent acquisitions and the significance of our goodwill on the Consolidated Balance Sheets, this is
our most critical accounting estimate. Assets acquired and liabilities assumed in a business combination are recorded at their
estimated fair values on the date of acquisition. The difference between the purchase price amount and the net fair value of
assets acquired and liabilities assumed is recognized as goodwill on the balance sheet if the purchase price exceeds the
estimated net fair value or as a bargain purchase gain on the income statement if the purchase price is less than the estimated net
fair value. Determining the fair value of assets acquired and liabilities assumed requires management’s judgment, often utilizes
independent valuation experts and involves the use of significant estimates and assumptions with respect to the timing and
amounts of future cash inflows and outflows, discount rates, market prices and asset lives, among other items. The judgments
made in the determination of the estimated fair value assigned to the assets acquired and liabilities assumed, as well as the
estimated useful life of each asset and the duration of each liability, could significantly impact the financial statements in
periods after acquisition, such as through depreciation and amortization expense. The allocation of the purchase price may be
modified up to one year after the acquisition date as more information is obtained about the fair value of assets acquired and
liabilities assumed. Fair values of acquired developed technology and customer relationships are estimated using the income
approach. Management applies significant judgment in estimating the fair value of intangible assets acquired, which involved
the use of significant estimates and assumptions with respect to the revenue growth rates, the obsolescence factors (specific to
developed technology), the customer attrition rates (specific to customer relationships), and the discount rates. Changes in
these judgments or estimates can have a material impact on the valuation of the respective assets and liabilities acquired and our
results of operations.
We perform an impairment assessment on goodwill and other indefinite-lived intangibles annually in the third fiscal quarter, or
whenever events or changes in circumstances indicate that the fair value of a reporting unit or indefinite-lived intangible may be
below its carrying value. These events or conditions include, but are not limited to, a significant adverse change in the business
environment; regulatory environment or legal factors; a current period operating or cash flow loss combined with a history of
such losses or a projection of continuing losses; a substantial decline in market capitalization of our stock; or a sale or
disposition of a significant portion of a reporting unit.
41
Table of Contents
The goodwill and indefinite-lived intangible asset impairment assessments require either evaluating qualitative factors or
performing a quantitative assessment to determine if the carrying value is more likely than not in excess of its fair value.
Examples of qualitative factors that are considered include the results and changes to assumptions used in the most recent
quantitative impairment test, current and long-range projected financial results, changes in the strategic outlook or
organizational structure of the reporting units or business unit for the indefinite-lived asset and industry macro-economic
factors. The long-range financial forecasts of the reporting units, which are based upon management’s long-term view of our
markets and are used by senior management and the Board to evaluate operating performance, are compared to the forecasts
used in the prior year analysis to determine if management expectations for the business have changed. Management changes in
strategic outlook or organizational structure represent internally driven strategic or organizational changes that could have a
material impact on our results of operations or product offerings. Industry, market changes and macroeconomic indicators
represent our view on changes outside of the Company that could have a material impact on our results of operations, product
offerings or future cash flow forecasts. In the event we were to determine that a reporting unit’s or indefinite-lived intangible’s
carrying value would more likely than not exceed its fair value, quantitative testing would be performed comparing carrying
values to estimated fair values. Changes in management intentions, market conditions, operating performance and other similar
circumstances could affect the assumptions used in this qualitative impairment test.
Quantitative testing of the reporting units consists of a comparison of the fair value of the reporting units to their carrying value.
In determining the estimated fair value of the reporting units when performing a quantitative analysis, we consider both the
market approach and the income approach. Under the market approach, we utilize the guideline company method, which
involves calculating valuation multiples based on operating data from comparable publicly traded companies. Under the
income approach, the fair value of the reporting unit is based on the present value of estimated future cash flows utilizing a
market-based discount rate determined separately for each reporting unit. To determine the estimated fair values of our
reporting units, the Company uses assumptions and estimates including the determination of guideline companies and market
multiples, projected sales, projected gross margins and discount rates.
An impairment charge is recorded for the amount by which a reporting unit's carrying value exceeds the estimated fair value of
the goodwill, not to exceed the carrying amount of its goodwill.
Quantitative testing of indefinite-lived intangibles consists of a comparison of the fair value of the indefinite-lived intangible
asset to its carrying value. We estimate the fair value of indefinite-lived intangibles using the relief-from-royalty method. The
fair value derived is measured as the discounted cash flow savings realized from owning such trade names and not being
required to pay a royalty for their use. Assumptions utilized in the determination of fair value include projected sales, discount
rates and royalty rates. An impairment charge is recorded for the amount the carrying value exceeds the estimated fair value of
the indefinite-lived intangible.
There are inherent uncertainties related to each of the above listed assumptions and inputs, and our judgment in applying them.
Changes in the assumptions used in our goodwill and indefinite-lived intangible assets could result in impairment charges that
could be material to our Consolidated Financial Statements in any given period.
Income Taxes
We compute our deferred income taxes using an asset and liability approach to reflect the net tax effects of temporary
differences between the financial reporting carrying amounts of assets and liabilities and the corresponding income tax
amounts. We have a variety of deferred tax assets in numerous tax jurisdictions. These deferred tax assets are subject to
periodic assessment as to recoverability and if it is determined that it is more likely than not that the benefits will not be
realized, valuation allowances are recognized. In evaluating whether it is more likely than not that we would recover these
deferred tax assets, future taxable income, the reversal of existing temporary differences and tax planning strategies are
considered.
We believe that our estimates for the valuation allowances recorded against deferred tax assets are appropriate based on current
facts and circumstances. As of September 30, 2020, we had $50.8 million of valuation allowances on deferred tax assets, on a
tax-effected basis, primarily related to certain foreign deferred tax attributes and state tax credit carryforwards as it is more
likely than not that some portion or all of these tax attributes will not be realized.
We account for uncertain income tax positions using a threshold and measurement attribute for the financial statement
recognition and measurement of a tax position taken or expected to be taken in a tax return. The difference between the tax
benefit recognized in the financial statements for an uncertain income tax position and the tax benefit claimed in the tax return
is referred to as an unrecognized tax benefit.
42
Table of Contents
We also have on-going audits in various stages of completion with the IRS and several state and foreign jurisdictions, one or
more of which may conclude within the next 12 months. Such settlements could involve some or all of the following: the
payment of additional taxes and penalties, the adjustment of certain deferred taxes and/or the recognition of previously
unrecognized tax benefits. The resolution of these matters, in combination with the expiration of certain statutes of limitations
in various jurisdictions, make it reasonably possible that our unrecognized tax benefits may decrease as a result of either
payment or recognition of up to $1.8 million in the next 12 months, excluding interest.
The U.S. Internal Revenue Service and Treasury Department continue to release proposed guidance with respect to the Tax Act.
We continue to evaluate what impact, if any, each piece of guidance may have on our related tax positions and our effective tax
rate if, and when, such guidance is finalized.
Recently Issued Accounting Guidance
For a summary of recently issued accounting guidance applicable to us, see Note 1. Summary of Significant Accounting
Policies.
Item 7A.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to various market risks, including fluctuations in interest rates, collection risk associated with our accounts and
notes receivable portfolio and variability in currency exchange rates. We established policies, procedures, and internal
processes governing our management of market risks and the use of financial instruments to manage our exposure to such risks.
We are subject to variability in foreign currency exchange rates due to our international operations. Exposure to this variability
is periodically managed primarily through the use of natural hedges, whereby funding obligations and assets are both managed
in the local currency. From time-to-time, we enter into currency exchange contracts to manage exposures arising from
fluctuating exchange rates related to specific and forecasted transactions. We operate this program pursuant to documented
corporate risk management policies and do not enter into derivative transactions for speculative purposes. The sensitivity of
earnings and cash flows to variability in exchange rates is assessed by applying an appropriate range of potential rate
fluctuations to our assets, obligations and projected results of operations denominated in foreign currencies. The maximum
length of time over which we hedge transaction exposures is generally 15 months. Derivative gains and losses, initially reported
as a component of Accumulated other comprehensive income (loss), are reclassified to earnings in the period when the
transaction affects earnings.
Refer to Note 6. Derivative Instruments and Hedging Activity and Note 8. Retirement and Postretirement Benefit Plans for
additional discussions about our derivative agreements and our pension plan assets. We may need to make additional pension
plan contributions and our pension expense in future years may increase if market volatility and disruption causes declines in
asset values and low interest rates result in a high pension obligation. Investment strategies and policies are set by the plan’s
fiduciaries. Long-term strategic investment objectives utilize a diversified mix of equity and fixed income securities to preserve
the funded status of the trusts and balance risk and return. The plan fiduciaries oversee the investment allocation process, which
includes selecting investment managers, setting long-term strategic targets and monitoring asset allocations.
43
Table of Contents
Item 8.
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Financial Statements:
Management’s Report on Internal Control Over Financial Reporting
Report of Independent Registered Public Accounting Firm
Statements of Consolidated Income
Statements of Consolidated Comprehensive Income (Loss)
Consolidated Balance Sheets
Statements of Consolidated Cash Flows
Statements of Consolidated Shareholders’ Equity
Notes to Consolidated Financial Statements:
Note 1. Summary of Significant Accounting Policies
Note 2. Supplementary Financial Statement Information
Note 3. Business Combinations
Note 4. Goodwill and Intangible Assets
Note 5. Financing Agreements
Note 6. Derivative Instruments and Hedging Activity
Note 7. Leases
Note 8. Retirement and Postretirement Benefit Plans
Note 9. Other Comprehensive Income
Note 10. Special Charges
Note 11. Income Taxes
Note 12. Earnings per Common Share
Note 13. Common Stock
Note 14. Segment Reporting
Note 15. Quarterly Financial Information (Unaudited)
Note 16. Commitments and Contingencies
Financial Statement Schedule:
Schedule II — Valuation and Qualifying Accounts
All other schedules are omitted because they are not applicable or the required information is shown in the
financial statements or the notes thereto.
Page
45
46
48
49
50
51
52
53
53
64
65
69
71
73
74
77
82
84
85
88
89
92
94
95
96
44
Table of Contents
MANAGEMENT’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING
Management is responsible for establishing and maintaining adequate internal control over financial reporting for Hill-Rom
Holdings, Inc. (“we” or “our”). Our internal control over financial reporting is a process designed, under the supervision of our
principal executive, principal financial and principal accounting officers, and effected by our Board of Directors, management
and other personnel, to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of
our Consolidated Financial Statements for external purposes in accordance with accounting principles generally accepted in the
United States. Our internal control over financial reporting includes policies and procedures that:
1) Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and
dispositions of our assets;
2) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of our Consolidated
Financial Statements in accordance with accounting principles generally accepted in the United States and that our
receipts and expenditures are being made only in accordance with authorizations of our management and our Board of
Directors; and
3) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition
of our assets that could have a material effect on our Consolidated Financial Statements.
Because of its inherent limitations, our internal control over financial reporting may not prevent or detect misstatements. Also,
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate
because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate.
Management performed an assessment of the effectiveness of our internal control over financial reporting as of September 30,
2020 using criteria established in the Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO). Based on these criteria, management concluded that we maintained
effective internal control over financial reporting as of September 30, 2020.
The effectiveness of our internal control over financial reporting as of September 30, 2020 has been audited by
PricewaterhouseCoopers LLP, our independent registered public accounting firm, who also audited our Consolidated Financial
Statements, as stated in their report included herein.
/s/ John P. Groetelaars
John P. Groetelaars
President and Chief Executive Officer
/s/ Barbara W. Bodem
Barbara W. Bodem
Senior Vice President and Chief Financial Officer
/s/ Richard M. Wagner
Richard M. Wagner
Vice President, Controller and Chief Accounting Officer
45
Table of Contents
Report of Independent Registered Public Accounting Firm
To the Board of Directors and Shareholders of Hill-Rom Holdings, Inc.
Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheets of Hill-Rom Holdings, Inc. and its subsidiaries (the
“Company”) as of September 30, 2020 and 2019, and the related consolidated statements of income, of comprehensive income
(loss), of shareholders' equity and of cash flows for each of the three years in the period ended September 30, 2020, including
the related notes and schedule of valuation and qualifying accounts for each of the three years in the period ended September
30, 2020 listed in the accompanying index (collectively referred to as the “consolidated financial statements”). We also have
audited the Company's internal control over financial reporting as of September 30, 2020, based on criteria established in
Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway
Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial
position of the Company as of September 30, 2020 and 2019, and the results of its operations and its cash flows for each of the
three years in the period ended September 30, 2020 in conformity with accounting principles generally accepted in the United
States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over
financial reporting as of September 30, 2020, based on criteria established in Internal Control - Integrated Framework (2013)
issued by the COSO.
Changes in Accounting Principles
As discussed in Note 1 to the consolidated financial statements, the Company changed the manner in which it accounts for
leases in fiscal 2020 and the manner in which it accounts for revenues from contracts with customers in fiscal 2019.
Basis for Opinions
The Company's management is responsible for these consolidated financial statements, for maintaining effective internal
control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included
in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express
opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting
based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the
audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement,
whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material
respects.
Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement
of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks.
Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated
financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal
control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the
risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based
on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the
circumstances. We believe that our audits provide a reasonable basis for our opinions.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures
that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and
dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit
46
Table of Contents
preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and
expenditures of the company are being made only in accordance with authorizations of management and directors of the
company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or
disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also,
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate
because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Critical Audit Matters
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial
statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or
disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or
complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated
financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate
opinion on the critical audit matter or on the accounts or disclosures to which it relates.
Goodwill Impairment Assessment - Reporting Unit Which Comprises the Surgical Solutions Reportable Segment
As described in Notes 1 and 4 to the consolidated financial statements, the Company’s consolidated goodwill balance as of
September 30, 2020 was $1,836 million. The goodwill associated with the Surgical Solutions reportable segment as of
September 30, 2020 was $222 million. As disclosed by management, an impairment assessment is performed on goodwill
annually in the third fiscal quarter, or whenever events or changes in circumstances indicate that the fair value of a reporting
unit may be below its carrying value. To determine the estimated fair values of the Company’s reporting units, management
considers both the market and income approach, which require management to develop assumptions and estimates including the
determination of guideline companies and market multiples, projected sales, projected gross margins, and discount rates.
The principal considerations for our determination that performing procedures relating to the goodwill impairment assessment
of the reporting unit which comprises the Surgical Solutions reportable segment is a critical audit matter are the significant
judgment by management when developing the fair value measurement of the reporting unit; this in turn led to a high degree of
auditor judgment, subjectivity and effort in performing procedures and evaluating management’s significant assumptions
related to the determination of guideline companies and market multiples, projected sales, projected gross margins, and the
discount rate. In addition, the audit effort involved the use of professionals with specialized skill and knowledge.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall
opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to
management’s goodwill impairment assessment, including controls over the valuation of the Company’s reporting unit and
controls over the development of the assumptions related to the guideline companies and market multiples, projected sales,
projected gross margins, and the discount rate. These procedures also included, among others, testing management’s process for
developing the fair value estimate; evaluating the appropriateness of both the market and income approach; testing the
completeness, accuracy, and relevance of underlying data used; and evaluating the significant assumptions used by management
related to the determination of guideline companies and market multiples, projected sales, projected gross margins, and the
discount rate. Evaluating management’s assumptions related to projected sales and projected gross margins involved evaluating
whether the assumptions utilized were reasonable considering (i) the current and past performance of the business, (ii) the
consistency with external market and industry data, and (iii) whether these assumptions were consistent with evidence obtained
in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in evaluating the Company’s
market and income approaches, the determination of guideline companies and market multiples, and the discount rate.
/s/ PricewaterhouseCoopers LLP
Chicago, Illinois
November 13, 2020
We have served as the Company’s auditor since 1985.
47
Table of Contents
Hill-Rom Holdings, Inc. and Subsidiaries
STATEMENTS OF CONSOLIDATED INCOME
(In millions, except per share data)
Net Revenue
Product sales and service
Rental revenue
Total net revenue
Cost of Net Revenue
Cost of goods sold
Rental expenses
Total cost of net revenue (excludes acquisition-related intangible asset
amortization)
Research and development expenses
Selling and administrative expenses
Acquisition-related intangible asset amortization
Special charges
Operating Profit
Interest expense
Loss on extinguishment of debt
Investment income (expense) and other, net
Income Before Income Taxes
Income tax expense (benefit)
Net Income
Net Income per Basic Common Share
Net Income per Diluted Common Share
Year Ended September 30
2019
2018
2020
$
2,571.2 $
309.8
2,881.0
2,615.0 $
292.3
2,907.3
2,469.6
378.4
2,848.0
1,259.9
146.0
1,330.7
151.6
1,274.1
179.7
1,405.9
1,482.3
1,453.8
136.5
820.4
109.0
41.5
367.7
139.5
818.6
122.4
28.4
316.1
(74.0)
(15.6)
(6.9)
(89.6)
(3.3)
(14.6)
135.6
784.7
106.9
77.6
289.4
(95.0)
—
2.8
271.2
208.6
197.2
48.2
56.4
(55.2)
223.0 $
152.2 $
252.4
3.35 $
2.28 $
3.81
3.32 $
2.25 $
3.73
$
$
$
Average Basic Common Shares Outstanding (in thousands)
66,631
66,772
66,234
Average Diluted Common Shares Outstanding (in thousands)
67,212
67,660
67,612
See Notes to Consolidated Financial Statements
48
Table of Contents
Hill-Rom Holdings, Inc. and Subsidiaries
STATEMENTS OF CONSOLIDATED COMPREHENSIVE INCOME (LOSS)
(In millions)
Year Ended September 30
2019
2018
2020
Net Income
$
223.0 $
152.2 $
252.4
Other Comprehensive Income (Loss), net of tax:
Derivative instruments designated as hedges
Foreign currency translation adjustment
Change in pension and postretirement defined benefit plans
Total Other Comprehensive Income (Loss), net of tax
Total Comprehensive Income
See Notes to Consolidated Financial Statements
(36.5)
34.7
4.1
2.3
(10.4)
(40.1)
(13.6)
(64.1)
12.5
(24.0)
8.5
(3.0)
$
225.3 $
88.1 $
249.4
49
Table of Contents
Hill-Rom Holdings, Inc. and Subsidiaries
CONSOLIDATED BALANCE SHEETS
(In millions, except share amounts)
ASSETS
Current Assets
Cash and cash equivalents
Restricted cash
Trade accounts receivable, net of allowances of $25.9 and $20.6 in fiscal 2020 and 2019
Inventories, net of reserves of $73.0 and $57.3 in fiscal 2020 and 2019
Other current assets
Total current assets
Property, plant and equipment
Less accumulated depreciation
Property, plant and equipment, net
Goodwill
Other intangible assets and software, net
Deferred income taxes
Other assets
Total Assets
LIABILITIES
Current Liabilities
Trade accounts payable
Short-term borrowings
Accrued compensation
Accrued product warranties
Accrued rebates
Deferred revenue
Other current liabilities
Total current liabilities
Long-term debt
Accrued pension and postretirement benefits
Deferred income taxes
Other long-term liabilities
Total Liabilities
Commitments and Contingencies
SHAREHOLDERS' EQUITY
Capital Stock:
Preferred stock - without par value: Authorized - 1,000,000 shares; none issued or outstanding
Common stock - without par value: Authorized - 199,000,000
September 30,
2020
September 30,
2019
$
$
$
296.5 $
—
594.9
352.0
121.5
1,364.9
858.2
(552.1)
306.1
1,835.5
976.7
32.9
155.0
4,671.1 $
236.5 $
222.3
144.9
30.8
44.8
110.1
162.8
952.2
1,655.7
89.3
113.0
134.8
2,945.0
214.1
419.7
653.3
269.6
106.7
1,663.4
829.6
(532.8)
296.8
1,800.9
1,033.5
33.1
91.3
4,919.0
197.6
660.4
130.4
29.7
47.7
107.3
95.2
1,268.3
1,783.1
80.8
143.0
70.5
3,345.7
4.4
4.4
Issued - 88,457,634 shares as of September 30, 2020 and September 30, 2019; Outstanding:
66,640,832 shares as of September 30, 2020 and 66,625,011 shares as of September 30, 2019
Additional paid-in capital
Retained earnings
Accumulated other comprehensive income (loss)
Treasury stock, common shares at cost: 21,816,802 as of September 30, 2020 and 21,832,623 as of
September 30, 2019
Total Shareholders’ Equity
Total Liabilities and Shareholders' Equity
$
See Notes to Consolidated Financial Statements
667.0
2,132.2
(180.2)
(897.3)
1,726.1
4,671.1 $
637.4
1,967.4
(182.5)
(853.4)
1,573.3
4,919.0
50
Table of Contents
Hill-Rom Holdings, Inc. and Subsidiaries
STATEMENTS OF CONSOLIDATED CASH FLOWS
(In millions)
Operating Activities
Net income
Adjustments to reconcile net income to net cash, cash equivalents and restricted cash provided
by operating activities:
Depreciation and amortization of property, plant, equipment and software
Acquisition-related intangible asset amortization
Amortization of debt discounts and issuance costs
Loss on extinguishment of debt
Benefit for deferred income taxes
Loss on disposal of property, equipment, intangible assets, and impairments
Stock compensation
Other operating activities
Change in working capital excluding cash, current debt, acquisitions and dispositions:
Trade accounts receivable
Inventories
Other current assets
Trade accounts payable
Accrued expenses and other liabilities
Other assets and liabilities
Net cash, cash equivalents and restricted cash provided by operating activities
Investing Activities
Purchases of property, plant, equipment and software
Proceeds on sale of property and equipment
Payment for acquisition of businesses, net of cash acquired
Payments for acquisition of intangible assets
Payments for acquisition of investments
Proceeds on sale of businesses
Other investing activities
Net cash, cash equivalents and restricted cash used in investing activities
Financing Activities
Proceeds from borrowing on long-term debt
Payments of long-term debt
Borrowings on Revolving Credit Facility
Payments on Revolving Credit Facility
Borrowings on Securitization Facility
Payments on Securitization Facility
Borrowings on Note Securitization Facility
Payments on Note Securitization Facility
Proceeds from issuance of senior unsecured notes
Payment of debt issuance costs
Prepayment premium on extinguishment of 5.75% Notes
Redemption of 5.75% Notes
Cash dividends
Proceeds on exercise of stock options
Stock repurchases for stock award withholding obligations
Stock repurchases in the open market
Other financing activities
Net cash, cash equivalents and restricted cash (used in) provided by financing activities
Effect of exchange rate changes on cash, cash equivalents and restricted cash
Net Cash Flows
Cash, Cash Equivalents and Restricted Cash:
At beginning of period
At end of period
See Notes to Consolidated Financial Statements
51
Year Ended September 30
2019
2018
2020
$
223.0 $
152.2 $
252.4
69.8
109.0
4.0
15.6
(19.0)
2.7
38.4
27.1
71.3
(91.8)
(14.8)
24.0
15.4
7.0
481.7
(105.9)
2.5
(28.4)
—
—
0.8
(0.2)
(131.2)
—
(50.1)
190.0
(270.0)
17.7
(45.5)
32.6
(21.2)
—
—
(12.2)
(425.0)
(58.0)
8.6
(16.5)
(54.1)
8.7
(695.0)
7.2
(337.3)
72.4
122.4
7.1
3.0
(18.8)
3.4
34.4
28.3
(62.3)
(0.9)
15.7
13.2
28.8
2.5
401.4
(73.4)
2.9
(303.4)
(17.1)
(26.6)
166.6
2.0
(249.0)
1,000.0
(1,038.5)
420.0
(340.0)
5.5
(5.5)
68.9
(62.7)
425.0
(12.7)
—
—
(55.4)
14.5
(4.7)
(117.2)
7.5
304.7
(6.3)
450.8
89.6
106.9
7.4
—
(84.8)
2.7
28.1
34.1
(7.7)
(18.7)
(29.4)
12.5
(1.6)
3.7
395.2
(89.5)
4.2
—
—
—
1.0
1.9
(82.4)
1.0
(351.0)
75.0
(165.0)
71.6
(40.7)
122.4
(50.0)
—
(0.4)
—
—
(51.8)
40.0
(14.1)
—
6.4
(356.6)
(5.0)
(48.8)
633.8
296.5 $
183.0
633.8 $
231.8
183.0
$
Table of Contents
Hill-Rom Holdings, Inc. and Subsidiaries
STATEMENTS OF CONSOLIDATED SHAREHOLDERS’ EQUITY
(In millions, except share amounts)
Common Stock
Shares
Issued
Amount
Additional
Paid-in
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Income (Loss)
Treasury
Stock
Noncontrolling
Interests
Total
Balance as of September 30, 2017
Net income
VIE activity
Other comprehensive income (loss), net of tax of ($5.9)
Dividends ($0.78 per common share)
Stock repurchases for stock award withholding obligations
Stock compensation on equity-classified awards
Stock option exercises
Distribution of stock awards
Shares issued under employee stock purchase plan
Balance as of September 30, 2018
Cumulative effect of ASC 606 adoption, net of tax of $4.8
Cumulative effect of ASU 2016-16 adoption, net of tax of $0.2
Reclassification due to ASU 2018-02 adoption
Net income
Other comprehensive income (loss), net of tax of $7.0
Dividends ($0.83 per common share)
Stock repurchases for stock award withholding obligations
Stock repurchases in the open market
Stock compensation on equity-classified awards
Stock option exercises
Distribution of stock awards
Shares issued under employee stock purchase plan
Balance as of September 30, 2019
Net income
Other comprehensive income (loss), net of tax benefit of $9.6
Dividends ($0.87 per common share)
Stock repurchases for stock award withholding obligations
Stock repurchases in the open market
Stock compensation on equity-classified awards
Stock option exercises
Distribution of stock awards
Shares issued under employee stock purchase plan
Other
Balance as of September 30, 2020
See Notes to Consolidated Financial Statements
88,457,634 $
—
—
—
—
—
—
—
—
—
88,457,634
—
—
—
—
—
—
—
—
—
—
—
—
88,457,634
—
—
—
—
—
—
—
—
—
—
88,457,634 $
584.4 $
—
—
—
0.6
—
27.4
3.6
(17.3)
4.2
602.9
—
—
—
—
—
0.5
—
—
33.9
2.6
(7.7)
5.2
637.4
—
—
0.5
—
—
37.8
2.9
(17.1)
5.5
—
667.0 $
1,676.2 $
252.4
—
—
(52.4)
—
—
—
—
—
1,876.2
(4.9)
(5.6)
5.4
152.2
—
(55.9)
—
—
—
—
—
—
1,967.4
223.0
—
(58.5)
—
—
—
—
—
—
0.3
2,132.2 $
4.4 $
—
—
—
—
—
—
—
—
—
4.4
—
—
—
—
—
—
—
—
—
—
—
—
4.4
—
—
—
—
—
—
—
—
—
—
4.4 $
52
(110.0) $
—
—
(3.0)
—
—
—
—
—
—
(113.0)
—
—
(5.4)
—
(64.1)
—
—
—
—
—
—
—
(182.5)
—
2.3
—
—
—
—
—
—
—
—
(180.2) $
(796.8) $
—
—
—
—
(14.1)
—
36.4
17.3
2.9
(754.3)
—
—
—
—
—
—
(4.7)
(117.2)
—
11.9
7.7
3.2
(853.4)
—
—
—
(16.5)
(54.1)
—
5.7
17.1
3.9
—
(897.3) $
7.4 $
—
(7.4)
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
— $
1,365.6
252.4
(7.4)
(3.0)
(51.8)
(14.1)
27.4
40.0
—
7.1
1,616.2
(4.9)
(5.6)
—
152.2
(64.1)
(55.4)
(4.7)
(117.2)
33.9
14.5
—
8.4
1,573.3
223.0
2.3
(58.0)
(16.5)
(54.1)
37.8
8.6
—
9.4
0.3
1,726.1
Table of Contents
Hill-Rom Holdings, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share data)
Note 1. Summary of Significant Accounting Policies
Nature of Operations
Hill-Rom Holdings, Inc. (the “Company,” “Hillrom,” “we,” “us,” or “our”) was incorporated on August 7, 1969, in the State of
Indiana and is headquartered in Chicago, Illinois. We are a global medical technology leader whose approximately 10,000
employees have a single purpose: enhancing outcomes for patients and their caregivers by Advancing Connected Care™.
Around the world, our innovations touch over 7 million patients each day. Our products and services help enable earlier
diagnosis and treatment, optimize surgical efficiency and accelerate patient recovery while simplifying clinical communication
and shifting care closer to home. We make these outcomes possible through digital and connected care solutions and
collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices,
advanced equipment for the surgical space and more, delivering actionable, real-time insights at the point of care.
Basis of Presentation and Principles of Consolidation
The Consolidated Financial Statements include the accounts of Hillrom and its wholly-owned subsidiaries. Intercompany
accounts and transactions have been eliminated in consolidation. Where our ownership interest is less than 100%, the
noncontrolling interests are reported in our Consolidated Financial Statements. Certain prior year amounts have been
reclassified to conform to the current year presentation.
Prior Period Reclassification
Beginning in fiscal year 2020, we are presenting Acquisition-related intangible asset amortization as a separate line item on our
Statements of Consolidated Income for all periods presented. Acquisition-related intangible asset amortization was previously
included in Selling and administrative expenses. Additionally, we will no longer present Gross Profit as a subtotal on our
Statements of Consolidated Income.
The following table presents Acquisition-related intangible asset amortization and Selling and administrative expenses,
excluding the Acquisition-related intangible asset amortization, for the fiscal years ended September 30, 2019 and 2018.
Selling and administrative expense, previously reported
Less: Acquisition-related intangible asset amortization
Selling and administrative expense, currently reported
Use of Estimates
Year Ended September 30
2018
2019
$
$
941.0 $
(122.4)
818.6 $
891.6
(106.9)
784.7
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that
affect the reported amounts of certain assets and liabilities and disclosure of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenue and expense in the period. Actual results could differ from those
estimates. Examples of such estimates include, but are not limited to, our allowance for doubtful accounts receivable, inventory
reserves, accrued warranties, the impairment of intangible assets and goodwill, use of the spot yield curve approach for pension
expense, income taxes and commitments and contingencies. See below for more information.
53
Table of Contents
Government Programs Related to COVID-19
On March 25, 2020, the U.S. government approved the Coronavirus Aid, Relief and Economic Security (“CARES”) Act to
provide economic stimulus to address the impact of the pandemic. The governments in certain other non-U.S. countries have
also approved legislation in their jurisdictions to address the impact of the pandemic. We evaluated our eligibility and assessed
the conditions and requirements of participation in many programs. For the programs in which we elected to participate, we
recognized $3.2 million in government grants and cost abatements associated with state aid within the Statement of
Consolidated Income for the fiscal year ended September 30, 2020. In addition, we deferred the payment of the employer share
of the U.S. Federal Insurance Contributions Act (“FICA”) tax payments totaling $13.8 million in accordance with the CARES
Act within the Consolidated Balance Sheet as of September 30, 2020. We continue to evaluate what impact, if any, the CARES
Act, or any similar legislation in other non-U.S. jurisdictions, may have on our results of operations.
Cash and Cash Equivalents
We consider investments in marketable securities and other highly liquid instruments with a maturity of three months or less at
date of purchase to be cash equivalents. All of our marketable securities may be freely traded.
Restricted Cash
Restricted cash represents funds that are restricted to satisfy designated current liabilities. As of September 30, 2019, restricted
cash consisted of amounts held in a trust account to redeem all of our previously outstanding senior unsecured 5.75% notes due
September 2023. The restricted cash was used to redeem these senior notes on October 7, 2019. See Note 5. Financing
Agreements for additional information.
Trade Accounts Receivable
Trade accounts receivable are recorded at the invoiced amount and do not bear interest, unless the transaction is an installment
sale with extended payment terms. Allowances for doubtful accounts are recorded as a component of Selling and administrative
expenses and represent our best estimate of the amount of probable credit losses and collection risk in our existing accounts
receivable. Receivables are generally reviewed for collectability based on historical collection experience for each receivable
type and are also reviewed individually for collectability. Account balances are charged against the allowance when we believe
it is probable the receivable will not be recovered. We do not have any off-balance sheet credit exposure related to our
customers.
Within rental revenue, domestic third-party payers’ reimbursement process requires extensive documentation, which has had
the effect of slowing both the billing and cash collection cycles relative to the rest of the business, and therefore, increasing total
accounts receivable. Because of the extensive documentation required and the requirement to settle a claim with the primary
payer prior to billing the secondary and/or patient portion of the claim, the collection period for a claim in a portion of our
business may, in some cases, be extended.
We generally hold our trade accounts receivable until they are paid. Certain long-term receivables are occasionally sold to third
parties; however, any recognized gain or loss on such sales has historically not been material.
Inventories
Inventories are valued at lower of cost or market. Inventory costs are determined by the last-in, first-out (“LIFO”) method for
approximately 16% and 30% of our inventories as of September 30, 2020 and September 30, 2019. Costs for other inventories
have been determined principally by the first-in, first-out (“FIFO”) method. If the FIFO method of inventory accounting had
been used for all inventories, they would have been approximately $5.5 million and $0.3 million higher than reported as of
September 30, 2020 and September 30, 2019. Inventories consist of the following:
Inventories, net of reserves:
Finished products
Work in process
Raw materials
Total inventories, net of reserves
54
Year Ended September 30
2020
2019
$
$
167.6 $
48.4
136.0
352.0 $
120.5
42.4
106.7
269.6
Table of Contents
We record reserves when the facts and circumstances indicate that particular inventories will not be sold at prices in excess of
current carrying costs. These estimates are based on historical experience and expected future trends.
Property, Plant and Equipment
Property, plant and equipment is recorded at cost and depreciated over the estimated useful life of the assets using principally
the straight-line method. Ranges of estimated useful lives are as follows:
Land improvements
Buildings and building equipment
Machinery and equipment
Equipment leased to others
Useful Life
6 - 15 years
10 - 40 years
3 - 10 years
2 - 10 years
When property, plant and equipment is retired from service or otherwise disposed of, the cost and related amount of
depreciation is eliminated from the asset and accumulated depreciation accounts. The difference, if any, between the net asset
value and the proceeds on sale are charged or credited to income.
Total depreciation expense in fiscal years ended September 30, 2020, 2019 and 2018 was $60.6 million, $62.1 million and
$78.6 million. The major components of property, plant and equipment and the related accumulated depreciation were as
follows:
Land and land improvements
Buildings and building equipment
Machinery and equipment
Equipment leased to others
Total
Goodwill
Year Ended September 30
2020
2019
Cost
Accumulated
Depreciation
Cost
Accumulated
Depreciation
$
16.9 $
4.4 $
16.7 $
208.2
416.3
216.8
95.4
303.4
148.9
199.7
397.0
216.2
$
858.2 $
552.1 $
829.6 $
3.9
91.1
285.2
152.6
532.8
Goodwill represents the excess of the purchase price paid over the estimated fair value of the net assets acquired and liabilities
assumed in the acquisition of a business. Goodwill is not amortized, but is tested for impairment at least annually or on an
interim basis if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit
below its carrying value. See Note 4. Goodwill and Intangible Assets for additional information.
Fair Value Measurements
Fair value measurements are classified and disclosed in one of the following three categories:
•
•
•
Level 1: Financial instruments with unadjusted quoted prices in active markets that are accessible at the
measurement date for identical, unrestricted assets and liabilities.
Level 2: Financial instruments with observable inputs other than those included in Level 1 such as quoted prices
for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or
can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3: Financial instruments with unobservable inputs that are supported by little or no market activity and that
are significant to the fair value of the assets or liabilities. Unobservable inputs reflect our own assumptions that
market participants would use in pricing the asset or liability (including assumptions about risk). Unobservable
inputs shall be developed based on the best information available in the circumstances, which might include our
own data.
55
Table of Contents
We record cash and cash equivalents, as disclosed on our Consolidated Balance Sheets, as Level 1 instruments and certain other
investments and derivatives as Level 2 instruments as they are not actively quoted. Except for the adoption of revised disclosure
guidance related to investments held by our pension plan as discussed in Note 8. Retirement and Postretirement Benefit Plans,
there have been no significant changes in our classification among assets and liabilities. Refer to Note 5. Financing Agreements
for disclosure of our debt instrument fair values.
Warranties and Guarantees
We routinely grant limited warranties on our products with respect to defects in material and workmanship. The terms of these
warranties are generally one year; however, certain components and products have substantially longer warranty periods. We
recognize a reserve with respect to these obligations at the time of product sale, with subsequent warranty claims recorded
directly against the reserve. The amount of the warranty reserve is determined based on historical trend experience for the
covered products. For more significant warranty-related matters, which might require a field corrective action, separate reserves
are established when such events are identified and the cost of correction can be reasonably estimated.
In the normal course of business, we enter into various other guarantees and indemnities in our relationships with suppliers,
service providers, customers, business partners and others. Examples of these arrangements would include guarantees of
product performance, indemnifications to service providers and indemnifications of our actions to business partners. These
guarantees and indemnifications have not historically had a material impact on our financial condition or results of operations,
nor do we expect them to although indemnifications associated with our actions generally have no dollar limitations.
In conjunction with our acquisition and divestiture activities, we entered into select guarantees and indemnifications of
performance with respect to the fulfillment of our commitments under applicable purchase and sale agreements. The
arrangements generally indemnify the buyer or seller for damages associated with breach of contract, inaccuracies in
representations and warranties surviving the closing date and satisfaction of liabilities and commitments retained under the
applicable contract. With respect to divestitures, we also routinely enter into non-competition agreements for varying periods of
time. Guarantees and indemnifications with respect to acquisition and divestiture activities, if triggered, could have an adverse
impact on our Consolidated Financial Statements.
A rollforward of changes in our warranty reserve is as follows:
Year Ended September 30
2019
2020
Balance at the beginning of the period
Provision for warranties in the period
Warranty reserves acquired
Warranty reserves assumed 1
Warranty claims incurred in the period
Balance at the end of the period
1 As a result of the asset acquisition in our Front Line Care segment discussed in Note 3. Business Combinations.
29.7 $
18.6
—
—
(17.5)
30.8 $
$
$
20.5
23.0
0.2
2.8
(16.8)
29.7
Accrued Rebates
We provide rebates and sales incentives to certain customer groups and distributors. We also have arrangements where we
provide rebates to certain distributors that sell to end-user customers at prices determined under a contract between us and the
end-user customer. Provisions for rebates are recorded as a reduction in net revenue when revenue is recognized.
Retirement Plans
We sponsor retirement and postretirement benefit plans covering certain employees. Expense recognized in relation to these
defined benefit retirement and postretirement health care plans is based upon actuarial valuations and inherent in those
valuations are key assumptions including discount and mortality rates, and where applicable, expected returns on assets,
projected future salary rates and projected health care cost trends. The discount rates used in the valuation of our defined benefit
pension and postretirement plans are evaluated annually based on current market conditions. In setting these rates we utilize
long-term bond indices and yield curves as a preliminary indication of interest rate movements, and then make adjustments to
the respective indices to reflect differences in the terms of the bonds covered under the indices in comparison to the projected
outflow of our obligations. Our overall expected long-term rate of return on pension assets is based on historical and expected
56
Table of Contents
future returns, which are inflation adjusted and weighted for the expected return for each component of the investment
portfolio. Our rate of assumed compensation increase is also based on our specific historical trends wage adjustments.
We account for our defined benefit pension and other postretirement plans by recognizing the funded status of a benefit plan in
the balance sheet. We also recognize in Accumulated other comprehensive income (loss) certain gains and losses that arose in
the period. See Note 8. Retirement and Postretirement Benefit Plans for key assumptions and further discussion related to our
pension and postretirement plans.
Environmental Liabilities
Expenditures that relate to an existing environmental condition caused by past operations, and which do not contribute to future
revenue generation, are expensed. A reserve is established when it is probable that a liability has been incurred and the amount
of the loss can be reasonably estimated. These reserves are determined without consideration of possible loss recoveries from
third parties.
Specific costs included in environmental expense and reserves include site assessment, development of a remediation plan,
clean-up costs, post-remediation expenditures, monitoring, fines, penalties and legal fees. Reserve amounts represent the
expected undiscounted future cash outflows associated with such plans and actions.
Self Insurance
We are generally self-insured up to certain stop-loss limits for certain employee health benefits, including medical, drug and
dental. Our policy is to estimate reserves based upon several factors including known claims, estimated incurred but not
reported claims and outside actuarial analysis, which are based on historical information along with certain assumptions about
future events. Such estimated reserves are classified as Other current liabilities and Other long-term liabilities in the
Consolidated Balance Sheets. Refer to Note 16. Commitments and Contingencies for additional information.
Treasury Stock
Treasury stock consists of our common shares that have been issued, but subsequently reacquired. We account for treasury
stock purchases under the cost method. When these shares are reissued, we use an average-cost method to determine cost. The
difference between proceeds and the cost basis of the treasury stock is recorded to Additional paid-in capital.
Revenue Recognition — Sales and Rentals
Revenue is presented in the Consolidated Statements of Income net of sales discounts and allowances, GPO fees, price
concessions, rebates and customer returns for products sales and rental revenue services.
Disaggregation of Revenue
The Company disaggregates revenue recognized from contracts with customers by geography and reportable segments
consistent with the way in which management operates and views the business. See Note 14. Segment Reporting for the
presentation of the Company's revenue disaggregation.
Performance Obligations & Transaction Price Determination
Revenue is recognized as performance obligations are satisfied, either at a point in time or over time, driven by the nature of the
performance obligation that is contracted to be provided to our customers. A performance obligation is a promise in a contract
to transfer a distinct good or service to the customer, and is the unit of account in the contract. Revenue is measured as the
amount of consideration we expect to receive in exchange for satisfying the performance obligations. Certain of our contracts
have multiple performance obligations. A contract’s transaction price is allocated to the distinct performance obligations and
recognized as revenue when, or as, each performance obligation is satisfied. We allocate the contract’s transaction price to each
performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract.
The majority of our product sales revenue is recognized at a point in time, primarily based on the transfer of title, except in
circumstances where we are also required to install the equipment, for which revenue is recognized upon customer acceptance
of the installation. Performance obligations involving the provision of services and revenue from rental usage of our products
are recognized over the time period specified in the contractual arrangement with the customer.
57
Table of Contents
Revenue is presented net of several types of variable consideration including rebates, discounts and product returns, which are
estimated at the time of sale generally using the expected value method, although the most likely amount method is also used
for certain types of variable consideration. These estimates take into consideration historical experience, current contractual and
statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment
patterns.
Deferred Contract Costs
Certain costs associated with obtaining or fulfilling a contract with a customer (collectively referred to as “deferred contract
costs”) are capitalized until such time as the related performance obligations are completed and the related revenue is
recognized. Deferred contract costs are recorded as Other current assets and Other assets.
Costs to obtain a contract are primarily comprised of sales commissions paid upon receipt of a purchase order for certain
products, primarily care communications. Commissions are expensed commensurate with the timing of revenue recognition,
which is generally 12 to 36 months.
Costs to fulfill a contract includes equipment, installation and other costs directly related to certain performance obligations not
completed. These costs primarily relate to our care communications products and other construction projects that require
installation or ongoing service maintenance. These costs are expensed commensurate with the timing of revenue recognition,
which is generally 12 to 24 months.
The following table summarizes deferred contract cost activity for the fiscal year ended September 30, 2020:
September 30, 2020
Ending Balance
Amortization
Statement of Consolidated Income Classification
Costs to obtain a contract
Other current assets
Other assets
Costs to fulfill a contract
Other current assets
Other assets
Contract Balances
$
$
6.7 $
1.8
26.9 $
3.4
(17.5) Selling and administrative expenses
—
(75.2) Cost of goods sold
—
Contract liabilities represent deferred revenues that arise as a result of cash received from customers at inception of contracts or
where the timing of billing for services precedes satisfaction of our performance obligations. Such remaining performance
obligations represent the portion of the contract price for which work has not been performed and are primarily related to our
installation and service contracts. These contract liabilities are recorded in Deferred revenue and Other long-term liabilities. We
expect to satisfy the majority of the remaining performance obligations and recognize revenue related to installation and service
contracts within 12 to 24 months.
The nature of our products and services does not give rise to contract assets as we typically do not have instances where a right
to payment for goods and services already transferred to a customer exists that is conditional on something other than the
passage of time.
58
Table of Contents
The following table summarizes contract liability activity for the fiscal year ended September 30, 2020. The contract liability
balance represents the transaction price allocated to the remaining performance obligations.
Balance as of September 30, 2019
Deferred revenue acquired
New revenue deferrals
Revenue recognized upon satisfaction of performance obligations
Balance as of September 30, 2020
Accounting & Practical Expedient Elections
Contract
Liabilities
$
$
125.8
2.9
300.7
(291.3)
138.1
We account for shipping and handling activities as fulfillment costs within Cost of goods sold. These activities are not
considered to be a separate performance obligation. Taxes assessed by a governmental authority that are directly imposed on a
revenue producing transaction between us and our customers, including but not limited to sales taxes, use taxes and value added
taxes, are excluded from revenue and cost.
We adopted the significant financing practical expedient under which the impacts of financing are considered immaterial if the
duration of the financing is one year or less. Customer payments are due at various times up to 90 days from the date of
invoice, though in some countries and for certain customer types, credit terms are longer based on local industry standard.
Cost of Net Revenue
Cost of goods sold for product sales consists primarily of purchased material costs, fixed manufacturing expense, variable direct
labor, overhead costs and costs associated with the distribution and delivery of products to our customers. Rental expenses
consist of costs associated directly with rental revenue, including depreciation, maintenance, logistics and service center facility
and personnel costs.
Research and Development Costs
Research and development costs relate primarily to internal costs for salaries and direct overhead expenses as well as the cost of
outside vendors to conduct R&D activities. These costs are expensed as incurred. In addition, certain costs for software
development technology held for sale are capitalized as intangibles when technological feasibility in the software is established
and are amortized over a period of three years to five years once the software is ready for its intended use. The amounts
capitalized in fiscal 2020, 2019 and 2018 were approximately $15.3 million, $8.0 million and $2.4 million.
Comprehensive Income
We include the after-tax effect of unrealized gains or losses on interest and foreign currency hedges, foreign currency
translation adjustments and pension or other defined benefit postretirement plans’ actuarial gains or losses and prior service
costs or credits in Accumulated other comprehensive income (loss). See Note 9. Other Comprehensive Income of our
Consolidated Financial Statements for further details.
Foreign Currency
The functional currency of foreign operations is generally the local currency in the country of domicile. Assets and liabilities of
foreign operations are primarily translated into U.S. dollars at year-end rates of exchange and the income statements are
translated at the average rates of exchange prevailing in the year. Adjustments resulting from translation of the financial
statements of foreign operations into U.S. dollars are excluded from the determination of net income, but included as a
component of Accumulated other comprehensive income (loss). Foreign currency gains and losses resulting from foreign
currency transactions are included in our results of operations and are not material. Foreign currency movements on items
designated as net investment hedges were recorded in Accumulated other comprehensive income (loss).
59
Table of Contents
Stock-Based Compensation
We account for stock-based compensation under fair value provisions. Stock-based compensation cost is measured at the grant
date based on the value of the award and is recognized as expense over the vesting period. We estimate forfeitures on stock-
based compensation, which are based on historical and expected forfeiture rates. In order to determine the fair value of stock
options on the date of grant, we utilize a Binomial model. In order to determine the fair value of other performance-based stock
awards on the date of grant, we utilize a Monte Carlo model. Inherent in these models are assumptions related to a volatility
factor, expected life, risk-free interest rate, dividend yield and expected forfeitures. The risk-free interest rate is based on factual
data derived from public sources. The volatility factor, expected life, dividend yield and expected forfeiture assumptions require
judgment utilizing historical information, peer data and future expectations. Restricted stock units (“RSUs”) are measured based
on the fair market price of our common stock on the date of grant, as reported by the New York Stock Exchange, multiplied by
the number of units granted. See Note 13. Common Stock for further details.
Income Taxes
Hillrom and its eligible subsidiaries file a consolidated U.S. income tax return. Foreign operations file income tax returns in a
number of jurisdictions. We have a variety of deferred tax assets in numerous tax jurisdictions which are computed using an
asset and liability approach to reflect the net tax effects of temporary differences between the financial reporting carrying
amounts of assets and liabilities and the corresponding income tax amounts. These deferred tax assets are subject to periodic
assessment as to recoverability. If it is determined that it is more likely than not that the benefits will not be realized, valuation
allowances are recognized. In evaluating whether it is more likely than not that we would recover these deferred tax assets,
future taxable income, the reversal of existing temporary differences and tax planning strategies are considered.
As of fiscal year ended September 30, 2020, we had valuation allowances on deferred tax assets, on a tax-effected basis,
primarily related to certain foreign deferred tax attributes that are not expected to be utilized. We believe that our estimates for
the valuation allowances recorded against deferred tax assets are appropriate based on current facts and circumstances.
We account for uncertain income tax positions using a threshold and measurement attribute for the financial statement
recognition and measurement of a tax position taken or expected to be taken in a tax return. The difference between the tax
benefit recognized in the financial statements for an uncertain income tax position and the tax benefit claimed in the tax return
is referred to as an unrecognized tax benefit. See Note 11. Income Taxes for further details.
Derivative Instruments and Hedging Activity
We use derivative financial instruments to manage the economic impact of fluctuations in currency exchange and interest rates.
Derivative financial instruments related to currency exchange rates include forward purchase and sale agreements that generally
have terms no greater than 15 months. Additionally, interest rate swaps and cross-currency interest rate swaps are sometimes
used to convert some or all of our long-term debt to either a fixed or variable rate.
Derivative financial instruments are recognized in the Consolidated Balance Sheets as either assets or liabilities and are
measured at fair value. Changes in the fair value of derivatives are recorded each period in the Statement of Consolidated
Income or the Statement of Consolidated Comprehensive Income (Loss), depending on whether a derivative is designated and
considered effective as part of a hedge transaction, and if it is, the type of hedge transaction. The Company's derivatives are
considered to be highly effective under hedge accounting principles. The Company does not hold or issue derivative financial
instruments for speculative purposes. As a result of being effective, gains and losses on derivative instruments reported in
Accumulated other comprehensive income (loss) are subsequently included in the Statement of Consolidated Income in the
periods in which earnings are affected by the hedged item. These activities have not had a material effect on our Consolidated
Financial Statements for the periods presented herein.
60
Table of Contents
Recently Adopted Accounting Guidance
In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)
2016-02, Leases (Topic 842) and subsequently issued related amendments, collectively referred to as “ASC 842”. The objective
of this guidance is to increase transparency and comparability among organizations through recognizing leased assets, called
right-of-use assets (“ROU”), and lease liabilities on the balance sheet and disclosing key information about leasing
arrangements. As a lessee, the new standard requires us to recognize both the ROU assets and lease liabilities in the balance
sheet for most leases, whereas under previous GAAP only finance lease liabilities (referred to as capital leases) were recognized
in the balance sheet. In addition, for both lessees and lessors, the definition of a lease has been revised, which may result in
changes to the classification of an arrangement as a lease. Under the new standard, an arrangement that conveys the right to
control the use of an identified asset by obtaining substantially all of its economic benefits and directing how it is used is a
lease, whereas the previous definition focused on the ability to control the use of the asset or to obtain its output. Quantitative
and qualitative disclosures related to the amount, timing and judgments of an entity’s accounting for leases and the related cash
flows are expanded under the new standard. Disclosure requirements apply to both lessees and lessors, whereas previous
disclosures related only to lessees. The recognition, measurement, and presentation of revenues, expenses, and cash flows
arising from a lease have not significantly changed from previous GAAP.
We adopted ASC 842 effective October 1, 2019 using the optional transition method approach. We elected the package of
practical expedients, which applies to both lessees and lessors, to (1) not reassess whether existing contracts contain leases, (2)
carryforward the existing lease classification, and (3) not reassess initial direct costs associated with existing leases.
As a lessee, the adoption of the guidance on October 1, 2019 resulted in the recognition of ROU assets of $82.5 million and
lease liabilities of $85.8 million, which all related to operating leases. The ROU assets were lower than the lease liabilities due
to the derecognition of deferred rent balances of $3.3 million. As a lessor, there was no impact as a result of the adoption. We
did not recognize any adjustment to the comparative period presented in the financial statements in accordance with our
adoption method. The guidance did not have a material impact on our Statements of Consolidated Income.
See Note 7. Leases for additional information on the impacts of ASC 842.
In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for
Goodwill Impairment. This standard eliminates Step 2 of the goodwill impairment test and requires a goodwill impairment to be
measured as the amount by which a reporting unit’s carrying amount exceeds its fair value, not to exceed the carrying amount
of its goodwill. ASU 2017-04 is effective for our first quarter of fiscal 2021 and requires a prospective transition method. Early
adoption is permitted. We early adopted this standard in the first quarter of fiscal 2020 and the guidance did not have a material
impact on our Consolidated Financial Statements.
In October 2018, the FASB issued ASU 2018-16, Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight
Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. The
purpose of the standard is to allow the use of the OIS rate based on the SOFR for hedge accounting purposes, which allows
entities to designate changes in the fair values of fixed-rate financial assets or liabilities attributable to the OIS rate as the
hedged risk. The amendment recognizes the OIS rate based on the SOFR as likely London Interbank Offered Rate (“LIBOR”)
replacements and supports the marketplace transition by adding the new reference rate as a benchmark rate. We adopted this
standard in the first quarter of fiscal 2020. The adoption of this ASU did not impact our financial statements as we have not yet
utilized the OIS rate based on the SOFR for borrowings under our lending arrangements or as a benchmark rate for hedge
accounting purposes. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the
Effects of Reference Rate Reform on Financial Reporting. The purpose of the standard is to provide guidance for the effects of
the marketplace transition from LIBOR to a new reference rate as a benchmark rate. ASU 2020-04 is optional and is effective
for a limited period of time from March 12, 2020 through December 31, 2022. We will continue to monitor, assess, and plan
for the phase out of LIBOR.
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09,
Revenue from Contracts with Customers (“ASC 606”), which provides guidance for revenue recognition. The standard’s core
principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that
reflects the consideration to which the company expects to be entitled in exchange for those goods or services. We adopted the
new standard in the first quarter of fiscal 2019 using the modified retrospective approach. The cumulative effect of initially
applying ASC 606 was an adjustment to decrease the opening Retained earnings by $4.9 million, which is net of a $4.8 million
tax effect, as of October 1, 2018.
61
Table of Contents
In January 2016, the FASB issued ASU 2016-01, Financial Instruments (Topic 825-10) – Recognition and Measurement of
Financial Assets and Financial Liabilities. This standard requires equity securities to be measured at fair value with changes in
fair value recognized through net income and eliminated the cost method for equity securities without readily determinable fair
values. In February 2018, the FASB issued ASU 2018-03, Technical Corrections and Improvements to Financial Instruments –
Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This standard issued
six technical corrections and improvements to clarify guidance in ASU 2016-01, which primarily impacted the accounting for
equity investments, financial liabilities under fair value option, and the presentation and disclosure requirements of financial
instruments. We adopted ASU 2016-01 and ASU 2018-03 prospectively in the first quarter of fiscal 2019 and the new updates
did not have a material impact on our Consolidated Financial Statements. We applied the practicability election within this
standard under which our investments in equities that are not recorded under the consolidation or equity method of accounting
guidance are valued at cost, less impairment, plus or minus observable price changes (in orderly transactions) of an identical or
similar investment of the same issuer.
In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts
and Cash Payments. The purpose of the standard is to reduce diversity in practice in how certain transactions are classified in
the statement of cash flows. The standard addresses specific issues including debt prepayment and extinguishment costs,
settlement of zero-coupon debt, contingent consideration payments made after a business combination, proceeds from the
settlement of insurance claims and certain life insurance policies, distributions received from equity method investees,
beneficial interests in securitization transactions, and the application of the predominance principle in separately identifiable
cash flows. We adopted ASU 2016-15 in the first quarter of fiscal 2019 using a retrospective transition method and elected to
continue to use the nature of distribution approach for distributions received from equity method investees. The impact of the
adoption of ASU 2016-15 did not have a material impact on our Consolidated Financial Statements.
In October 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory (Topic 740). This
standard requires immediate recognition of the income tax consequences of intercompany asset transfers other than inventory.
We adopted ASU 2016-16 in the first quarter of fiscal 2019 using the modified retrospective approach with a cumulative effect
adjustment directly to retained earnings. The cumulative effect of applying ASU 2016-16 was an adjustment to decrease
prepaid taxes by $5.8 million and increase deferred tax assets by $0.2 million with a corresponding decrease to the opening
balance of Retained earnings of $5.6 million.
In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. This standard
requires that companies include amounts generally described as restricted cash and restricted cash equivalents, along with cash
and cash equivalents, when reconciling the beginning-of-period and end-of-period amounts shown on the statement of cash
flows. We retrospectively adopted ASU 2016-18 in the first quarter of fiscal 2019, resulting in no change to our historical
Statements of Consolidated Cash Flows. We have included restricted cash with cash and cash equivalents accordingly in our
Statement of Consolidated Cash Flows for the fiscal year ended September 30, 2019.
In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business.
This standard provides clarification on the definition of a business and provides guidance on whether transactions should be
recorded as acquisitions (or disposals) of assets or businesses. We adopted ASU 2017-01 in the first quarter of fiscal 2019. ASU
2017-01 did not have a material impact on our Consolidated Financial Statements.
In February 2017, the FASB issued ASU 2017-07, Compensation – Retirement Benefits (Topic 715): Improving the
Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. This standard requires employers to
include only the service cost component of net periodic pension cost in operating expenses, together with other employee
compensation costs. The other components of net periodic pension cost, including interest cost, expected return on plan assets,
amortization of prior service cost and settlement and curtailment effects, are to be included in non-operating expenses. The
amendment allows a practical expedient that permits an employer to use the amounts disclosed in its pension and other
postretirement benefit plan note for the prior comparative periods as the estimation basis for applying the retrospective
presentation requirements. We adopted ASU 2017-07 in the first quarter of fiscal 2019 and applied the practical expedient upon
adoption. ASU 2017-07 did not have a material impact on our Consolidated Financial Statements. As a result of the adoption of
ASU 2017-07, we reclassified $0.1 million for fiscal 2018 and $1.6 million for fiscal 2017 from Selling and administrative
expenses to Investment income (expense) and other, net. See Note 8. Retirement and Postretirement Benefit Plans for
additional information on our retirement and postretirement plans.
In February 2018, the FASB issued ASU 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220). The
standard allows entities to reclassify tax effects stranded in accumulated other comprehensive income as a result of tax reform
to retained earnings. We adopted ASU 2018-02 in the first quarter of fiscal 2019. As a result of the adoption of ASU 2018-02,
62
Table of Contents
we reclassified $5.4 million from Accumulated other comprehensive income (loss) to Retained earnings. We applied the
individual item approach for releasing income tax effects from Accumulated other comprehensive income (loss).
Recently Issued Accounting Guidance
In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326) - Measurement of Credit
Losses of Financial Instruments and has subsequently issued related amendments, collectively referred to as “Topic 326”. Topic
326 requires entities to measure credit losses for financial assets measured at amortized cost based on expected losses rather
than incurred losses. For available-for-sale debt securities with unrealized losses, entities will be required to recognize credit
losses through an allowance for credit losses. Topic 326 is effective for our first quarter of fiscal 2021 and requires a modified
retrospective transition method. Early adoption is permitted. We do not expect the adoption to have a material impact on our
Consolidated Financial Statements.
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to
the Disclosure Requirements for Fair Value Measurement. The purpose of the standard is to improve the overall usefulness of
fair value disclosures to financial statement users and reduce unnecessary costs to companies when preparing the disclosures.
ASU 2018-13 is effective for our first quarter of fiscal 2021 and requires the application of the prospective method of transition
(for only the most recent interim or annual period presented in the initial fiscal year of adoption) to the new disclosure
requirements for (1) changes in unrealized gains and losses included in other comprehensive income and (2) the range and
weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. ASU 2018-13 also
requires prospective application to any modifications to disclosures made because of the change to the requirements for the
narrative description of measurement uncertainty. The effects of all other amendments made by ASU 2018-13 must be applied
retrospectively to all periods presented. Early adoption is permitted. We are currently in the process of evaluating the impact of
adoption on our Consolidated Financial Statements.
In August 2018, the FASB issued ASU 2018-14, Compensation – Retirement Benefits – Defined Benefit Plans – General (Topic
715-20): Disclosure Framework – Changes to the Disclosure Requirements for Defined Benefit Plans. The purpose of the
standard is to improve the overall usefulness of defined benefit pension and other postretirement plan disclosures to financial
statement users and reduce unnecessary costs to companies when preparing the disclosures. ASU 2018-14 is effective for our
fourth quarter of fiscal 2021 and requires a retrospective transition method. Early adoption is permitted. We are currently in the
process of evaluating the impact of adoption on our Consolidated Financial Statements.
In August 2018, the FASB issued ASU 2018-15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40):
Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The
update aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement for capitalizing
implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use
software license). ASU 2018-15 is effective for our first quarter of fiscal 2021 and allows a retrospective or a prospective
transition method to all implementation costs incurred after the date of adoption. Early adoption is permitted. We are currently
in the process of evaluating the impact of adoption on our Consolidated Financial Statements.
In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction
between Topic 808 and Topic 606. The purpose of the standard is to (1) clarify that transactions between participants in a
collaborative agreement should be accounted for under Topic 606 and (2) add unit-of-account guidance in Topic 808 to align
with Topic 606. ASU 2018-18 is effective for our first quarter of fiscal 2021 and must be applied retrospectively to the first
quarter of fiscal 2020, the date of initial application of Topic 606. Early adoption is permitted. We are currently in the process
of evaluating the impact of adoption on our Consolidated Financial Statements.
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.
The purpose of the standard is to remove certain exceptions to the general principles of Topic 740: Income Taxes in order to
reduce the cost and complexity of its application and to maintain or improve the usefulness of the information provided to users
of financial statements. ASU 2019-12 is effective for our first quarter of fiscal 2022 and will be applied either retrospectively
or prospectively depending on the specific Topic 740 exception affected. Early adoption is permitted. We are currently in the
process of evaluating the impact of adoption on our Consolidated Financial Statements.
Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require
adoption until a future date are not expected to have a material impact on the Company’s Consolidated Financial Statements
upon adoption.
63
Table of Contents
Note 2. Supplementary Financial Statement Information
Supplemental Balance Sheet Information
Investments
During the fiscal year ended September 30, 2019, we acquired $26.6 million of non-marketable equity securities that are valued
at cost.
During the fiscal year ended September 30, 2020, we sold an equity investment with a carrying value of $3.1 million and
recognized a loss of $0.3 million and recognized an impairment loss of $1.7 million on a cost method investment. These losses
were recorded as a component of Investment income (expense) and other, net.
As of September 30, 2020 and 2019, investments totaling $49.0 million and $51.1 million were recorded as a component of
Other assets.
Supplemental Cash Flow Information
Cash paid for income taxes
Cash paid for interest
Non-cash investing activities:
Change in capital expenditures not paid
Sale of equity method investment
Total non-cash investing activities:
Non-cash financing activities:
Year Ended September 30
2020
2019
2018
$
88.0 $
54.4 $
72.4
91.8
$
$
4.9 $
8.0 $
2.1
—
7.0 $
8.0 $
44.8
90.4
(1.6)
—
(1.6)
56.6
36.2
Treasury stock issued under stock compensations plans
$
26.7 $
22.7 $
Distribution of shares issued under stock-based compensation plans
30.0
15.4
64
Table of Contents
Note 3. Business Combinations
Acquisitions
Assets acquired and liabilities assumed in a business combination are recorded at their estimated fair values on the date of
acquisition. The difference between the purchase price amount and the net fair value of assets acquired and liabilities assumed
is recognized as goodwill on the balance sheet if the purchase price exceeds the estimated net fair value or as a bargain purchase
gain on the income statement if the purchase price is less than the estimated net fair value. The allocation of the purchase price
may be modified up to one year after the acquisition date as more information is obtained about the fair value of assets acquired
and liabilities assumed.
During fiscal 2020 and 2019, we acquired the following companies:
Fiscal Year Company Name
2020
Excel Medical
2020
Connecta
Description of the Business
Clinical communications software company
located in the United States
Clinical communications software company
based in Mexico.
2020
2019
2019
Videomed 1
Voalte
Breathe
Developer of integrated video solutions in
operating rooms located in Italy.
Clinical communications software company
located in the United States.
Developer and manufacturer of a patented
wearable, non-invasive ventilation technology
that supports improved patient mobility, which
is located in the United States.
Description of the Acquisition
Purchased all of the outstanding equity
interest.
Purchased the multiplatform medical device
integration and connectivity software
programs, products, and solutions of the
company.
Purchased all of the outstanding equity
interest.
Purchased all of the outstanding equity
interest.
Purchased all of the outstanding equity
interest.
1 On July 21, 2020, we acquired the remaining 74% outstanding equity interest in Videomed for total aggregate consideration
of $10.7 million. As a result of the transaction, the previously held 26% equity investment was adjusted to reflect the fair
value as of the acquisition date and a gain of $3.0 million was recognized in Investment income (expense) and other, net for
the fiscal year ended September 30, 2020. The fair value of the previously held equity investment was estimated using the
discounted cash flow method of the income approach that incorporated a discount for the lack of marketability.
65
Table of Contents
The following tables summarize additional details for each acquisition that closed during the fiscal years ended September 30,
2020 and 2019:
Acquisition Details:
Date of acquisition
Cash paid
Contingent consideration 1
Total consideration 2
Contingent consideration payable up to: 3
Segment information:
Company Name
Excel Medical
Connecta
Videomed
January 10, 2020 May 18, 2020
July 21, 2020
$
$
$
13.1 $
6.1
19.2 $
15.0 $
7.5 $
0.2
7.7 $
4.0 $
7.8
2.9
10.7
3.7
Patient Support
Systems
Front Line Care
Surgical
Solutions
The following summarizes the fair value of assets acquired and liabilities assumed for each fiscal 2020 acquisition: 4
Trade accounts receivable
Inventories
Other current assets
Goodwill 5
Developed technology 6
Other assets
Trade accounts payable
Deferred revenue
Other current liabilities
Other long-term liabilities
Fair value of assets acquired and liabilities assumed
Less: Fair value adjustment of previously held investment
Total purchase price, net of cash acquired
$
$
0.6 $
0.2
0.1
10.5
10.9
0.1
—
(2.7)
(0.5)
—
19.2
—
19.2 $
— $
—
—
4.8
2.9
—
—
—
—
—
7.7
—
7.7 $
2.5
0.9
0.2
10.0
4.4
0.6
(1.2)
(0.2)
(1.1)
(2.4)
13.7
(3.0)
10.7
$
0.3 $
2.2 $
Acquisition costs for the fiscal year ended September 30, 2020:
Acquisition and integration costs recognized in Selling and
0.4
administrative expenses
1 This amount represents the fair value of the contingent consideration on the acquisition date. For Excel Medical, contingent
consideration also includes $1.6 million, which was withheld at the close of the transaction and is payable upon completion
of a supply contract modification. As of September 30, 2020, we recognized $1.4 million of acquisition and integration costs
for the fair value adjustment of the Excel Medical contingent consideration. The fair value adjustments related to Connecta
and Videomed contingent consideration were not significant as of September 30, 2020.
2 The purchase price for fiscal 2020 acquisitions are subject to post-closing adjustments.
3 The contingent consideration will be payable if commercial milestones defined in the sale and purchase agreements are
achieved within the specified time period following the date of acquisition. For Excel Medical, Connecta and Videomed, the
specified time periods are 2 years, 3.5 years and 2 years, respectively.
4 The fair values of assets acquired and liabilities assumed are still considered to be preliminary. The values reflect net
working capital and fair value adjustments as of the fiscal year ended September 30, 2020. We do not expect further
adjustments to be significant.
5 Goodwill recognized in our acquisitions is attributable to the following:
Excel Medical - Accelerating our leadership in care communications platform and advancing our digital and mobile
communications platform and capabilities.
Connecta - Advancing connected care in Mexico as well as creating lower cost opportunities to expand to other emerging
markets.
Videomed - Expanding our operating room integration platform and our market leadership in advancing connected care.
Goodwill in connection with the Excel Medical and Connecta acquisitions is deductible for tax purposes in the United States.
Goodwill for the Videomed acquisition is not deductible for tax purposes in Italy.
6 Useful lives for the acquired developed technology intangible assets range from 5 years to 10 years.
66
Table of Contents
Acquisition Details:
Date of acquisition
Cash paid
Contingent consideration
Total consideration 1
Contingent consideration payable up to: 2
Segment information:
Company Name
Voalte
Breathe
April 1, 2019
September 3, 2019
$
$
$
175.8 $
5.2
181.0 $
15.0 $
127.6
—
127.6
—
Patient Support
Systems
Front Line Care
The following summarizes the fair value of assets acquired and liabilities assumed for each fiscal 2019 acquisition:
Trade accounts receivable
Inventories
Other current assets
Property, plant and equipment
Goodwill 3
Non-competition agreements 4
Trade name 4
Customer relationships 4
Developed technology 4
Other assets
Trade accounts payable
Deferred revenue
Other current liabilities
Deferred income taxes
Other long-term liabilities
Total purchase price, net of cash acquired
Acquisition costs for the fiscal year ended September 30, 2020:
Acquisition and integration costs recognized in Selling and administrative
expenses 5
Acquisition and integration costs recognized in Special charges
Acquisition costs for the fiscal year ended September 30, 2019:
$
$
$
5.8 $
0.1
2.7
0.2
98.5
2.7
13.5
29.0
55.0
—
(1.7)
(10.7)
(4.3)
(9.8)
—
181.0 $
(8.4) $
—
0.3
5.7
0.1
2.1
59.8
—
4.0
0.4
56.0
0.2
(0.5)
—
(1.6)
1.9
(0.8)
127.6
2.5
3.1
Acquisition and integration costs recognized in Selling and administrative
expenses 5
Acquisition and integration costs recognized in Special charges
1 The purchase price for fiscal 2019 acquisitions are considered final.
2 Contingent consideration was not paid as the commercial milestones were not met within 1 year of the acquisition date.
3 Goodwill recognized in our acquisitions is attributable to the following:
Voalte - Enhancing synergies, accelerating our leadership in care communications platform and advancing our digital and
mobile communications platform and capabilities.
Breathe - Enhancing synergies and accelerating our leadership in respiratory health products.
12.1 $
1.7
6.4
—
$
Goodwill associated with the acquisitions of Voalte and Breathe is not deductible for tax purposes in the United States.
4 The intangible asset useful lives for non-competition agreements, trade name, customer relationships and developed
technology range from 2 years to 11 years.
5 Acquisition and integration costs recognized for Voalte during fiscal 2020 and fiscal 2019 include $(8.4) million and $3.2
million related to fair value adjustments to contingent consideration. Hillrom did not pay any contingent consideration as the
commercial milestones were not met within 1 year of the acquisition date.
67
Table of Contents
Asset Acquisition
On October 1, 2018, we acquired the right to use patented technology and certain related assets from a supplier to our Front
Line Care segment. We paid $17.1 million of cash and committed to guaranteed minimum future royalty payments of
$22.0 million, which are presented in Other intangible assets and software, net and are being amortized over the 7-year term of
the agreement.
Dispositions
On August 2, 2019, we completed a disposition to sell certain of our surgical consumable products and related assets for a
purchase price of $166.6 million, which is net of cash and working capital adjustments. In fiscal 2019, we recorded a pre-tax
loss on this disposition of $15.9 million, including transaction costs of $4.0 million, in Investment income (expense) and other,
net. During the fiscal year ended September 30, 2020, we recorded an additional loss of $4.2 million related to this transaction
primarily due to income taxes. This disposition did not have a significant effect on our operations or financial results, and,
therefore, has not been reported as a discontinued operation.
In fiscal 2018, we conveyed certain net assets related to our third-party rental business that was part of our Patient Support
Systems segment, which was comprised of purchased moveable medical equipment that could be rented to customers, to
Universal Hospital Services, Inc. (“UHS”) in exchange for UHS’s agreement to dismiss its previously disclosed litigation
against us (“Settlement Agreement”). As a result, we recorded a loss of $24.5 million in Special charges, which included $20.9
million related to the non-cash loss reserve for the assets conveyed, and other Settlement Agreement related costs of
approximately $3.6 million. The transaction closed in fiscal 2018.
68
Table of Contents
Note 4. Goodwill and Intangible Assets
Goodwill
As discussed in Note 14. Segment Reporting, we operate in three reportable business segments. Goodwill impairment testing is
performed at the reporting unit level. Goodwill is assigned to reporting units at the date the goodwill is initially recorded and is
reallocated as necessary based on the composition of reporting units over time. Once goodwill is assigned to reporting units, it
no longer retains its association with a particular acquisition, and all of the activities within a reporting unit, whether acquired
or organically grown, are available to support the value of the goodwill.
The following summarizes goodwill activity by reportable segment:
Balances as of September 30, 2018
Goodwill
Accumulated impairment losses
Goodwill, net as of September 30, 2018
Changes in Goodwill in the period:
Goodwill related to acquisitions
Goodwill related to disposition
Currency translation effect
Balances as of September 30, 2019
Goodwill
Accumulated impairment losses
Goodwill, net as of September 30, 2019
Changes in Goodwill in the period:
Goodwill related to acquisitions
Currency translation effect
Balances as of September 30, 2020
Goodwill
Accumulated impairment losses
Goodwill, net as of September 30, 2020
Patient
Support
Systems
Front Line
Care
Surgical
Solutions
Total
$
544.4 $
1,370.6 $
296.1 $
2,211.1
(472.8)
—
71.6
1,370.6
—
296.1
(472.8)
1,738.3
98.4
—
60.2
—
(2.3)
(6.1)
—
(81.7)
(5.9)
158.6
(81.7)
(14.3)
640.5
(472.8)
167.7
1,424.7
—
1,424.7
10.6
2.4
4.4
3.5
208.5
—
208.5
10.0
3.7
2,273.7
(472.8)
1,800.9
25.0
9.6
653.5
1,432.6
(472.8)
180.7 $
—
1,432.6 $
$
222.2
—
222.2 $
2,308.3
(472.8)
1,835.5
Testing for goodwill is performed annually, or on an interim basis upon the occurrence of a triggering event or change in
circumstances that would more likely than not reduce the fair value of a reporting unit below its carrying amount. The annual
evaluation of goodwill for impairment was performed as of April 30, 2020 and did not result in any impairment.
69
Table of Contents
Slower recovery resulting from extended project delays, an increase in discount rates, unfavorable changes in earnings
multiples, or a decline in future cash flow projections, among other factors, may cause a change in circumstances indicating that
the carrying value of our goodwill may not be recoverable. If future financial assumptions significantly differ from those
evaluated in the assessment noted above due to duration or magnitude of the impact of COVID-19, we can provide no
assurance that a future goodwill impairment charge would not be incurred.
The below table summarizes our changes in goodwill related to the acquisitions that occurred during the fiscal years ended
September 30, 2020 and 2019. Refer to Note 3. Business Combinations for additional information regarding these acquisitions.
Voalte
.
Breathe
Excel Medical
Connecta
Videomed
Company Name
Date of Acquisition
April 1, 2019
September 3, 2019
January 10, 2020 May 18, 2020
July 21, 2020
Segment assigned Goodwill
Percentage of Goodwill
assigned to segment
Patient Support
Systems
Front Line Care
Patient Support
Systems
Front Line Care
Surgical
Solution
100%
100%
100%
100%
100%
For the fiscal year ended September 30, 2019, we completed a disposition to sell certain of our surgical consumable products
and related assets. All goodwill associated with this disposition was included in our Surgical Solutions segment. Refer to Note
3. Business Combinations for additional information.
Intangible Assets
Intangible assets are stated at cost and consist predominantly of software, patents, acquired technology, trademarks, trade names
and acquired customer relationship assets. With the exception of certain indefinite-lived trade names, our intangible assets are
amortized on a straight-line basis over periods generally ranging from 1 to 20 years and our capitalized software costs are
amortized on a straight-line basis over periods ranging from 3 to 10 years.
Many of our intangible assets are not deductible for income tax purposes. A summary of intangible assets and the related
accumulated amortization follows:
September 30
2020
2019
Customer relationships
Trademarks and trade names
Developed technology
Software 1
Software for internal use
Software to be sold
Other 2
Total definite-lived
Indefinite-lived 3
Cost
Accumulated
Amortization
Cost
Accumulated
Amortization
333.8
$
633.2 $
358.7 $
658.1 $
45.3
287.9
159.3
55.1
25.8
25.7
116.5
119.2
29.5
17.7
51.5
278.6
136.6
39.9
28.4
$
1,206.6 $
667.3 $
1,193.1 $
437.4
—
437.4
24.0
79.5
115.4
27.6
16.7
597.0
—
Total identifiable intangible assets
597.0
1 Software consists mainly of capitalized costs associated with internal use software, including applicable costs associated
with the implementation and upgrade of our enterprise resource planning systems. In addition, software includes capitalized
development costs for software products to be sold. Software amortization expense was $9.2 million, $10.3 million and
$11.1 million for the fiscal years ended September 30, 2020, 2019 and 2018 and was primarily included in Selling and
administrative expenses.
1,630.5 $
1,644.0 $
667.3 $
$
2 Other intangible assets primarily comprised of patents, non-competition agreements and intellectual property rights.
3 Indefinite-lived intangible assets represent primarily the Welch Allyn trade name with a carrying value of $434.0 million
as of September 30, 2020 and 2019.
70
Table of Contents
Testing for indefinite-lived intangible asset impairment is performed annually, or on an interim basis upon the occurrence of a
triggering event or change in circumstances that would more likely than not reduce the fair value of the indefinite-lived
intangible asset below its carrying amount. The annual evaluation of indefinite-lived intangible assets was performed as of
April 30, 2020 and did not result in any impairment.
Amortization expense for definite-lived intangible assets for the fiscal years ended September 30, 2020, 2019 and 2018 was
$118.2 million, $132.7 million and $117.9 million. Amortization expense for definite-lived intangible assets is expected to
approximate the following for each of the next five fiscal years and thereafter:
2021
2022
2023
2024
2025
2026 and beyond
Note 5. Financing Agreements
Total debt consists of the following:
Current portion of long-term debt1
Securitization Facility
Note Securitization Facility
Total Short-term borrowings
Revolving credit facility, matures August 2024
Senior secured Term Loan A, long-term-portion, matures August 2024
Senior unsecured 5.00% notes due on February 15, 2025
Senior unsecured 4.375% notes due on September 17, 2027
Unsecured 7.00% debentures due on February 15, 2025
Unsecured 6.75% debentures due on December 15, 2027
Other
Total Long-term debt
Total debt
Amount
$
121.5
105.1
85.9
72.0
58.1
96.7
September 30,
2020
September 30,
2019
$
$
$
50.1 $
82.2
90.0
222.3 $
— $
895.4
297.5
419.5
13.4
29.7
0.2
471.7
110.0
78.7
660.4
80.0
944.0
296.9
418.7
13.5
29.7
0.3
$
$
1,655.7 $
1,878.0 $
1,783.1
2,443.5
1 For September 30, 2019, includes the Senior unsecured 5.75% notes due on September 17, 2023
Short-Term Borrowings
Securitization Facilities
In April 2020, we renewed our 364-day accounts receivable securitization program (the “Securitization Facility”) with certain
financial institutions for borrowings up to $110.0 million. We also renewed our additional 364-day facility for borrowings up to
$90.0 million (the “Note Securitization Facility”) in April 2020. The terms and conditions of the renewed April 2020 facilities
are substantially similar to the May 2019 facilities. Under the terms of each the Securitization Facility and Note Securitization
Facility, certain of our accounts receivable secure the amounts borrowed and cannot be used to pay our other debts or liabilities.
The amount of permissible borrowings outstanding is determined based on the amount of qualifying accounts receivable at any
point in time. Borrowings outstanding under the Securitization Facility and Note Securitization Facility bear interest at 1-month
U.S. LIBOR plus the applicable margin of 0.8% and 0.9% and are included as a component of Short-term borrowings, while the
accounts receivable securing these obligations remain as a component of Trade accounts receivable, net of allowances.
71
Table of Contents
Long-Term Debt
As of September 30, 2020, there were no outstanding borrowings on the Revolving Credit Facility and available borrowing
capacity was $1,191.0 million after giving effect to the $9.0 million of outstanding standby letters of credit. As of
September 30, 2019, there were $80.0 million outstanding borrowings on the Revolving Credit Facility, and available
borrowing capacity was $1,112.8 million after giving effect to $7.2 million of outstanding standby letters of credit.
In August 2019, we entered into a senior credit agreement (the “Senior Credit Agreement”) for purposes of refinancing our
then-existing senior secured credit facilities maturing in 2021 (the “Prior Senior Secured Credit Facilities”). The Prior Senior
Secured Credit Facilities consisted of a senior secured term loan facility (“2021 TLA Facility”) with an original principal
amount of $1,462.5 million and a Senior Secured Revolving Credit Facility (“2021 Revolving Credit Facility”) providing
borrowing capacity of up to $700.0 million, both maturing in September 2021. In fiscal 2019, we paid the outstanding balance
of $1,038.4 million on the 2021 TLA Facility.
The Senior Credit Agreement consists of two facilities as follows:
•
•
$1,000.0 million senior secured Term Loan A facility, maturing in August 2024 (“2024 TLA Facility”)
Revolving Credit Facility, providing borrowing capacity of up to $1,200.0 million, maturing in August 2024 (“2024
Revolving Credit Facility”)
In connection with the refinancing of the Prior Senior Secured Credit Facilities, we recorded $3.3 million in Loss on
extinguishment of debt primarily related to the debt issuance costs previously capitalized for the 2021 TLA Facility in fiscal
2019. We capitalized debt issuance costs of $2.5 million in connection with the 2024 TLA Facility and $3.7 million in
connection with the 2024 Revolving Credit Facility.
The Senior Credit Agreement facilities bear interest at variable rates which currently approximate 1.4%. These interest rates are
based primarily on LIBOR, but under certain conditions could also be based on the U.S. Federal Funds Rate or the U.S. Prime
Rate, at our option. We are able to voluntarily prepay outstanding loans under the 2024 TLA Facility at any time. In fiscal 2020,
we made the required minimum payments of $50.0 million on the 2024 TLA Facility. In fiscal 2019, we made no payments on
the 2024 TLA Facility.
The following table summarizes the maturities of the 2024 TLA Facility for fiscal 2021 through 2024:
2021
2022
2023
2024
Long-Term Debt Redemption
Amount
$
50.0
50.0
75.0
775.0
In September 2019, we issued senior unsecured notes of $425.0 million maturing September 2027 that bear interest at a fixed
rate of 4.375% annually and capitalized debt issuance costs of $6.3 million. On October 7, 2019, we used the net proceeds from
the offering of these notes, together with funds borrowed from the 2024 Revolving Credit Facility, to redeem all of our
previously outstanding senior unsecured 5.75% notes due September 2023 (the “2023 Notes”) and pay the prepayment
premium of $12.2 million. The 30-day notice required to redeem the 2023 Notes was filed on September 7, 2019 and, as a
result, the outstanding liability of $421.6 million as of September 30, 2019 was classified as current within short-term
borrowings. In October 2019, we recorded a loss on extinguishment of debt of $15.6 million, which was comprised of a
$12.2 million prepayment premium and $3.4 million of debt issuance costs previously capitalized.
Fair Value
The fair value of our debt is estimated based on the quoted market prices for the same or similar issues or on the current rates
offered to us for debt of the same remaining maturities. The book values of our Securitization Facility, 2024 TLA Facility, and
2024 Revolving Credit Facility approximate fair value.
72
Table of Contents
The estimated fair values of our long-term debt instruments are described in the table below:
Senior unsecured 5.00% notes due on February 14, 2025
Senior unsecured 4.375% notes due on September 15, 2027
Unsecured debentures
Total
September 30,
2020
September 30,
2019
$
$
310.1 $
441.2
48.0
799.3 $
312.4
435.4
48.1
795.9
The estimated fair values of our long-term unsecured debentures were based on observable inputs such as quoted prices in
markets that are not active. The estimated fair values of our Senior Notes were based on quoted prices for similar liabilities.
These fair value measurements were classified as Level 2, as described in Note 1. Summary of Significant Accounting Policies.
Debt Covenants
The facilities provided by the Senior Credit Agreement are held with a syndicate of banks, which includes 13 institutions. Our
general corporate assets, with exceptions including those of certain of our subsidiaries, collateralize these obligations. The
Senior Credit Agreement contains financial covenants that specify a maximum secured net leverage ratio and a minimum
interest coverage ratio. These financial covenants are measured at the end of each quarter. The required maximum secured net
leverage ratio is 3.00x and the required minimum interest coverage ratio is 4.00x. As of September 30, 2020, we were in
compliance with all debt covenants under our financing agreements.
Note 6. Derivative Instruments and Hedging Activity
We are exposed to various market risks, including fluctuations in interest rates and variability in foreign currency exchange
rates. We established policies, procedures and internal processes governing our management of market risks and the use of
financial instruments to manage our exposure to such risks. We employ cash flow hedges, net investment hedges, and other
undesignated derivative instruments to manage these risks.
Cash Flow Hedges
To manage our exposure to market risk from fluctuations in interest rates, we enter into interest rate swaps that are designated
as cash flow hedges. As of September 30, 2020, we had interest rate swap agreements with an aggregate notional amount of
$750.0 million to hedge the variability of cash flows through August 2024 associated with a portion of the variable interest rate
payments on outstanding borrowings under our Senior Credit Agreement. As of September 30, 2019, we had interest rate swap
agreements, with an aggregate notional amount of $750.0 million to hedge the variability of cash flows associated with a
portion of the variable interest rate payments on outstanding borrowings under our Senior Credit Agreement through September
2021.
We are subject to variability in foreign currency exchange rates due to our international operations. We enter into currency
exchange contracts that are designated as cash flow hedges to manage our exposure arising from fluctuating exchange rates
related to specific and projected transactions. We operate this program pursuant to documented corporate risk management
policies and do not enter into derivative transactions for speculative purposes. The sensitivity of earnings and cash flows to
variability in exchange rates is assessed by applying an appropriate range of potential rate fluctuations to our assets, obligations,
and projected results of operations denominated in foreign currencies. Our currency risk consists primarily of foreign currency
denominated firm commitments and projected foreign currency denominated intercompany and third-party transactions. As of
September 30, 2020, the notional amount of outstanding currency exchange contracts was $64.4 million. As of September 30,
2019, the notional amount of outstanding currency exchange contracts was $6.7 million. The maximum length of time over
which we hedge transaction exposures is generally 15 months. Derivative gains and losses, initially reported as a component of
Accumulated other comprehensive income (loss), are reclassified to earnings in the period when the transaction affects
earnings.
73
Table of Contents
Net Investment Hedges
As of September 30, 2020, we had outstanding cross-currency swap agreements, with an aggregate notional amount of $198.3
million to hedge the variability of U.S. dollar-Euro exchange rates through July 2023. These cross-currency swaps are
designated as net investment hedges of subsidiaries using Euro as their functional currency.
We assess hedge effectiveness under the spot-to-spot method and record changes in fair value attributable to the translation of
foreign currencies through Accumulated other comprehensive income (loss). We amortize the impact of all other changes in fair
value of the derivative through Interest expense, which was income of $5.2 million for both the fiscal years ended September
30, 2020 and 2019.
Undesignated Derivative Instruments
We use forward contracts to mitigate the foreign exchange revaluation risk associated with recorded monetary assets and
liabilities that are denominated in a non-functional currency. These derivative instruments are not formally designated as hedges
and the terms of these instruments generally do not exceed one month. As of September 30, 2020, we had outstanding forward
contracts not designated as hedges with aggregate notional amounts of $169.9 million. As of September 30, 2019, we had
outstanding forward contracts not designated as hedges with aggregate notional amounts of $76.7 million. The following table
summarizes unrealized and realized gains and losses for forward contracts not designated as hedges, which are recorded in
Investment income (expense) and other, net.
Unrealized gains (losses)
Realized gains (losses)
Fair Value
Year Ended September 30
2020
2019
$
— $
3.0
(0.2)
(2.9)
We classify fair value measurements on our derivative instruments as Level 2. The estimated fair values of our derivative
instruments are described in the table below:
Derivative Instruments
Interest Rate Swaps
Interest Rate Swaps
Currency Exchange Contracts
Cross-Currency Swaps
Undesignated Forward Contracts
Total
September 30,
2020
Consolidated Balance
Sheet Classification
September 30,
2019
Consolidated Balance
Sheet Classification
$
$
$
— Other assets
$
0.9 Other assets
(46.3) Other current liabilities
(7.7) Other current liabilities
(0.4) Other current liabilities
0.2 Other current assets
9.7 Other assets
— Other assets
16.9 Other assets
(0.2) Other current liabilities
(37.0)
$
10.1
Note 7. Leases
Hillrom as the Lessee
We determine if an arrangement is a lease or contains a lease at contract inception. We lease real estate, automobiles, and
equipment under various operating leases. A lease liability and ROU asset is recognized for operating leases with terms greater
than one year at the lease commencement date. The lease liability is measured as the present value of all remaining fixed
payments calculated using our estimated secured incremental borrowing rate. The ROU asset is measured as the sum of the
lease liability and any initial indirect costs incurred, less any lease incentives received. We use our estimated secured
incremental borrowing rate as most lease agreements do not specify an interest rate. Our lease agreements include leases that
have both lease and non-lease components. We elected to account for lease components and the associated non-lease
components as a single lease component.
Our leases have remaining lease terms of approximately 1 year to 8 years. Many of our real estate and equipment leases include
options to renew. Renewal periods are generally not included when calculating the remaining lease term unless we are
reasonably certain to exercise a renewal option based on beneficial terms or significance of the leased asset to our operations.
74
Table of Contents
Expense for operating leases and leases with a term of one year or less is recognized on a straight-line basis over the lease term.
Lease expense is recorded in Cost of goods sold or Selling and administrative expenses based on the purpose of the leased asset.
The following table summarizes our lease expense:
Operating lease expense
Short-term leases and variable lease payments
Total
September 30, 2020
$
$
27.8
11.5
39.3
The following table summarizes the balance sheet classification of our operating leases and amounts of the ROU asset and lease
liability as of September 30, 2020:
Right-of-use assets
Current lease liabilities
Non-current lease liabilities
Other assets
Other current liabilities
Other long-term liabilities
$
$
$
72.3
22.8
54.4
Consolidated Balance Sheet Classification
September 30, 2020
The following table summarizes our supplemental information related to operating leases as of September 30, 2020:
September 30, 2020
Supplemental information:
Weighted-average discount rate
Weighted-average remaining lease term in years
Cash Flow information:
Operating cash flows paid for amounts included in the measurement of lease liabilities
$
Right of use assets obtained in exchange for new lease liabilities
The following table summarizes the maturities of our operating leases as of September 30, 2020:
2021
2022
2023
2024
2025
Thereafter
Total lease payments
Less: imputed interest
Total lease liability
3.3 %
4.48
27.6
16.6
25.1
20.2
14.4
9.0
5.4
10.4
84.5
(7.3)
77.2
Amount
$
$
$
$
$
$
$
$
$
75
Table of Contents
Disclosures Related to Periods Prior to Adopting the New Lease Guidance
Future minimum payments under non-cancellable operating leases (excluding executory costs) aggregating $94.9 million for
manufacturing facilities, warehouse distribution centers, service centers, sales offices, automobiles, and other equipment
consisted of the following as of the fiscal year ended September 30, 2019:
2020
2021
2022
2023
2024
2025 and beyond
Amount
$
25.7
21.4
15.7
11.1
6.4
14.6
Rental expense in the fiscal years ended September 30, 2019 and 2018 was $39.8 million and $41.3 million.
Hillrom as the Lessor
We make certain products available to customers under short-term lease arrangements. Rental usage of these products is
provided as an alternative to product sales and is short-term in nature. Products primarily include smart beds, including, but not
limited to, bariatric, critical care, maternal, and home care beds, as well as other surfaces. These lease arrangements provide our
customers with our products during periods of peak demand or often times for specialty purposes. Additionally, we provide
wearable, non-invasive ventilation products to patients covered by monthly medical insurance reimbursements, which are
considered month-to-month leasing arrangements. Income arising from these lease arrangements where we are the lessor is
recognized within Rental revenue. We accounted for these lease arrangements as operating leases.
76
Table of Contents
Note 8. Retirement and Postretirement Benefit Plans
Our retirement plans consist of defined benefit plans, postretirement health care plans and defined contribution savings plans.
Plans cover certain employees both in and outside of the United States.
Retirement Plans
We sponsor five defined benefit retirement plans. Those plans include a master defined benefit retirement plan in the United
States, a nonqualified supplemental executive defined benefit retirement plan, and three defined benefit retirement plans
covering employees in Germany and France. Benefits for such plans are based primarily on years of service and the employee’s
level of compensation in specific periods of employment. We contribute funds to trusts as necessary to provide for current
service and any unfunded projected future benefit obligation over a reasonable period of time. All of our plans have a
September 30 measurement date.
Effect on Operations
The following table details the components of net pension expense for our defined benefit retirement plans:
Year Ended September 30
2019
2018
2020
Statements of Consolidated
Income Classification
Service cost
Service cost
Interest cost
Expected return on plan assets
Amortization of unrecognized prior
service cost, net
Amortization of net loss
Net periodic benefit cost
Settlement loss 1
Special termination benefits 2
Net pension expense
$
1.8 $
3.4
1.8 $
2.7
1.6 Cost of goods sold
3.2 Selling and administrative expenses
8.7
12.5
11.0
(14.0)
(14.8)
(15.7)
—
6.9
6.8
0.1
2.4
4.7
0.1
4.5
4.7
Investment income (expense) and
other, net
Investment income (expense) and
other, net
Investment income (expense) and
other, net
Investment income (expense) and
other, net
8.5
0.5
15.8 $
—
—
4.7 $
$
Investment income (expense) and
other, net
—
— Special charges
4.7
1 On March 9, 2020, we transferred pension assets totaling $40.6 million to purchase annuity contracts for a certain
population of retirees with a third-party insurance company. As a result, we recognized a non-cash settlement loss of $8.5
million for the fiscal year ended September 30, 2020, which is recorded as a component of Investment income (expense) and
other, net in the Consolidated Statements of Income.
2 In September 2020, we offered certain employees in the United States the option to participate in a voluntary early
retirement plan. The employees who accepted the offer received special termination benefits, which were recorded as a
component of Special charges in the Consolidated Statements of Income.
77
Table of Contents
Obligations and Funded Status
The change in benefit obligations, plan assets and funded status, along with amounts recognized in the Consolidated Balance
Sheets for our defined benefit retirement plans were as follows:
Change in benefit obligation:
Benefit obligation at beginning of year
Service cost
Interest cost
Actuarial loss
Benefits paid
Acquisition1
Plan settlements
Special termination benefits
Exchange rate loss (gain)
Benefit obligation at end of year
Change in plan assets:
Fair value of plan assets at beginning of year
Actual return on plan assets
Employer contributions
Benefits paid
Acquisition1
Plan settlements
Fair value of plan assets at end of year
Funded status and net amounts recognized
Amounts recorded in the Consolidated Balance Sheets:
Accrued pension benefits, current portion
Accrued pension benefits, long-term
Net amount recognized
Year Ended September 30
2020
2019
$
380.4 $
334.6
5.2
8.7
28.7
4.5
12.5
43.4
(12.6)
(13.3)
3.5
(44.2)
0.5
1.6
371.8
310.6
33.4
1.0
(12.6)
3.5
(44.2)
291.7
$
(80.1) $
—
—
—
(1.3)
380.4
279.8
35.1
9.0
(13.3)
—
—
310.6
(69.8)
$
$
(1.5) $
(78.6)
(80.1) $
(1.2)
(68.6)
(69.8)
1 Represents the plan assets and obligations assumed as part of the defined benefit retirement plan of Excel Medical, which
was acquired on January 10, 2020, and subsequently settled and terminated as of September 30, 2020.
In addition to the amounts above, net actuarial losses of $64.9 million and prior service costs of $0.4 million, less the tax effect
of $16.3 million are included as components of Accumulated other comprehensive income (loss) as of September 30, 2020. In
addition to the amounts above, net actuarial losses of $70.6 million and prior service costs of $0.4 million, less the tax effect of
$17.2 million, are included as components of Accumulated other comprehensive income (loss) as of September 30, 2019.
The estimated net actuarial loss and prior service cost for our defined benefit retirement plans that will be amortized from
Accumulated other comprehensive income (loss) into net periodic benefit cost over the next fiscal year are $6.3 million and
$0.1 million.
78
Table of Contents
Accumulated Benefit Obligation
The accumulated benefit obligation for all defined benefit pension plans was $352.1 million and $362.9 million as of
September 30, 2020 and September 30, 2019, respectively. Selected information for our plans, including plans with
accumulated benefit obligations exceeding plan assets, was as follows:
September 30, 2020
ABO
Plan Assets
PBO
PBO
September 30, 2019
ABO
Master plan
International plans
Supplemental executive plan
$
$
343.2 $
23.0
5.6
371.8 $
325.7 $
20.8
5.6
352.1 $
291.7 $
—
—
291.7 $
353.4 $
21.7
5.3
380.4 $
Actuarial Assumptions
The weighted average assumptions used in accounting for our domestic pension plans were as follows:
Plan Assets
310.5
0.1
—
310.6
338.0 $
19.6
5.3
362.9 $
Weighted average assumptions to determine benefit
obligations at the measurement date:
Discount rate for obligation
Rate of compensation increase
Weighted average assumptions to determine benefit
cost for the year:
Discount rate for expense
Expected rate of return on plan assets
Rate of compensation increase
2020
2019
2018
2.7%
2.6%
3.2%
5.3%
2.6%
3.2%
2.6%
4.2%
5.5%
3.0%
4.2%
3.0%
3.9%
6.0%
3.0%
The discount rates used in the valuation of our defined benefit pension plans are evaluated annually based on current market
conditions. In setting these rates, we utilize long-term bond indices and yield curves as a preliminary indication of interest rate
movements, and then make adjustments to the respective indices to reflect differences in the terms of the bonds covered under
the indices in comparison to the projected outflow of our pension obligations. The overall expected long-term rate of return is
based on historical and expected future returns, which are inflation adjusted and weighted for the expected return for each
component of the investment portfolio, as well as taking into consideration economic and capital market conditions. The rate of
assumed compensation increase is also based on our specific historical trends of past wage adjustments. The weighted average
discount rate assumptions used for our international plans are lower than our domestic plan assumptions and do not
significantly affect the consolidated net benefit obligation or net periodic benefit cost balances.
Plan Assets
The weighted average asset allocations of our master defined benefit retirement plan as of September 30, 2020 and 2019, by
asset category, along with target allocations, are as follows:
Equity securities
Fixed income securities
Total
2020 and 2019
Target
Allocation
2020
Actual
Allocation
2019
Actual
Allocation
31%-37%
63%-69%
34%
66%
100%
32%
68%
100%
We have a Plan Committee that sets investment guidelines with the assistance of an external consultant. These guidelines are
established based on market conditions, risk tolerance, funding requirements and expected benefit payments. The Plan
Committee also oversees the investment allocation process and monitors asset performance. As pension liabilities are long-term
in nature, we employ a long-term total return approach to maximize the long-term rate of return on plan assets for a prudent
79
Table of Contents
level of risk. Target allocations are guidelines, not limitations, and plan fiduciaries may occasionally approve allocations above
or below a target range or elect to rebalance the portfolio within the targeted range.
The investment portfolio contains a diversified portfolio of fixed income securities and equities. Securities are also diversified
in terms of domestic and international securities, short-term and long-term securities, growth and value styles, large cap and
small cap stocks. The primary investment strategy is a dynamic target allocation method that periodically rebalances among
various investment categories depending on the current funded positions. This program is designed to actively move from
return-seeking investments (such as equities) toward liability-hedging investments (such as long-duration fixed income) as
funding levels improve.
Trust assets are invested subject to the following policy restrictions: short-term securities must be rated A2/P2 or higher; all
fixed-income securities shall have a credit quality rating “BBB” or higher; and investments in equities in any one company may
not exceed 10% of the equity portfolio.
Fair Value Measurements of Plan Assets
Cash as part of plan assets was $2.1 million and $4.2 million as of September 30, 2020 and 2019, respectively, and was
classified as a Level 1 financial instrument.
The following table summarizes these assets by category:
Equities
U.S. companies
International companies
Fixed income securities
Total plan assets at fair value, excluding cash
Year Ended September 30
2020
2019
$
$
49.7 $
48.9
191.0
289.6 $
49.6
50.2
206.6
306.4
These investments are commingled funds and/or collective trusts valued using the net asset value (“NAV”) unit price provided
by the fund administrator. The NAV is based on the value of the underlying assets owned by the fund.
Cash Flows
Our U.S. master defined benefit plan is funded in excess of 85%, as measured under the requirements of the Pension Protection
Act of 2006, and therefore we expect that the plan will not be subject to the “at risk” funding requirements of this legislation.
In the fiscal years ended September 30, 2020 and 2019, we contributed cash of $1.0 million and $9.0 million, respectively, to
our defined benefit retirement plans, of which $8.0 million was a voluntary contribution to our U.S. defined benefit retirement
plan in the fiscal year ended 2019. We will not be required to contribute to our master defined benefit retirement plan in fiscal
2021 due to the current funding level; however, minimal contributions will be required for our unfunded plans.
Estimated Future Benefit Payments
The benefit payments, which are expected to be funded through plan assets and company contributions and reflect expected
future service, are expected to be paid as follows:
2021
2022
2023
2024
2025
2026-2030
$
Pension Benefits
12.0
13.1
13.9
14.9
15.5
90.5
80
Table of Contents
Defined Contribution Savings Plans
We have defined contribution savings plans that cover substantially all U.S. employees and certain non-U.S. employees. The
general purpose of these plans is to provide additional financial security in retirement by providing employees with an incentive
to make regular savings. Our contributions to the plans are based on eligibility and employee contributions. Expense under
these plans for the fiscal years ended September 30, 2020, 2019 and 2018 was $31.9 million, $29.0 million and $28.4 million.
Postretirement Health Care Plans
In addition to defined benefit retirement plans, we also offer two postretirement health care plans in the United States that
provide health care benefits to qualified retirees and their dependents. The plans are closed to new participants and include
retiree cost sharing provisions and generally extends retiree coverage for medical and prescription benefits beyond the COBRA
continuation period to the date of Medicare eligibility. These plans have a measurement date of September 30.
The net periodic benefit cost related to postretirement health care plans has not been significant for the fiscal years ended
September 30, 2020, 2019 or 2018. In September 2020, we offered certain employees in the United States the option to
participate in a voluntary early retirement plan. The employees who accepted the offer received special termination benefits of
$0.4 million which were recorded as a component of Special charges in the Consolidated Statements of Income.
The change in the accumulated postretirement benefit obligation was as follows:
Change in benefit obligation:
Benefit obligation at beginning of year
Service cost
Interest cost
Actuarial gain
Benefits paid
Retiree contributions
Special termination benefits
Benefit obligation at end of year
Amounts recorded in the Consolidated Balance Sheets:
Accrued benefits obligation, current portion
Accrued benefits obligation, long-term
Net amount recognized
Year Ended September 30
2020
2019
$
$
$
$
12.7 $
0.1
0.2
(0.4)
(1.0)
0.2
0.4
12.2 $
1.6 $
10.6
12.2 $
17.0
0.3
0.5
(4.1)
(1.3)
0.3
—
12.7
1.3
11.4
12.7
In addition to the amounts above, net actuarial gains of $10.9 million and prior service credits of $0.4 million, less the tax effect
of $2.9 million are included as components of Accumulated other comprehensive income (loss) as of September 30, 2020. Net
actuarial gains of $11.9 million and prior service credits of $0.6 million, less the tax effect of $2.4 million are included as
components of Accumulated other comprehensive income (loss) as of September 30, 2019.
The estimated net actuarial gain and prior service benefit for our postretirement health care plans that will be amortized from
Accumulated other comprehensive income (loss) into net periodic benefit cost over the next fiscal year are $1.6 million and
$0.2 million.
The below table summarizes the discount rates used in accounting for our postretirement plans:
Discount rate used to determine:
Net periodic benefit cost for the postretirement health care plans
Benefit obligation
2.6 %
1.8 %
4.0 %
3.0 %
3.3 %
4.0 %
2020
September 30
2019
2018
81
Table of Contents
As of September 30, 2020, the health care cost trend rates for the plans were generally assumed to be in the ranges of 5.8% to
6.4%, trending down to a rate of 4.5% over the long-term. A one-percentage-point increase/decrease in the assumed health care
cost trend rates as of September 30, 2020 would cause an increase/decrease in service and interest costs of less than $0.1
million, along with an increase/decrease in the benefit obligation of $0.6 million.
We fund the postretirement health care plans as benefits are paid and current plan benefits are expected to require contributions
of approximately $1.6 million in fiscal 2021 and approximately $1.0 million per fiscal year thereafter.
Note 9. Other Comprehensive Income
The following tables represent the changes in Other comprehensive income (loss) and Accumulated other comprehensive
income (loss) by component for the fiscal years ended September 30, 2020, 2019 and 2018.
Year Ended September 30, 2020
Other comprehensive income (loss)
Accumulated other
comprehensive income (loss)
Prior to
reclassification
Reclassification
from
Pre-tax
Tax
effect
Net of
tax
Beginning
balance
Net
activity
Ending
balance 2
Derivative instruments
designated as hedges 1:
Currency exchange
contracts
Interest rate swaps
Cross-currency swaps
$
1.9 $
(2.6) $
(0.7) $
0.2 $
(0.5) $
0.2 $
(0.5) $
(0.3)
(35.4)
(7.2)
(4.2)
(39.6)
—
(7.2)
9.1
1.7
(30.5)
(5.5)
(5.2)
12.2
(30.5)
(5.5)
(35.7)
6.7
Derivative instruments
designated as hedges total
$
Foreign currency translation
adjustment
Change in pension and
postretirement defined
benefit plans
Total
$
(40.7) $
(6.8) $ (47.5) $ 11.0 $
(36.5) $
7.2 $
(36.5) $
(29.3)
34.7
—
34.7
—
34.7
(145.4)
34.7
(110.7)
0.9
(5.1) $
4.6
5.5
(1.4)
4.1
(44.3)
4.1
(40.2)
(2.2) $
(7.3) $
9.6 $
2.3 $
(182.5) $
2.3 $
(180.2)
Year Ended September 30, 2019
Other comprehensive income (loss)
Accumulated other comprehensive income (loss)
Prior to
reclassification
Reclassification
from
Pre-
tax
Tax
effect
Net of
tax
Beginning
balance
Impacts of ASU
2018-02
Adoption as of
October 1, 2018
Net
activity
Ending
balance
Derivative instruments
designated as hedges 1:
Currency exchange
contracts
$
(0.6) $
0.6 $ — $ — $ — $
0.2 $
— $ — $
0.2
Interest rate swaps
Cross-currency swaps
(24.8)
18.0
(6.8)
(31.6)
7.3
(24.3)
—
18.0
(4.1)
13.9
18.3
(1.7)
0.8
—
(24.3)
13.9
(5.2)
12.2
Derivative instruments
designated as hedges total
$
(7.4) $
(6.2) $ (13.6) $ 3.2 $ (10.4) $
16.8 $
0.8 $ (10.4) $
7.2
Foreign currency translation
adjustment
Change in pension and
postretirement defined
benefit plans
(40.1)
—
(40.1)
—
(40.1)
(105.3)
—
(40.1)
(145.4)
(19.4)
2.0
(17.4)
3.8
(13.6)
(24.5)
(6.2)
(13.6)
(44.3)
Total
$
(66.9) $
(4.2) $ (71.1) $ 7.0 $ (64.1) $
(113.0) $
(5.4) $ (64.1) $ (182.5)
82
Table of Contents
Year Ended September 30, 2018
Other comprehensive income (loss)
Accumulated other comprehensive
income (loss)
Prior to
reclassification
Reclassification
from
Pre-tax
Tax
effect
Net of
tax
Beginning
balance
Net
activity
Ending
balance
Derivative instruments
designated as hedges 1:
Currency exchange
contracts
$
Interest rate swaps
Cross-currency
swaps
Derivative instruments
designated as hedges
total
Foreign currency
translation adjustment
Change in pension and
postretirement defined
benefit plans
0.4 $
22.8
0.3 $ 0.7 $ (0.1) $ 0.6 $
(0.4) $
0.6 $
(5.3) 17.5
(3.9) 13.6
4.7
13.6
0.2
18.3
(2.2)
—
(2.2)
0.5
(1.7)
—
(1.7)
(1.7)
$
21.0 $
(5.0) $ 16.0 $ (3.5) $ 12.5 $
4.3 $ 12.5 $
16.8
(24.0)
—
(24.0) —
(24.0)
(81.3)
(24.0)
(105.3)
7.9
3.0
10.9
(2.4)
8.5
(33.0)
8.5
(24.5)
$
Total
(110.0) $
1 See Note 6. Derivative Instruments and Hedging Activity for information regarding our hedging strategies
2 The estimated net amount of gains and losses reported in Accumulated other comprehensive income (loss) related to our
derivative instruments designated as hedges as of September 30, 2020 that are expected to be reclassified into earnings within
the next 12 months is expense of $7.5 million.
(2.0) $ 2.9 $ (5.9) $ (3.0) $
(3.0) $ (113.0)
4.9 $
The following table represents the items reclassified out of Accumulated other comprehensive income (loss) and the related tax
effects for the fiscal years ended September 30, 2020, 2019 and 2018:
Year Ended September 30
2020
2019
2018
Amount
reclassified
Tax
effect
Net of
tax
Amount
reclassified
Tax
effect 4
Net of
tax
Amount
reclassified Tax effect
Net of
tax
Derivative instruments
designated as hedges:
Currency exchange
contracts 1
Interest rate swaps 2
Derivative instruments
designated as hedges
total
Change in pension and
postretirement defined
benefit plans 3
$
$
$
(2.6) $ 0.5 $ (2.1) $
(3.2)
1.0
(4.2)
0.6 $ (0.2) $ 0.4 $
(5.2)
(6.8)
1.6
0.3 $
(5.3)
— $ 0.3
(4.1)
1.2
(6.8) $ 1.5 $ (5.3) $
(6.2) $ 1.4 $ (4.8) $
(5.0) $
1.2
(3.8)
4.6 $ (1.4) $ 3.2 $
2.0 $ (2.4) $ (0.4) $
3.0 $
(1.0) $ 2.0
1 Reclassified from Accumulated other comprehensive income (loss) into Investment income (expense) and other, net.
2 Reclassified from Accumulated other comprehensive income (loss) into Interest expense.
3 Reclassified from Accumulated other comprehensive income (loss) into Cost of goods sold and Investment income (expense)
and other, net. These components are included in the computation of net periodic pension expense.
4 As a result of the adoption of ASU 2018-02, we reclassified $5.4 million from Accumulated other comprehensive income
(loss) to Retained earnings.
83
Table of Contents
Note 10. Special Charges
Special charges are incurred in connection with various transformative initiatives, restructuring and exit activities, and
organizational changes to improve our business alignment and cost structure. Although these charges are infrequent and
unusual in nature, additional Special charges are expected to be incurred. It is not practicable to estimate the amount of these
future expected costs until such time as the evaluations are complete. The following table summarizes the Special charges
recognized for the fiscal years ended September 30, 2020, 2019 and 2018.
Special charges
Global information technology transformation
$
Workforce reduction plan
Integration-related activities
Site consolidation and other cost optimization activities,
including related severance cost
Disposition
Legal claim recovery
Total Special charges
Global Information Technology Transformation
Year Ended September 30
2019
2018
2020
15.9 $
6.7
13.1 $
5.8
—
—
1.3 $
—
19.8 $
7.3
—
—
—
—
38.4
15.9
24.5
(1.2)
77.6
$
41.5 $
28.4 $
In fiscal 2019, management initiated a global information technology transformation, including rationalizing and transforming
our enterprise resource planning software solutions and other complementary information technology systems. In addition to
the expenses noted in the table above, $22.0 million and $2.0 million was capitalized as software in Other intangible assets and
software, net for the fiscal years ended September 30, 2020 and 2019, respectively.
The objective of this initiative is to consolidate and streamline our key workstreams that interact with customers and vendors
and support our financial reporting processes while maintaining the security of our data. The solutions designed under this
initiative will be implemented over the next five to seven years.
Workforce Reduction Plan
On September 15, 2020, we committed to a workforce reduction plan as part of the continued business optimization initiatives
to advance our strategy and growth platforms and improve our operations and cost structure. The workforce reduction plan
includes a voluntary retirement program and involuntary severance actions. For the fiscal year ended September 30, 2020, we
have incurred $6.7 million related to this initiative within Special charges. We expect substantially all costs related to the
execution of the workforce reduction plan to be incurred in fiscal year ended 2021, which will bring the aggregated total cost to
approximately $35 million.
Integration-Related Activities
We incurred costs, including severance and benefit costs, associated with business realignment and integration activities
focused on reducing complexity, increasing efficiency, and improving our cost structure. We acquired several businesses in the
fiscal years ended September 30, 2020 and 2019 as disclosed within Note 3. Business Combinations for which we also continue
to incur integration-related costs and severance costs.
84
Table of Contents
Site Consolidation and Other Cost Optimization Activities, Including Related Severance Cost
We continue to streamline our operations and simplify our supply chain by transforming and consolidating certain
manufacturing and distribution operations.
Dispositions
In fiscal 2018, we recorded a loss of $24.5 million in Special charges related to the UHS Settlement Agreement.
Legal Claim Recovery
In fiscal 2018, we received a settlement payment for a legal claim and recorded a gain of $1.2 million in Special charges.
For all accrued severance and other benefit charges described above, we record reserves within Other current liabilities. The
following table summarizes the reserve activity for severance and other benefits for the fiscal years ended September 30, 2020
and 2019:
Balance as of September 30, 2018
Expenses
Cash Payments
Reversals
Balance as of September 30, 2019
Expenses
Cash Payments
Reversals
Balance as of September 30, 2020
Note 11. Income Taxes
$
$
$
8.5
16.4
(15.1)
(1.3)
8.5
14.6
(11.1)
(0.7)
11.3
The significant components of income before income taxes and the consolidated income tax provision were as follows:
Income before income taxes:
Domestic
Foreign
Total
Income tax expense:
Current provision
U.S. Federal
State
Foreign
Total current provision
Deferred provision:
U.S. Federal
State
Foreign
Total deferred provision
Income tax expense
2020
Year Ended September 30
2019
2018
137.0 $
134.2
271.2 $
122.5 $
86.1
208.6 $
101.8
95.4
197.2
38.1 $
10.8
18.3
67.2
(15.6)
(2.8)
(0.6)
(19.0)
48.2 $
51.0 $
6.0
18.2
75.2
(12.0)
(2.5)
(4.3)
(18.8)
56.4 $
5.9
3.5
20.2
29.6
(83.4)
(2.8)
1.4
(84.8)
(55.2)
$
$
$
$
85
Table of Contents
Differences between income tax expense reported for financial reporting purposes and that computed based upon the
application of the statutory U.S. Federal tax rate to the reported income before income taxes were as follows:
U.S. Federal income tax 1
State income tax 2
Foreign income tax 3
Application of federal research tax credits
Application of foreign tax credits
Valuation of tax attributes
Foreign inclusions
Domestic manufacturer’s deduction
Global intangible low-taxed income inclusion
Disposition of subsidiary
Current period change in uncertain tax positions
Other, net
Income tax expense
1 At statutory rate.
2 Net of U.S. Federal benefit.
3 U.S. Federal tax rate differential.
Excess tax benefits from share based awards
(4.7)
(1.7)
(5.2)
(2.5)
U.S. tax benefit of foreign currency loss
U.S. tax reform deferred tax remeasurement
U.S. tax reform transition tax
—
—
—
—
—
—
Foreign-derived intangible income deduction
(7.8)
(2.9)
Year Ended September 30
2020
2019
2018
% of
Pretax
Income Amount
% of
Pretax
Income Amount
% of
Pretax
Income
Amount
$
57.0
21.0 % $
43.8
21.0 % $
48.4
24.5 %
4.1
(15.0)
(6.2)
(11.6)
5.0
7.7
—
1.5
(5.5)
(2.3)
(4.3)
1.9
2.9
—
3.3
(10.1)
(5.6)
(0.1)
2.2
—
—
1.6
(4.9)
(2.7)
—
1.1
—
—
—
—
(1.0)
(4.3)
9.6
18.2
4.6
1.0
—
—
(0.5)
(2.0)
4.6
8.7
2.2
0.4
12.6
4.1
—
3.0
4.6
1.5
—
1.1
2.9
1.5
(25.9)
(13.2)
(5.6)
(1.0)
(2.9)
(0.5)
23.4
11.9
(0.9)
(0.9)
(16.1)
(9.2)
(0.4)
(0.4)
(8.2)
(4.7)
(93.8)
(47.6)
22.9
11.6
—
—
—
1.5
—
—
—
0.8
(0.9)
(0.4)
$
48.2
17.8 % $
56.4
27.0 % $
(55.2)
(28.0) %
86
Table of Contents
The tax effect of temporary differences that gave rise to the deferred tax assets and liabilities were as follows:
Deferred tax assets:
Employee benefit accruals
Inventory
Net operating loss carryforwards
Tax credit carryforwards
Lease liabilities
Other, net
Less: Valuation allowance
Total deferred tax assets
Deferred tax liabilities:
Depreciation
Amortization
Lease Assets
Other, net
Total deferred tax liabilities
Deferred tax liability - net
September 30,
2020
September 30,
2019
$
48.3 $
14.7
69.7
26.4
18.8
36.2
214.1
(50.8)
163.3
(19.2)
(201.0)
(17.6)
(5.6)
(243.4)
(80.1) $
$
42.9
10.0
69.8
22.6
—
25.3
170.6
(45.0)
125.6
(14.5)
(215.4)
—
(5.6)
(235.5)
(109.9)
As of September 30, 2020, we had $40.5 million of deferred tax assets related to operating loss carryforwards in foreign
jurisdictions that are subject to various carryforward periods with the majority eligible to be carried forward for an unlimited
period. Additionally, we had $21.6 million of deferred tax assets related to U.S. Federal net operating loss (“NOL”)
carryforwards, some of which will be carried forward for an unlimited period and some of which will expire between 2021 and
2036 and $7.6 million of deferred tax assets related to state NOL carryforwards, some of which will be carried forward for an
unlimited period and some of which expire between 2021 and 2040. We had $23.9 million of deferred tax assets related to state
tax credits, some of which will be carried forward for an unlimited period and some of which will expire between 2021 and
2030. We had $1.1 million of deferred tax assets related to capital loss carryforwards which will expire in 2025. We had
$2.1 million of deferred tax assets related to foreign tax credit carryforwards which will expire in 2030. We are considering
carryback opportunities for the capital loss carryforward and the foreign tax credit carryforward.
The gross deferred tax assets as of September 30, 2020 were reduced by valuation allowances of $50.8 million primarily related
to certain foreign deferred tax attributes and state tax credit carryforwards as it is more likely than not that some portion or all of
these tax attributes will not be realized. In evaluating whether it is more likely than not that we would recover our deferred tax
assets, future taxable income, the reversal of existing temporary differences and tax planning strategies were considered. We
believe that our estimates for the valuation allowances recorded against deferred tax assets are appropriate based on current
facts and circumstances. During the fiscal year ended September 30, 2020, the valuation allowance increased by $5.8 million.
The increase related primarily to foreign net operating losses and state tax credits that more likely that not will not be realized.
We operate under tax holidays in both Singapore and Puerto Rico. The Singapore tax holiday is effective through 2024. The
Puerto Rico tax holiday is effective through 2025, but we have disposed of this operation in fiscal 2019 and thus will not
recognize any benefit in the future. Both incentives are conditional on meeting certain employment and/or investment
thresholds. The impact of these tax holidays decreased foreign taxes by $3.3 million for the fiscal year ended September 30,
2020, $5.2 million for the fiscal year ended September 30, 2019 and $4.3 million in the fiscal year ended September 30, 2018.
The benefit of the tax holidays on net income per diluted share was $0.05, $0.08 and $0.06 in fiscal 2020, 2019 and 2018.
With regard to our non-U.S. subsidiaries, it is our practice and intention to reinvest the earnings in those businesses, to fund
capital expenditures and other operating cash needs. Because the undistributed earnings of non-U.S. subsidiaries are considered
to be permanently reinvested, no U.S. deferred income taxes or foreign withholding taxes have been provided on earnings
subsequent to the enactment of the Tax Act. As of September 30, 2020, we have approximately $37.3 million of undistributed
earnings in our non-U.S. subsidiaries that are considered to be permanently reinvested. If such earnings were repatriated, we do
not anticipate incurring a significant amount of additional tax expense.
87
Table of Contents
We file a consolidated federal income tax return as well as multiple state, local and foreign jurisdiction tax returns. In the
normal course of business, we are subject to examination by the taxing authorities in each of the jurisdictions where we file tax
returns. In fiscal 2020, the U.S. Internal Revenue Service (“IRS”) concluded its audit of fiscal 2018 and initiated its post-filing
examination of the fiscal 2019 consolidated federal return. We continue to participate in the IRS Compliance Assurance
Program (“CAP”) for fiscal 2020 and fiscal 2021. We are in the application process to remain in the CAP for fiscal 2022. The
CAP provides the opportunity for the IRS to review certain tax matters prior to us filing our tax return for the year, thereby
reducing the time it takes to complete the post-filing examination. We are also subject to state and local or foreign income tax
examinations by taxing authorities for years back to fiscal 2015.
We also have on-going audits in various stages of completion in several state and foreign jurisdictions, one or more of which
may conclude within the next 12 months. Such settlements could involve some or all of the following: the payment of
additional taxes and related penalties, the adjustment of certain deferred taxes and/or the recognition of unrecognized tax
benefits. The resolution of these matters, in combination with the expiration of certain statutes of limitations in various
jurisdictions, make it reasonably possible that our unrecognized tax benefits may decrease as a result of either payment or
recognition by up to $1.8 million in the next 12 months, excluding interest.
The total amount of gross unrecognized tax benefits as of September 30, 2020, 2019 and 2018 were $3.9 million, $9.6 million
and $6.2 million, which includes $3.5 million, $9.3 million and $5.6 million that, if recognized, would impact the effective tax
rate in future periods. The remaining amount relates to items which, if recognized, would not impact our effective tax rate.
A rollforward of the beginning and ending amount of unrecognized tax benefits is as follows:
Balance as of October 1
Increases in tax position of prior years
Increases in tax position during the current year
Settlements with taxing authorities
Lapse of applicable statute of limitations
Foreign currency adjustments
Total change
Balance as of September 30
Year Ended September 30
2019
2018
2020
$
$
9.6 $
—
—
(5.8)
(0.2)
0.3
(5.7)
3.9 $
6.2 $
5.8
—
(1.1)
(1.0)
(0.3)
3.4
9.6 $
4.5
2.3
0.3
—
(0.9)
—
1.7
6.2
In fiscal 2020, we settled the position with the IRS related to the Transition Tax in the amount of $5.8 million, which reduced
our unrecognized tax benefits.
We recognize accrued interest and penalties related to unrecognized tax benefits as a component of income tax expense.
Accrued interest and penalties, which are not presented in the rollforward table above, were $1.4 million, $1.7 million and $2.1
million as of September 30, 2020, 2019 and 2018. Related to interest and penalties, we recognized an income tax benefit of $0.4
million, $0.4 million, and $0.5 million as of September 30, 2020, 2019 and 2018.
Note 12. Earnings per Common Share
Basic earnings per share is calculated based upon the weighted average number of outstanding common shares for the period,
plus the effect of deferred vested shares. Diluted earnings per share is calculated consistent with the basic earnings per share
calculation plus the effect of dilutive unissued common shares related to stock-based employee compensation programs. For all
periods presented, anti-dilutive stock options were excluded from the calculation of diluted earnings per share. Cumulative
88
Table of Contents
treasury stock acquired, less cumulative shares reissued, have been excluded in determining the average number of shares
outstanding.
Earnings per share are calculated as follows (share information in thousands):
Net Income
Net Income per Basic Common Share
Net Income per Diluted Common Share
Year Ended September 30
2020
2019
2018
223.0 $
152.2 $
252.4
3.35 $
2.28 $
3.81
3.32 $
2.25 $
3.73
$
$
$
Average Basic Common Shares Outstanding (in thousands)
Add: Potential effect of exercise of stock options and other unvested equity awards
Average Diluted Common Shares Outstanding (in thousands)
66,631
66,772
581
888
67,212
67,660
66,234
1,378
67,612
Shares with anti-dilutive effect excluded from the computation of Diluted EPS
342
288
263
Note 13. Common Stock
Share Repurchases
Under the Board-approved share repurchase program, authorization of $340.0 million was previously granted to repurchase
shares. In September 2019, the Board approved an additional $170.0 million for repurchases. Repurchases may be made on the
open market or via private transactions, and are used to manage our capital structure, offset the dilutive impact of stock-based
compensation and return cash to shareholders. This program does not have an expiration date and there are no plans to
terminate this program in the future. For the fiscal year ended September 30, 2020, we repurchased 0.5 million shares of our
common stock in the open market valued at $54.1 million. For the fiscal year ended September 30, 2019, we repurchased 1.2
million shares of our common stock in the open market valued at $117.2 million. We did not repurchase shares in fiscal 2018 in
the open market. As of September 30, 2020, a cumulative total of $346.6 million had been used, leaving us with availability of
$163.4 million for future repurchases.
The following table summarizes common stock purchased in connection with employee payroll tax withholding for restricted
stock distributions for the following fiscal years:
Total number of shares purchased
Dollar value of shares purchased
Stock-Based Compensation
Year Ended September 30
2020
2019
2018
158,521
$
16.5 $
48,908
4.7 $
158,182
14.1
We have stock-based compensation plans under which employees and non-employee directors may be granted options to
purchase shares of Company common stock at the fair market value at the time of grant. In addition to stock options, we grant
performance share units (“PSUs”) and RSUs to certain management level employees and vested restricted stock to non-
employee directors. We also offer eligible employees the opportunity to buy shares of our common stock at a discount via an
Employee Stock Purchase Plan (“ESPP”).
Our primary stock-based compensation program is the Stock Incentive Plan, which has been approved by our shareholders.
Under the Stock Incentive Plan, we have a total of 15.3 million authorized shares. As of September 30, 2020, approximately 1.2
million shares were available for future grants under our stock-based compensation plans. We generally settle our stock-based
awards with treasury shares. As of September 30, 2020, we had 21.8 million treasury shares available for use to settle stock-
based awards.
89
Table of Contents
The stock-based compensation cost that was charged against income for all plans was $38.4 million, $34.4 million and $28.1
million for the fiscal years ended September 30, 2020, 2019 and 2018.
We recognize a tax benefit based on the increase in value from the grant date to the exercise date for stock options and from the
grant date to the distribution date for the performance share units and restricted share units. The tax benefit is recorded during
the year in which the exercise or distribution occurs. The tax benefit for exercises and distributions for the fiscal years ended
September 30, 2020, 2019 and 2018 was $4.7 million, $5.2 million, and $16.1 million.
Options
Stock options granted by our Compensation Committee of our Board under the Stock Incentive Plan are non-qualified stock
options. These awards are generally granted with exercise prices equal to the average of the high and low prices of our common
stock on the date of grant. They vest in equal annual installments over a three- or four-year period and the maximum contractual
term is ten years. We use a Binomial option-pricing model to estimate the fair value of stock options, and compensation cost is
recognized on a straight-line basis over the requisite service period.
The following table sets forth the weighted average fair value per share of stock options and the related valuation assumptions
used in the determination of those fair values:
Year Ended September 30
2019
2018
2020
Weighted average fair value per share
$
24.80 $
25.28 $
22.50
Valuation assumptions:
Risk-free interest rate
Expected dividend yield
Expected volatility
Weighted average expected life (years)
1.6%
0.8%
27.7%
4.7
3.0%
0.8%
30.5%
4.7
2.2%
0.9%
30.8%
4.9
The risk-free interest rate is based upon observed U.S. Treasury interest rates appropriate for the term of our employee stock
options. Expected dividend yield is based on the history and our expectation of dividend payouts. Expected volatility was based
on our historical stock price volatility. Expected life represents the weighted average period the stock options are expected to
remain outstanding and is a derived output of the Binomial model. The expected life of employee stock options is impacted by
the above assumptions as well as the post-vesting forfeiture rate and the exercise factor used in the Binomial model. These two
variables are based on the history of exercises and forfeitures for previous stock options granted by us.
The following table summarizes transactions under our stock option plans for the fiscal year ended September 30, 2020:
Balance Outstanding as of October 1, 2019
Granted
Exercised
Cancelled/Forfeited
Balance Outstanding as of September 30, 2020
Exercisable as of September 30, 2020
Options Expected to Vest
Weighted
Average
Number of
Shares
(in thousands)
Weighted
Average
Exercise
Price
Weighted
Average
Remaining
Contractual
Term
Aggregate
Intrinsic
Value
(in millions)
718 $
71.14
188
103.11
(144)
(22)
740 $
334 $
391
60.08
80.54
81.14
65.87
93.56
—
—
—
—
6.9 $
5.3 $
8.2
—
—
—
—
7.9
6.8
1.1
The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value, based on our closing stock price of
$83.51, as reported by the New York Stock Exchange on September 30, 2020. This amount, which changes continuously based
on the fair value of our common stock, would have been received by the option holders had all option holders exercised their
options as of the balance sheet date.
90
Table of Contents
The total intrinsic value of options exercised in the fiscal years ended September 30, 2020, 2019 and 2018 was $6.9 million,
$17.7 million and $54.7 million.
As of September 30, 2020, there was $5.5 million of unrecognized compensation expense related to stock options granted under
the Stock Incentive Plan. This unrecognized compensation expense does not consider potential forfeitures, and is expected to be
recognized over a weighted average period of 2.1 years.
Restricted Stock Units
RSUs are granted to certain employees with fair values equal to the average of the high and low prices of our common stock on
the date of grant, multiplied by the number of units granted. RSU grants are contingent upon continued employment and vest
over periods ranging from one to four years. Dividends, payable in common stock equivalents, accrue on the grants and are
subject to the same specified terms as the original grants, including the risk of forfeiture.
The following table summarizes transactions for our nonvested RSUs for the fiscal year ended 2020:
Nonvested RSUs as of October 1, 2019
Granted
Vested
Forfeited
Nonvested RSUs as of September 30, 2020
Number of
Share Units
(in thousands)
Weighted
Average
Grant Date
Fair Value
371 $
242
(234)
(42)
337 $
95.76
101.74
78.08
95.14
112.41
As of September 30, 2020, there was $19.3 million of total unrecognized compensation expense related to nonvested RSUs
granted under the Stock Incentive Plan. This unrecognized compensation expense does not consider potential forfeitures, and is
expected to be recognized over a weighted average period of 1.7 years. The total vest date fair value of shares that vested in the
fiscal years ended September 30, 2020, 2019 and 2018 was $18.1 million, $16.6 million and $21.9 million.
Performance Share Units
Our Compensation Committee grants PSUs to certain employees and these awards are subject to any stock dividends, stock
splits, and other similar rights inuring to common stock, but unlike our RSUs are not entitled to dividend reinvestment. Vesting
of the grants is contingent upon achievement of performance targets and corresponding service requirements.
The fair value of the PSUs is equal to the average of the high and low prices of our common stock on the date of grant,
multiplied by the number of units granted. For PSUs with a market condition such as total shareholder return, the Monte-Carlo
simulation method is used to determine fair value. The Monte-Carlo simulation is a generally accepted statistical technique used
to generate a defined number of stock price paths in order to develop a reasonable estimate of the range of our and our group of
peer companies’ future expected stock prices.
The following table sets forth the weighted average fair value per share for PSUs and the related valuation assumptions used in
the determination of those fair values. PSUs granted for the fiscal years ended September 30, 2020, 2019 and 2018 are based on
company-specific performance targets, with a total shareholder return collar.
Year Ended September 30
2019
2018
2020
Weighted average fair value per share
$
110.53 $
112.79 $
87.42
Valuation assumptions:
Risk-free interest rate
Expected volatility
1.6%
23.8%
3.0%
22.8%
1.9%
21.9%
The basis for the assumptions listed above is similar to the valuation assumptions used for stock options, as discussed
previously.
91
Table of Contents
The following table summarizes transactions for our nonvested PSUs in fiscal 2020:
Nonvested PSUs as of October 1, 2019
Granted
Vested
Forfeited
Nonvested PSUs as of September 30, 2020
Number of
Share Units
(in thousands)
Weighted
Average
Grant Date
Fair Value
206 $
161
(187)
(15)
165 $
98.78
84.34
75.35
93.47
111.73
As of September 30, 2020, there was $7.3 million of unrecognized compensation expense related to PSUs granted under the
Stock Incentive Plan based on the expected achievement of certain performance targets or market conditions. This unrecognized
compensation expense as of September 30, 2020 does not reflect a reduction for our estimate of potential forfeitures and is
expected to be recognized over a weighted average period of 1.6 years. The total fair value of shares that vested in the fiscal
years ended September 30, 2020, 2019 and 2018 was $14.1 million, $8.0 million and $16.4 million.
Note 14. Segment Reporting
We disclose segment information that is consistent with the way in which management operates and views the business. Our
operating structure contains the following reportable segments:
•
•
•
Patient Support Systems – globally provides an ecosystem of our digital and connected care solutions: devices,
software, communications and integration technologies that improve care and deliver actionable insights to caregivers
and patients in the acute care setting. Key products include care communications and mobility solutions, connected
med-surg and ICU bed systems, sensors and surfaces, safe patient handling equipment and services.
Front Line Care – globally provides integrated patient monitoring and diagnostic technologies – from hospital to
home – that enable and support Hillrom’s connected care strategy. Our diverse portfolio includes secure, connected,
digital assessment technologies to help diagnose, treat and manage a wide variety of illnesses and diseases, including
respiratory therapy, cardiology, vision screening and physical assessment.
Surgical Solutions – globally enables peak procedural performance, connectivity and video integration products that
improve collaboration, workflow, safety and efficiency in the operating room, such as surgical video technologies,
tables, lights, pendants, precision positioning devices and other accessories.
Our performance within each reportable segment continues to be measured on a divisional income basis before non-allocated
operating and administrative costs, litigation, special charges, acquisition and integration costs, acquisition-related intangible
asset amortization, and other unusual events. Divisional income generally represents the division’s gross profit less its direct
operating costs along with an allocation of manufacturing and distribution costs, research and development and certain
corporate functional expenses.
Non-allocated operating costs, administrative costs, and other includes functional expenses that support the entire organization
such as administration, finance, legal and human resources, expenses associated with strategic developments, acquisition-
related intangible asset amortization, and other events that are not indicative of operating trends. We exclude such amounts
from divisional income to allow management to evaluate and understand divisional operating trends. The chief operating
decision maker does not receive any asset information by operating segment and, accordingly, we do not report asset
information by operating segment.
Effective for fiscal 2020, the allocation of operating costs to each segment was modified to improve the alignment to how
management evaluates the performance of each segment. The fiscal 2019 and 2018 segment information has been recast to
conform to the current presentation. The reclassification did not impact our reported Consolidated Net Revenue or Income
Before Income Taxes.
92
Table of Contents
The following summarizes financial results by reportable segment:
Net Revenue - United States:
Patient Support Systems
Front Line Care
Surgical Solutions
Total net revenue - United States
Net Revenue - Outside of the United States (“OUS”):
Patient Support Systems
Front Line Care
Surgical Solutions
Total net revenue - OUS
Net Revenue:
Patient Support Systems
Front Line Care
Surgical Solutions
Total net revenue
Divisional income:
Patient Support Systems
Front Line Care
Surgical Solutions
Other operating costs:
Non-allocated operating costs, administrative costs, and other
Special charges
Operating profit
Interest expense
Loss on extinguishment of debt
Investment income and other, net
Income before income taxes
Depreciation and amortization of property, plant, equipment and intangibles:
Patient Support Systems
Front Line Care
Surgical Solutions
Corporate
Total depreciation and amortization of property, plant, equipment and
intangibles
93
Year Ended September 30
2020
2019
2018
$
1,133.6 $
1,135.0 $
1,054.6
707.4
125.8
700.6
221.2
680.3
221.5
$
1,966.8 $
2,056.8 $
1,956.4
$
405.5 $
355.5 $
317.6
191.1
277.5
217.5
$
914.2 $
850.5 $
374.9
279.9
236.8
891.6
$
1,539.1 $
1,490.5 $
1,429.5
1,025.0
316.9
978.1
438.7
960.2
458.3
$
2,881.0 $
2,907.3 $
2,848.0
$
332.3 $
299.9 $
301.8
39.5
266.4
61.2
264.4
41.5
283.0
28.4
$
367.7 $
316.1 $
(74.0)
(15.6)
(6.9)
(89.6)
(3.3)
(14.6)
285.0
253.0
53.1
224.1
77.6
289.4
(95.0)
—
2.8
$
271.2 $
208.6 $
197.2
$
43.5 $
36.2 $
95.4
7.4
32.5
101.9
28.4
28.3
37.4
110.7
20.8
27.6
$
178.8 $
194.8 $
196.5
Table of Contents
Geographic Information
Geographic data for net revenue and long-lived assets were as follows:
Year Ended September 30
2019
2018
2020
Net revenue to unaffiliated customers:
United States
Foreign
Total net revenue
Long-lived assets:
United States
Foreign
Total long-lived assets
$
$
$
$
1,966.8 $
914.2
2,881.0 $
2,056.8 $
850.5
2,907.3 $
1,956.4
891.6
2,848.0
222.7 $
83.4
306.1 $
212.5 $
84.3
296.8 $
239.5
88.8
328.3
Net revenue in the above table is attributed to geographic areas based on the location of the customer.
Note 15. Quarterly Financial Information (Unaudited)
The following table presents selected consolidated financial data by quarter for the fiscal years ended 2020 and 2019.
2020 Quarter Ended
Net Revenue
Operating Profit
Net Income
Net Income per Basic Common Share
Net Income per Diluted Common Share
2019 Quarter Ended
Net Revenue
Operating Profit
Net Income
Net Income per Basic Common Share
Net Income per Diluted Common Share
December 31,
2019
March 31,
2020
June 30,
2020
September 30,
2020
$
685.0 $
723.2 $
767.5 $
705.3
78.9
39.8
0.60
0.59
87.3
46.9
0.70
0.70
135.3
93.9
1.41
1.40
66.2
42.4
0.64
0.63
December 31,
2018
March 31,
2019
June 30,
2019
September 30,
2019
$
683.5 $
714.2 $
726.8 $
782.8
70.8
42.2
0.63
0.62
81.3
49.5
0.74
0.74
69.9
32.6
0.49
0.48
94.1
27.9
0.42
0.41
94
Table of Contents
Note 16. Commitments and Contingencies
General
We are subject to various other claims and contingencies arising out of the normal course of business, including those relating
to governmental investigations and proceedings, commercial transactions, product liability, employee related matters, antitrust,
safety, health, taxes, environmental and other matters. Litigation is subject to many uncertainties and the outcome of individual
litigated matters is not predictable with assurance. It is possible that some litigation matters for which reserves have not been
established could be decided unfavorably to us, and that any such unfavorable decisions could have a material adverse effect on
our financial condition, results of operations and cash flows.
Self Insurance
We are involved in various claims, including product and general liability, workers’ compensation, auto liability and
employment related matters. Such claims in the United States have deductibles and self-insured retentions at various limits up
to $1.0 million per occurrence or per claim, depending upon the type of coverage and policy period. International deductibles
and self-insured retentions are lower. We are also generally self-insured up to certain stop-loss limits for certain employee
health benefits, including medical, drug and dental. Our policy is to estimate reserves based upon a number of factors including
known claims, estimated incurred but not reported claims and outside actuarial analysis, which are based on historical
information along with certain assumptions about future events. Such estimated reserves are classified as Other current
liabilities and Other long-term liabilities in the Consolidated Balance Sheets.
95
Table of Contents
SCHEDULE II
HILL-ROM HOLDINGS, INC. AND SUBSIDIARIES
Valuation and Qualifying Accounts
Fiscal years ended September 30, 2020, 2019 and 2018
(In millions)
ADDITIONS
BALANCE AS
OF
BEGINNING
OF PERIOD
CHARGED TO
COSTS AND
EXPENSES
CHARGED TO
OTHER
ACCOUNTS
DEDUCTIONS
NET OF
RECOVERIES
BALANCE
AS OF END
OF PERIOD
$
$
20.6 $
21.8
25.1
45.0 $
80.2
58.2
$
$
8.8
5.0
2.5
4.6
2.2
23.1
$
(0.3) 1
1
0.7
0.2
1
(3.2) 2
(6.9) 2
(6.0) 2
$
3
3
0.5
4.5
—
0.7
(41.9) 4
(1.1)
$
$
25.9
20.6
21.8
50.8
45.0
80.2
DESCRIPTION
Reserves deducted from
assets to which they apply:
Allowance for possible
losses and sales returns -
accounts receivable:
Fiscal Year Ended:
September 30, 2020
September 30, 2019
September 30, 2018
Valuation allowance against
deferred tax assets:
Fiscal Year Ended:
September 30, 2020
September 30, 2019
September 30, 2018
1 Reduction of gross revenue for uncollectible health care rental reimbursements, cash discounts and other adjustments in
determining net revenue. Also includes the effect of acquired businesses, if any.
2 Generally reflects the write-off of specific receivables against recorded reserves.
3 Generally reflects the effect of acquired businesses, if any.
4 Primarily reflects utilization of valuation allowance as a result of forfeitures on net operating losses.
96
Table of Contents
Item 9.
None.
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE
Item 9A.
CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management, with the supervision and participation of our President and Chief Executive Officer and our Senior Vice
President and Chief Financial Officer (the “Certifying Officers”), has evaluated the effectiveness of the design and operation of
our disclosure controls and procedures as of September 30, 2020. Our disclosure controls and procedures are designed to ensure
that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as
amended, is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and
such information is accumulated and communicated to management, including our Certifying Officers and our Board, as
appropriate to allow timely decisions regarding required disclosure.
Based upon that evaluation, the Certifying Officers concluded that our disclosure controls and procedures were effective as of
September 30, 2020.
Management’s Report on Internal Control Over Financial Reporting
The report of management’s assessment of the effectiveness of our internal control over financial reporting as of September 30,
2020 and the related report of our independent registered public accounting firm, are included in Item 8 of this Form 10-K.
Changes in Internal Control Over Financial Reporting
There have been no changes to our internal controls over financial reporting for the quarter ended September 30, 2020.
Management’s report on our internal control over financial reporting is included in Item 8 of this Form 10-K.
Item 9B.
OTHER INFORMATION
None.
97
Table of Contents
Item 10.
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
PART III
The information required by this Item is incorporated herein by reference to our Proxy Statement to be filed
with the SEC in January 2021 relating to our 2021 Annual Meeting of Shareholders (the “2021 Proxy
Statement”), under the headings “Election of Directors,” “Section 16(a) Beneficial Ownership Reporting
Compliance,” and “Corporate Governance.” Information relating to our executive officers is included in this
Form 10-K in Part I, Item 1 under the caption “Executive Officers.”
Item 11.
EXECUTIVE COMPENSATION
The information required by this Item is incorporated herein by reference to the 2021 Proxy Statement, under
the heading “Executive Compensation.”
Item 12.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS
The information required by this Item is incorporated herein by reference to the 2021 Proxy Statement, under
the headings “Security Ownership of Certain Beneficial Owners and Management” and “Equity
Compensation Plan Information.”
Item 13.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR
INDEPENDENCE
The information required by this Item is incorporated herein by reference to the 2021 Proxy Statement, where
such information is included under the heading “Corporate Governance.”
Item 14.
PRINCIPAL ACCOUNTING FEES AND SERVICES
The information required by this Item is incorporated herein by reference to the 2021 Proxy Statement, where
such information is included under the heading “Proposals Requiring Your Vote - Ratification of
Appointment of Independent Registered Public Accounting Firm.”
98
Table of Contents
Item 15.
EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
PART IV
(a) The following documents have been filed as a part of this Form 10-K or, where noted, incorporated by reference:
(1) Financial Statements
The financial statements of the Company and its consolidated subsidiaries are listed under Part II, Item 8 on the
Index to the Consolidated Financial Statements.
(2) Financial Statement Schedules
The financial statement schedule filed in response to Part II, Item 8 and Part IV, Item 15(c) of Form 10-K is listed
under Part II, Item 8 on the Index to Consolidated Financial Statements.
(3) Exhibits (See changes to Exhibit Index below):
“The Exhibit Index, which follows the signature page to this Form 10-K and is hereby incorporated herein by
reference, sets forth a list of those exhibits filed herewith, and includes and identifies management contracts or
compensatory plans or arrangements required to be filed as exhibits to this Form 10-K by Item 601 (b)(10)(iii) of
Regulation S-K.”
The agreements included as exhibits to this Form 10-K are intended to provide information regarding their terms
and not to provide any other factual or disclosure information about us or the other parties to the agreements. The
agreements may contain representations and warranties by the parties to the agreements, including us, solely for
the benefit of the other parties to the applicable agreement. Such representation and warranties:
•
should not in all instances be treated as categorical statements of fact, but rather as a way of allocating
the risk to one of the parties if those statements prove to be inaccurate;
• may have been qualified by disclosures that were made to the other party in connection with the
negotiation of the applicable agreement, which disclosures are not necessarily reflected in the
agreement;
• may apply standards of materiality in a way that is different from what may be viewed as material to
•
certain investors; and
were made only as of the date of the applicable agreement or such other date or dates as may be
specified in the agreement and are subject to more recent developments.
Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they
were made or at any other time.
99
Table of Contents
HILL-ROM HOLDINGS, INC.
INDEX TO EXHIBITS
Management contracts and compensatory plans or arrangements are designated with “*”.
3.1
3.2
4.1
4.2
4.3
4.4
4.5
4.6
4.7
Restated and Amended Articles of Incorporation of Hill-Rom Holdings, Inc., as currently in effect (Incorporated
herein by reference to Exhibit 3.1 filed with the Company’s Form 8-K dated March 10, 2010)
Amended and Restated Code of By-laws of Hill-Rom Holdings, Inc., as currently in effect (Incorporated herein by
reference to Exhibit 3.1 filed with the Company’s Form 8-K dated November 6, 2020)
Indenture dated as of December 1, 1991, between Hill-Rom Holdings, Inc. and Union Bank, N.A. (as successor to
LaSalle Bank National Association and Harris Trust and Savings Bank) as Trustee (Incorporated herein by
reference to Exhibit (4) (a) to Registration Statement on Form S-3, Registration No. 33-44086)
Indenture dated as of February 14, 2017, between Hill-Rom Holdings, Inc., the guarantors party thereto, and
MUFG Union Bank, N.A., as Trustee (Incorporated herein by reference to Exhibit 4.1 to the Company’s Form 8-K
dated February 14, 2017)
First Supplemental Indenture dated May 12, 2017, among Hill-Rom Holdings, Inc., the guarantors party thereto,
and MUFG Union Bank, N.A., as Trustee (Incorporated herein by reference to Exhibit 4.7 to the Company’s Form
10-K dated November 17, 2017)
Indenture, dated September 19, 2019, among Hill-Rom Holdings, Inc., the subsidiary guarantors party thereto, and
Citibank, N.A., as Trustee (Incorporated herein by reference to Exhibit 4.1 to the Company’s Form 8-K dated
September 19, 2019)
First Supplemental Indenture dated October 16, 2019, among Hill-Rom Holdings, Inc., the guarantors party
thereto, and Citibank, N.A., as Trustee (Incorporated herein by reference to Exhibit 4.9 to the Company’s Form 10-
K dated November 15, 2019)
Second Supplemental Indenture dated May 3, 2019, among Hill-Rom Holdings, Inc., the guarantors party thereto,
and MUFG Union Bank, N.A., as Trustee
Third Supplemental Indenture dated October 16, 2019, among Hill-Rom Holdings, Inc., the guarantors party
thereto, and MUFG Union Bank, N.A., as Trustee (Incorporated herein by reference to Exhibit 4.10 to the
Company’s Form 10-K dated November 15, 2019)
4.8
Description of Securities
*10.1
Hill-Rom Holdings, Inc. Board of Directors’ Deferred Compensation Plan (Incorporated herein by reference to
Exhibit 10.10 filed with the Company’s Form 10-Q dated July 13, 2001)
*10.2
Hill-Rom Holdings, Inc. Director Phantom Stock Plan and form of award (Incorporated herein by reference to
Exhibit 10.11 filed with the Company’s Form 10-Q dated July 13, 2001)
*10.3
Form of Director Indemnity Agreement (Incorporated herein by reference to Exhibit 10.6 filed with the
Company’s Form 10-K dated December 23, 2003)
*10.4
Form of Indemnity Agreement between Hill-Rom Holdings, Inc. and certain executive officers (Incorporated
herein by reference to Exhibit 10.9 filed with the Company’s Form 10-K dated December 23, 2003)
100
Table of Contents
*10.5
Amended and Restated Hill-Rom Holdings, Inc. Stock Incentive Plan, as currently in effect (Incorporated herein by
reference to Exhibit 10.30 filed with the Company’s Form 10-K dated November 24, 2009)
*10.6
Hill-Rom Holdings, Inc. Short-Term Incentive Compensation Plan
*10.7
Hill-Rom Holdings, Inc. Amended and Restated Supplemental Executive Retirement Plan (Incorporated herein by
reference to Exhibit 10.69 filed with the Company’s Form 10-K dated November 16, 2011)
*10.8
Form of Indemnity Agreement between Hill-Rom Holdings, Inc. and certain executive officers (Incorporated
herein by reference to Exhibit 10.6 filed with the Company’s Form 10-K dated November 16, 2011)
*10.9
Form of Limited Recapture Agreement between Hill-Rom Holdings, Inc. and certain of its officers, including
Named Executive Officers (Incorporated herein by reference to Exhibit 10.34 filed with the Company’s Form 10-K
dated November 20, 2013)
*10.10
FY 2016 Non-Employee Director Compensation Policy (Incorporated herein by reference to Exhibit 10.31 filed
with the Company’s Form 10-K dated November 19, 2015)
10.11
10.12
10.13
10.14
Credit Agreement dated as of August 30, 2019 among Hill-Rom Holdings, Inc, Welch Allyn, Inc., the other
borrowers from time to time party thereto, the lenders party thereto and JPMorgan Chase Bank, N.A., as
Administrative Agent and Collateral Agent (Incorporated herein by reference to Exhibit 10.1 the Company's Form
8-K dated August 30, 2019)
Loan and Security Agreement dated May 5, 2017, among Hill-Rom Finance Company LLC, as Borrower, the
persons from time to time party hereto, as lenders and as Group Agents, The Bank of Tokyo-Mitsubishi UFJ, Ltd.,
as Administrative Agent, and Hill-Rom Company, Inc., as initial Servicer (Incorporated herein by reference to
Exhibit 10.1 to the Company’s Form 8-K dated May 5, 2017)
Purchase and Sale Agreement dated May 5, 2017, among Hill-Rom Company, Inc., as an originator and as
servicer, other originators from time to time party hereto, as originators, and Hill-Rom Finance Company LLC, as
Buyer (Incorporated herein by reference to Exhibit 10.2 to the Company’s Form 8-K dated May 5, 2017)
Performance Guaranty dated May 5, 2017, between Hill-Rom Holdings, Inc., the Bank of Tokyo-Mitsubishi UFJ,
Ltd., as administrative agent, for and on behalf of the Credit Parties and other Secured Parties from time to time
under the Loan and Security Agreement, dated as of the date hereof, among Hill-Rom Finance Company LLC,
Hill-Rom Company, Inc., as initial servicer, the Administrative Agent and BTMU (Incorporated herein by
reference to Exhibit 10.3 to the Company’s Form 8-K dated May 5, 2017)
*10.15
Hill-Rom Holdings, Inc. Employee Stock Purchase Plan, as amended and restated as of July 1, 2017 (Incorporated
herein by reference to Exhibit 10.22 to the Company's Form 10-K dated November 16, 2018)
*10.16
Form of Non-Qualified Stock Option Agreement for employees hired prior to August 1, 2016, under the Amended
and Restated Hill-Rom Holdings, Inc.’s Stock Incentive Plan (Incorporated herein by reference to Exhibit 10.30 to
the Company’s Form 10-K dated November 17, 2017)
*10.17
Form of Non-Qualified Stock Option Agreement for employees hired on and after August 1, 2016, under the
Amended and Restated Hill-Rom Holdings, Inc.’s Stock Incentive Plan (Incorporated herein by reference to
Exhibit 10.31 to the Company’s Form 10-K dated November 17, 2017)
*10.18
Form of Non-Qualified Stock Option Agreement (CEO version), under the Amended and Restated Hill-Rom
Holdings, Inc.’s Stock Incentive Plan (Incorporated herein by reference to Exhibit 10.32 to the Company’s Form
10-K dated November 17, 2017)
101
Table of Contents
*10.19
Form of Restricted Stock Unit Award Agreement for employees hired prior to August 1, 2016, under the Amended
and Restated Hill-Rom Holdings, Inc.’s Stock Incentive Plan (Incorporated herein by reference to Exhibit 10.33 to
the Company’s Form 10-K dated November 17, 2017)
*10.20
Form of Restricted Stock Unit Award Agreement for employees hired on and after August 1, 2016, under the
Amended and Restated Hill-Rom Holdings, Inc.’s Stock Incentive Plan (Incorporated herein by reference to
Exhibit 10.34 to the Company’s Form 10-K dated November 17, 2017)
*10.21
Form of Restricted Stock Unit Award Agreement (CEO version), under the Amended and Restated Hill-Rom
Holdings, Inc.’s Stock Incentive Plan (Incorporated herein by reference to Exhibit 10.35 to the Company’s Form
10-K dated November 17, 2017)
*10.22
Form of Performance-Based Restricted Stock Unit Award Agreement for employees hired prior to August 1, 2016,
under the Amended and Restated Hill-Rom Holdings, Inc.’s Stock Incentive Plan (Incorporated herein by reference
to Exhibit 10.36 to the Company’s Form 10-K dated November 17, 2017)
*10.23
Form of Performance-Based Restricted Stock Unit Award Agreement for employees hired on and after August 1,
2016, under the Amended and Restated Hill-Rom Holdings, Inc.’s Stock Incentive Plan (Incorporated herein by
reference to Exhibit 10.37 to the Company’s Form 10-K dated November 17, 2017)
*10.24
Form of Performance-Based Restricted Stock Unit Award Agreement (CEO version), under the Amended and
Restated Hill-Rom Holdings, Inc.’s Stock Incentive Plan (Incorporated herein by reference to Exhibit 10.38 to the
Company’s Form 10-K dated November 17, 2017)
10.25
10.26
10.27
10.28
10.29
10.30
10.31
Amendment No. 1 to Loan and Security Agreement, dated as of May 4, 2018, among Hill-Rom Company, Inc., as
initial servicer, Hill-Rom Finance Company LLC, as borrower, and MUFG Bank, Ltd., (f/k/a The Bank of Tokyo-
Mitsubishi UFJ, Ltd.), as Group Agent, as Committed Lender and as Administrative Agent (Incorporated herein by
reference to Exhibit 10.1 to the Company’s Form 8-K dated May 4, 2018)
Amendment No. 1 to Purchase and Sale Agreement, dated as of May 4, 2018, among Hill-Rom Company, Inc., as
initial servicer, each of the Originators party to the Purchase and Sale Agreement, as originators, and Hill-Rom
Finance Company LLC, as buyer (Incorporated herein by reference to Exhibit 10.2 to the Company’s Form 8-K
dated May 4, 2018)
Master Framework Agreement, dated as of May 4, 2018, by and among MUFG Bank, Ltd., as buyer, Hill-Rom
Company, Inc., Hill-Rom Manufacturing, Inc., and each additional seller from time to time party thereto, as sellers,
and Hill-Rom Company, as agent for the sellers (Incorporated herein by reference to Exhibit 10.3 to the
Company’s Form 8-K dated May 4, 2018)
1996 SIFMA Master Repurchase Agreement, including Annex I thereto, (as amended thereby), dated as of May 4,
2018, between Hill-Rom Company, Inc. and MUFG Bank, Ltd (Incorporated herein by reference to Exhibit 10.4 to
the Company’s Form 8-K dated May 4, 2018)
1996 SIFMA Master Repurchase Agreement, including Annex I thereto, (as amended thereby), dated as of May 4,
2018, between Hill-Rom Manufacturing, Inc. and MUFG Bank, Ltd (Incorporated herein by reference to Exhibit
10.5 to the Company’s Form 8-K dated May 4, 2018)
Guaranty, dated as of May 4, 2018, between Hill-Rom Holdings, Inc., and MUFG Bank, Ltd., as buyer under the
Master Framework Agreement (Incorporated herein by reference to Exhibit 10.6 to the Company’s Form 8-K dated
May 4, 2018)
Amendment No. 3 to Loan and Security Agreement, dated as of May 3, 2019, among Hill-Rom Company, Inc., as
initial servicer, Hill-Rom Finance Company LLC, as borrower, and MUFG Bank, Ltd., (f/k/a The Bank of Tokyo-
Mitsubishi UFJ, Ltd.), as Group Agent, as Committed Lender and as Administrative Agent (Incorporated herein by
reference to Exhibit 10.1 to the Company's Form 8-K dated May 3, 2019)
102
Table of Contents
10.32
Amendment No. 1 to Master Framework Agreement, dated as of May 3, 2019, by and among MUFG Bank, Ltd.,
as buyer, Hill-Rom Company, Inc., Hill-Rom Manufacturing, Inc., and each additional seller from time to time
party thereto, as sellers, and Hill-Rom Company, as agent for the sellers (Incorporated herein by reference to
Exhibit 10.2 to the Company's Form 8-K dated May 3, 2019)
*10.33
Letter Agreement executed March 21, 2018 between Hill-Rom Holdings, Inc. and Richard M. Wagner
(Incorporated herein by reference to Exhibit 10.1 filed with the Company's Form 8-K dated May 10, 2018)
*10.34
*10.35
*10.36
*10.37
*10.38
Amended and Restated Employment Agreement between Hill-Rom Holdings, Inc. and John P. Groetelaars dated
November 16, 2018 (Incorporated herein by reference to Exhibit 10.43 to the Company's Form 10-K dated
November 16, 2018)
Amended and Restated Employment Agreement between Hill-Rom Holdings, Inc. and Deborah Rasin dated
November 16, 2018 (Incorporated herein by reference to Exhibit 10.44 to the Company's Form 10-K dated
November 16, 2018)
Amended and Restated Change in Control Agreement between Hill-Rom Holdings, Inc. and John P. Groetelaars
dated November 16, 2018 (Incorporated herein by reference to Exhibit 10.47 to the Company's Form 10-K dated
November 16, 2018)
Change in Control Agreement between Hill-Rom Holdings, Inc. and Barbara Bodem with an effective date of
December 3, 2018 (Incorporated herein by reference to Exhibit 10.4 to the Company's Form 8-K dated November
27, 2018)
Form of Amended and Restated Change in Control Agreement dated November 16, 2018, between Hill-Rom
Holdings, Inc. and certain of its officers, including Messrs. Amy Dodrill, Mary Kay Ladone, Andreas Frank, Paul
Johnson, Kenneth Meyers, Richard Wagner, and Ms. Deborah Rasin (Incorporated herein by reference to Exhibit
10.48 to the Company's Form 10-K dated November 16, 2018)
*10.39
Amended and Restated Employment Agreement between Hill-Rom Holdings, Inc. and Andreas Frank dated
November 16, 2018 (Incorporated herein by reference to Exhibit 10.49 to the Company's Form 10-K dated
November 16, 2018)
*10.40
Amended and Restated Employment Agreement between Hill-Rom Holdings, Inc. and Paul Johnson dated
November 16, 2018 (Incorporated herein by reference to Exhibit 10.50 to the Company's Form 10-K dated
November 16, 2018)
*10.41
Amended and Restated Employment Agreement between Hill-Rom Holdings, Inc. and Kenneth Meyers dated
November 16, 2018 (Incorporated herein by reference to Exhibit 10.51 to the Company's Form 10-K dated
November 16, 2018)
10.42
Residential Lease Agreement between Hill-Rom Holdings, Inc. and Andreas Frank dated May 1, 2019
(Incorporated herein by reference to Exhibit 10.1 to the Company's Form 10-Q dated August 2, 2019)
*10.43
Employment Agreement between Hill-Rom Holdings, Inc. and Mary Kay Ladone with an effective date of
December 3, 2018
*10.44
Employment Agreement between Hill-Rom Holdings, Inc. and Barbara Bodem with an effective date of December
3, 2018 (Incorporated herein by reference to Exhibit 10.3 to the Company's Form 8-K dated November 27, 2018)
*10.45
Employment Agreement between Hill-Rom Holdings, Inc. and Amy Dodrill with an effective date of June 1, 2019
10.46
Amendment No. 4 to Loan and Security Agreement, dated as of April 27, 2020, among Hill-Rom Company, Inc.,
as initial servicer, Hill-Rom Finance Company LLC, as borrower, and MUFG Bank, Ltd., (f/k/a The Bank of
Tokyo-Mitsubishi UFJ, Ltd.), as Group Agent, as Committed Lender and as Administrative Agent (Incorporated
herein by reference to Exhibit 10.1 filed with the Company's Form 8-K dated April 27, 2020)
103
Table of Contents
10.47
10.48
10.49
Amendment No. 2 to Master Framework Agreement, dated as of April 27, 2020, by and among MUFG Bank, Ltd.,
as buyer, Hill-Rom Company, Inc., Hill-Rom Manufacturing, Inc., and each additional seller from time to time
party thereto, as sellers, and Hill-Rom Company, as agent for the sellers (Incorporated herein by reference to
Exhibit 10.2 filed with the Company's Form 8-K dated April 27, 2020)
Amendment No. 1 to Hill-Rom Company Master Repurchase Agreement, dated as of April 27, 2020, by and
among MUFG Bank, Ltd., as buyer, and Hill-Rom Company, Inc., as seller (Incorporated herein by reference to
Exhibit 10.3 filed with the Company's Form 8-K dated April 27, 2020)
Amendment No. 1 to Hill-Rom Manufacturing Master Repurchase Agreement, dated as of April 27, 2020, by and
among MUFG Bank, Ltd., as buyer, and Hill-Rom Manufacturing, Inc., as seller (Incorporated herein by reference
to Exhibit 10.4 filed with the Company's Form 8-K dated April 27, 2020)
*10.50
Form of Addendum to Form of Limited Recapture Agreement between Hill-Rom Holdings, Inc. and certain of its
officers, including Named Executive Officers
21
23
Subsidiaries of the Registrant
Consent of Independent Registered Public Accounting Firm
31.1
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2
Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1
32.2
Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906
of the Sarbanes-Oxley Act of 2002
Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002
101.INS
Inline XBRL Instance Document
101.SCH
Inline XBRL Taxonomy Extension Schema Document
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
Inline XBRL Extension Labels Linkbase Document
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document
104
Cover Page Interactive Data File (formatted as Inline XBRL document and contained in Exhibit 101)
104
Table of Contents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned, thereunto duly authorized.
HILL-ROM HOLDINGS, INC.
By:
/s/ John P. Groetelaars
John P. Groetelaars
President and Chief Executive Officer
Date: November 13, 2020
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following
persons on behalf of the registrant and in the capacities and on the date indicated.
/s/
James R. Giertz
James R. Giertz
Director
/s/ William H. Kucheman
William H. Kucheman
Director
/s/
/s/
/s/
/s/
Ronald A. Malone
Ronald A. Malone
Director
Gregory J. Moore
Gregory J. Moore
Director
Nancy M. Schlichting
Nancy M. Schlichting
Director
Stacy Enxing Seng
Stacy Enxing Seng
Director
/s/ William G. Dempsey
William G. Dempsey
Chair of the Board
/s/
/s/
/s/
/s/
John P. Groetelaars
John P. Groetelaars
President and Chief Executive Officer and Director
(Principal Executive Officer)
Barbara W. Bodem
Barbara W. Bodem
Senior Vice President and Chief Financial Officer
(Principal Financial Officer)
Richard M. Wagner
Richard M. Wagner
Vice President — Controller and
Chief Accounting Officer
(Principal Accounting Officer)
Gary L. Ellis
Gary L. Ellis
Director
/s/ Mary Garrett
Mary Garrett
Director
/s/
Felicia F. Norwood
Felicia F. Norwood
Director
Date: November 13, 2020
105